



美瑞健康国际产业集团  
Meilleure Health International Industry Group

**2025**  
Annual Report

Meilleure Health International Industry Group Limited  
美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability) (Stock Code : 2327)



# CONTENTS

<b>2</b>	Corporate Information
<b>3</b>	Co-Chairman's Statement
<b>9</b>	Management Discussion and Analysis
<b>21</b>	Directors' Report
<b>43</b>	Corporate Governance Report
<b>63</b>	Biography of Directors and Senior Management
<b>67</b>	Independent Auditor's Report
<b>71</b>	Audited Consolidated Financial Statements Consolidated Statement of Profit or Loss
<b>72</b>	Consolidated Statement of Comprehensive Income
<b>73</b>	Consolidated Statement of Financial Position
<b>75</b>	Consolidated Statement of Changes in Equity
<b>76</b>	Consolidated Statement of Cash Flows
<b>78</b>	Notes to the Consolidated Financial Statements
<b>171</b>	Five Year Financial Summary
<b>172</b>	Particulars of Properties
<b>173</b>	Glossary

# CORPORATE INFORMATION

## BOARD OF DIRECTORS

### Executive Directors

Mr. Zhou Xuzhou (*Co-Chairman*)  
Dr. Zeng Wentao (*Co-Chairman*)  
Ms. Zhou Wen Chuan (*Vice-Chairman and Chief Executive Officer*)

### Non-Executive Director

Dr. Mao Zhenhua

### Independent Non-Executive Directors

Professor Chau Chi Wai, Wilton  
Mr. Chen Shi  
Mr. Wu Peng

## AUTHORISED REPRESENTATIVES

Mr. Zhou Xuzhou  
Ms. Zhou Wen Chuan

## JOINT COMPANY SECRETARIES

Mr. Li Shu Pai (resigned on 31 December 2025)  
Ms. Chu Mei Yi (appointed on 31 December 2025)  
Mr. Tsoi Kwai Kwan (appointed on 31 December 2025)

## AUDIT COMMITTEE

Professor Chau Chi Wai, Wilton (*Chairman*)  
Dr. Mao Zhenhua  
Mr. Chen Shi

## REMUNERATION COMMITTEE

Mr. Chen Shi (*Chairman*)  
Professor Chau Chi Wai, Wilton  
Dr. Zeng Wentao

## NOMINATION COMMITTEE

Mr. Zhou Xuzhou (*Chairman*)  
Ms. Zhou Wen Chuan (appointed on 31 December 2025)  
Professor Chau Chi Wai, Wilton  
Mr. Chen Shi (appointed on 31 December 2025)  
Mr. Wu Peng

## STRATEGIC COMMITTEE

Dr. Mao Zhenhua (*Chairman*)  
Mr. Zhou Xuzhou  
Dr. Zeng Wentao

## REGISTERED OFFICE

Clarendon House  
2 Church Street  
Hamilton HM 11  
Bermuda

## HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG REGISTERED UNDER PART XIV OF THE COMPANIES ORDINANCE

Unit 2906  
Tower 1, Lippo Centre  
89 Queensway  
Admiralty  
Hong Kong

## AUDITOR

*Certified Public Accountants*  
ZHONGHUI ANDA CPA Limited  
*Public Interest Entity Auditor registered in accordance with the Financial Reporting Council Ordinance (Cap. 588 of the Laws of Hong Kong)*

## PRINCIPAL BANKERS

China CITIC Bank International Limited  
Nanyang Commercial Bank, Limited

## PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Codan Services Limited  
Clarendon House  
2 Church Street  
Hamilton HM 11  
Bermuda

## HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Investor Services Limited  
17/F, Far East Finance Centre  
16 Harcourt Road  
Hong Kong

## COMPANY WEBSITE

[www.meilleure.com.cn](http://www.meilleure.com.cn)

## STOCK CODE

2327



# CO-CHAIRMAN'S STATEMENT

Dear Shareholders,

On behalf of the Board, I hereby present to our shareholders the annual results of the Group for the Reporting Period.

## RECENT DEVELOPMENTS

Driven by rising public health awareness, an accelerating ageing population, a growing burden of chronic diseases, the rapid deployment of AI technology, and sustained policy support, China's health industry is rapidly transitioning from a "treatment-centric" to a "prevention-centric" model. This shift is giving rise to a multi-sector industrial ecosystem encompassing health management, biopharmaceuticals, medical devices, and elderly care services. "Health" has long transcended mere disease treatment, evolving into a grand proposition about "living longer and better". The State Council's Outline of the Healthy China 2030 Plan sets the direction, projecting the health industry to surpass RMB8 trillion by 2025 and reach RMB16 trillion by 2030, establishing it as a key pillar driving economic growth. A vision of "national health" and "industrial prosperity" advancing in tandem is rapidly unfolding. 2025 was a pivotal year for the broader health industry, marked by strong policy empowerment, profound industrial upgrading, and refined regulation. At the national level, multiple new policies have been introduced, with local governments implementing complementary industrial support measures to drive the industry's transition from scale expansion to high-quality innovation. In February 2025, multiple departments including the National Health Commission and the State Administration for Market Regulation jointly issued the "Guiding Opinions on Further Strengthening the Supervision of the Medical Aesthetics Industry", aiming to standardise the qualifications and service procedures of medical aesthetic institutions, enhance the management of practitioner qualifications, and clarify the primary responsibilities of online platforms. In April 2025, the Ministry of Commerce, the National Health Commission, and 10 other departments jointly issued the "Action Plan for Promoting Health-related Consumption", outlining ten key tasks. These include elevating healthy eating consumption standards, improving the supply of special foods, enriching fitness and sports consumption scenarios, bolstering services for the elderly, and developing new service businesses such as those providing health examinations. In May 2025, the Ministry of Industry and Information Technology, the Ministry of Civil Affairs, and the National Health Commission jointly issued the "Action Plan for the Development of the Smart Health and Elderly Care Industry (2025-2030)". This plan encourages the application of AI health assistants in elderly care facilities, supports the R&D of smart elderly care service products such as those for chronic disease management and daily care, and promotes the deep integration of "Internet Plus" medical services with elderly care services. In June 2025, the National Healthcare Security Administration, together with the National Financial Regulatory Administration, issued the "Commercial Health Insurance Catalogue for Innovative Drugs", which incorporates 19 highly innovative, clinically valuable yet expensive drugs, including 5 CAR-T therapies and 2 T-cell therapies, addressing the challenge of making high-cost innovative drugs accessible. In respect of the pharmaceutical and medical device distribution sector, the "Compliance Guide for Online Retail of Prescription Drugs (Draft for Comments)" was released for public consultation in September 2025; the "Quality Management Standards for Online Sales of Medical Devices" took effect in October 2025; and the "Provisions on the Administration of Filing for Internet-based Pharmaceutical and Medical Device Information Services" was issued in December 2025. These documents collectively formed a regulatory framework with detailed requirements for areas such as online sales of medical devices, Internet-based information services for pharmaceuticals and medical devices, and online retail of prescription drugs.

## CO-CHAIRMAN'S STATEMENT

In 2026, China's health industry will accelerate its transformation, driven by the combined forces of policy, technology, and societal demand. On the policy front, the deepening implementation of the "Healthy China 2030" strategy will unlock significant benefits. Socially, an ageing population and high prevalence of chronic diseases will create strong demand. Technologically, AI and big data will empower the widespread adoption of smart health services. With these multiple favourable factors at play, the health industry is shifting from scale expansion to value cultivation, injecting sustained momentum into the sector's high-quality development. China's economy currently navigates a critical phase of deep transformation and structural optimisation. Despite a complex external environment—including sluggish global recovery, rising trade protectionism, frequent geopolitical conflicts in hotspots, and increasingly complex great power rivalries—which continues to put pressure on the domestic economy, policy support is being continuously strengthened. Through extraordinary counter-cyclical adjustments, the Chinese government has prioritised boosting consumption and expanding domestic demand as core tasks, driving the recovery of investment and capital markets. This has enabled China's economy to demonstrate considerable resilience and flexibility. With the gradual recovery of market demand, the overall positive trajectory has been solidifying. As new challenges and opportunities continue to surface, the health industry stands to gain sustained benefits. Guided by the overarching "Healthy China" strategy, the Group will firmly adhere to its strategic focus on skin health management, accelerate synergistic innovation in cell therapy and health management services, and drive development through dual engines of technological R&D and brand value accumulation. Against the backdrop of an expanding health consumer market, deepening demographic ageing, and accelerating technological transformation, the Group aims to seize opportunities presented by industrial upgrading and consumption upgrades, achieving a leap from being a "provider of health products" to an "exporter of health concepts".

### OVERVIEW OF OPERATIONS

#### Healthcare-related Business Segment – Cell Treatment and Health Management Business

In 2025, China introduced a series of industrial policies that collectively established a multi-dimensional and systematic support framework covering R&D, clinical trials, manufacturing, regulation, and reimbursement. The year of 2025, thus, is widely regarded by the industry as the policy milestone marking China's cell therapy sector's transition towards standardised, high-quality development. It signifies the sector's formal entry into a new phase of accelerated growth characterized by clear guidelines, robust legal foundations, and a rapidly maturing ecosystem. In early 2025, the General Office of the State Council explicitly included clinically urgent cell and gene therapy drugs within the scope of priority review and approval in its "Opinions on Comprehensively Deepening the Reform of Drug and Medical Device Supervision to Promote High-Quality Development of the Pharmaceutical Industry." In January 2025, the Center for Food and Drug Inspection of the National Medical Products Administration (the "NMPA") released the "Guidelines for the Inspection of Cell Therapy Product Manufacturing," which provides detailed technical guidance for on-site inspections of manufacturing processes, covering the entire production chain from donor materials to final product release. In April 2025, the National Health Commission issued the "Application Guidelines for Key Special Projects under the National Key R&D Program, including 'Research on Prevention and Treatment of Common and Frequent Diseases'," incorporating "Stem Cell Research and Organ Repair" into the key special projects of the National Key R&D Program to channel scientific research efforts towards conquering major diseases. In September 2025, the State Council executive meeting reviewed, approved, and formally promulgated the "Administrative Regulations on Clinical Research and Clinical Translation of New Biomedical Technologies." This marks China's first comprehensive administrative regulation in the field of new biomedical technologies, shifting away from the previous reliance on departmental rules for managing areas such as stem cell research. In October 2025, the 15th Five-Year Plan proposal proactively mapped out future industries like biomedicine, outlining a grand macro-development blueprint for cutting-edge fields such as cell therapy. In December 2025, all five CAR-T cell therapy products were included in the inaugural commercial insurance catalogue for innovative medicines, pioneering an innovative payment model combining commercial insurance reimbursement with medication access guarantees. These systematic, forward-looking, and actionable policies introduced in 2025 have charted a clear and definitive development trajectory for China's cell therapy industry. A regulated, dynamic, and globally influential cell therapy ecosystem is rapidly taking shape. According to Precedence Research estimates, the global cell and gene therapy market was valued at US\$21.28 billion in 2024 and is projected to grow from US\$25.03 billion in 2025 to approximately US\$117.46 billion by 2034, representing a compound annual growth rate (CAGR) of 18.7%.



## CO-CHAIRMAN'S STATEMENT

The Group continues to expand its footprint in the cell therapy sector. In 2019, it strategically acquired a stake in Wingor Bio, a state-level high-tech enterprise, and in 2020, it established Mei Ai Kang to expand into the field of cellular immunotherapy.

As a leading enterprise in Shenzhen's local cell treatment industry, Wingor Bio leverages its powerful R&D innovation capabilities to deepen its presence. It maintains industry-leading expertise and holds honours such as "National High-Tech Enterprise", "Sci-Tech-based SME" in China and "Specialised and Sophisticated SME in Shenzhen". In terms of R&D, Wingor Bio's Investigational New Drug (IND) applications for new stem cell drugs have achieved significant progress, with the clinical trial applications for four cell drugs accepted by the NMPA. Among these, two cell therapy drugs have obtained implied permission for clinical trials and have been designated as key products by Guangdong-Hong Kong-Macao Greater Bay Area Center for Drug Evaluation and Inspection of the NMPA, which will significantly accelerate regulatory approval and marketing process. In terms of technology, Wingor Bio holds patents authorised by the China National Intellectual Property Administration (CNIPA) for blood preservation solution and its preparation method and application, preparation method of human umbilical cord mesenchymal stem cells, preparation method and application of mesenchymal stem cells, a dental pulp mesenchymal stem cell culture method, and a monitoring method and system for AI-assisted automated equipment. In addition, Wingor Bio's "Drug Conjugate Delivery Platform Construction Project Based on Extracellular Vesicles" has received support from Shenzhen government as it falls within strategic emerging industries. Regarding participation in policy formulation, Wingor Bio, as a principal drafting unit, contributed to the drafting of the "Clinical Application Guide for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Knee Osteoarthritis" (T/ZGCIT 015-2024) and the group standard for "Soft Agar Colony Formation Assay", both of which were released in 2025. Further, Wingor Bio has initiated clinical collaborations with multiple medical institutions, including the Affiliated Hospital of Guilin Medical University, the First People's Hospital of Changzhou, Zhongda Hospital Southeast University, and Shenzhen University General Hospital, to accelerate the translation of scientific and technological findings into clinical applications.

Wingor Bio achieved several significant milestones in 2025. In March 2025, Wingor Bio was granted invention patents by the CNIPA for "an electrotransfection buffer and its application in peptide loading into exosomes" and "a method for culturing human decidua mesenchymal stem cells and its application." Also in March, Wingor Bio was elected as a Vice President Unit of the Shenzhen Biological Medicine Promotion Association, contributing to the standardization and high-quality development of the supply chain. In July 2025, Wingor Bio disclosed interim positive results from the clinical trial of "Human Umbilical Cord Mesenchymal Stem Cell Injection (R&D Code: WG103)" for the treatment of acute ischemic stroke (AIS), initiating a Phase II clinical trial in the same month. On 8 August 2025, Wingor Bio was granted an invention patent by the CNIPA for "an AI-based method and system for monitoring cell culture." Also in August 2025, Wingor Bio achieved a milestone in its commercial financing efforts, securing tens of millions of RMB in market-based funding. In October 2025, the 9th Asia Cell & Gene Therapy Innovation Summit was held in Shenzhen, where Wingor Bio showcased its cutting-edge research findings in a special presentation and won three major awards. In November 2025, Wingor Bio was granted an invention patent by the CNIPA for "an adaptive cell thawing method and system based on multi-parameter feedback."

Mei Ai Kang has also had several achievements since its inception. In 2022, it cooperated with the Fifth Medical Centre of the General Hospital of the Chinese People's Liberation Army, the Fourth People's Hospital of Nanning, Shanghai Public Health Clinical Centre and Yunnan Provincial Infectious Disease Hospital to conduct clinical studies. Overcoming the adverse impacts of the COVID-19 pandemic, Mei Ai Kang completed enrollment of 17 cases and refined the clinical trial protocol by optimizing the clinical trial process. Mei Ai Kang is currently applying for a relevant patent cluster related to the project's core technology, and a patent for a self-transfusion injector has been approved. Meanwhile, its related patents for cell processing are currently in the process of application review. As of April 2025, a total of 132 clinical experiments have been completed, with data indicating significant therapeutic efficacy.

## CO-CHAIRMAN'S STATEMENT

In terms of downstream products and services as well as high-end health management, the Group's Shenzhen and Nanjing clinics offer international-standard, high-end health management services grounded in the principles of functional medicine. Backed by an experienced professional team, these clinics have cultivated a loyal client base. During the Reporting Period, the clinics operated steadily while continuously optimising management systems, improving service quality, and expanding new customer segments.

With the continuous introduction of relevant policies and regulations for the cell industry in China, and the gradual increase in cell and gene therapy clinical research conducted domestically over the years, the demand for the industrialisation and clinical application of related products is also getting higher and higher. Although the development model and regulatory policies of the industry are not entirely clear, the huge potential of the cell industry in the field of disease treatment is undeniable, and considerable market demand remains to be unlocked. The Group will continue to deepen its presence in the field of cell therapy R&D and its application, and explore the commercialisation pathways for cell therapy products, so as to achieve synergies between the health management business and other segments.

### Healthcare-related Business Segment – Skin Health Management Business

In recent years, the growing pursuit of beauty has ushered in an appearance-focused era, giving rise to various related emerging consumption scenarios. Non-invasive aesthetic treatments, with their affordability, noticeable results, and short recovery periods, fully address contemporary beauty aspirations. While achieving rapid market penetration, they deliver premium services and experiences to users. With that in mind, leveraging on its advantages in product R&D, medical care team, operation management, brand and channel for skin health management, the Group launched "Jixiaojian" (肌小簡), a curated brand combining medical aesthetics and skincare in the second half of 2021.

The Jixiaojian brand pioneers a cross-sector integration of aesthetic medicine and efficacy-focused skincare. Guided by the philosophy of "Extreme Professionalism, Maximum Efficacy, Zero Gimmicks", it champions innovation in skincare technology and introduces a new concept of intelligent skincare. By seamlessly combining the "treatment" aspect of aesthetic procedures with the "prevention" function of skincare products, Jixiaojian offers a curated "60% non-invasive aesthetic treatments + 40% simplified yet highly effective skincare" regimen—delivering an integrated, cost-effective holistic skincare solution for users. The Group has also established close partnerships with internationally renowned raw material suppliers DSM and Ashland, and successively launched multiple product lines under the brand of Jixiaojian, including comprehensive photoelectric repair series, medical-grade dressing series, and exosome-based premium anti-aging series. On the offline front, Jixiaojian has partnered with the prominent medical aesthetics chain group BeauCare Clinics (聯合麗格). Meanwhile, Jixiaojian has secured collaborations with some top-tier livestreamers on Taobao, Douyin, and Xiaohongshu online.

The Jixiaojian medical aesthetics clinic has been in operation for years. Its signature "Jixiaojian × Super Photon" exclusive treatment, built upon the Jixiaojian photoelectric repair series, offers an integrated skincare solution covering the entire pre-, intra-, and post-treatment process for super photon medical aesthetics procedures. This approach has garnered widespread recognition and recommendations from clients. In terms of aesthetic medical devices, the Group has established a strategic partnership with Lumenis, a globally renowned leader in laser aesthetics, becoming its clinical demonstration base. The Group has also collaborated with Peninsula Medical (半島), a prominent brand in medical equipment, to create the Bandao Soothing Treatment Device Project (半島舒敏治療儀特色項目), dubbed the "Golden Partner for Light Medical Aesthetics (輕醫美黃金搭檔)". On the R&D front, the Group has forged a close partnership with Shinehigh Innovation (深圳杉海創新), which possesses a CNAS-accredited testing laboratory, to establish a supramolecular laboratory dedicated to developing skincare product lines centred on supramolecular technology. The Group has also successfully partnered with Jland Biotech, the world's largest producer of recombinant collagen, to establish a strategic partnership in the field of recombinant collagen.

## CO-CHAIRMAN'S STATEMENT

The Group will continue to increase its investment in skin health management. Adhering to a professional and efficient business philosophy and maintaining a customer-centric focus, the Group will persistently drive the effective enhancement of product and service capabilities and strive to build a leading scientific skincare brand that integrates online and offline channels and combines medical aesthetics with effective skincare. The Group aims to leverage this skincare revolution—driven by generational shifts, evolving consumer awareness, and technological advancements—to transform the skincare habits of a generation and reshape the landscape of the skincare industry.

### **Overseas Business**

The Group proactively implemented its international business strategies and established localised management teams to expand overseas business. In terms of its European business, as early as 2019, the Group established a subsidiary in Switzerland and organised a local professional team to tap into the European market. In 2021, AlpReleaf, a premium CBD health and wellness brand independently developed and produced in Switzerland, was officially launched across Europe. Centred on high-quality CBD as its scientific core and dedicated to enhancing users' quality of life, AlpReleaf has introduced multiple product lines targeting relaxation, sleep support, and muscle soreness relief. The brand has obtained official certification from the European Union and the United Kingdom, granting it market access across 22 European countries. Leveraging its European local team and established sales network, the Group believes that these strategic initiatives can maximise the advantages of the Swiss brand, facilitating its sustained success in an ever-changing market environment.

For the business in Australia, a boutique townhouse project located in Yarrabend, Australia was developed and wholly-owned by the Group, in collaboration with Level 10 Pty Ltd., a leading construction company in Australia, and Rothelowman, a renowned design firm. Situated along the Yarra River in Melbourne, one of the world's most liveable cities, the project benefits from excellent surrounding amenities and convenient transportation links. Since its initial launch in 2022, sales work and subsequent construction have been progressing steadily.

As at the end of the Reporting Period, the Group's overseas business had been growing steadily. The Group will further strengthen its international strategic presence, accelerate the expansion of its global business, deepen its brand building, and intensify channel development efforts. This will enable the Group to expand and enhance its overseas operations, thereby generating sustained internal momentum for the Group's development.

# CO-CHAIRMAN'S STATEMENT

## PROSPECTS

The past year marked the conclusion of the 14th Five-Year Plan period and held significant importance in China's modernisation journey. Navigating the profound and complex shifts in both domestic and international landscapes, China's economy pressed forward with resilience, pursuing quality growth through innovation and laying a solid foundation for the new journey towards the second centenary goal. For the Group, in terms of assets, as at 31 December 2025, it had net current assets of approximately HK\$654.2 million. In terms of operations, the Group remained focused on the healthcare sector, continuously refining its skin health management products and business model while actively expanding sales channels and strengthening collaborations to solidify its business fundamentals. Furthermore, the Group will explore any promising business opportunities offering stable cash flows or high growth potential. Concurrently, the Group's overseas operations have steadily expanded in scale, with distribution channels broadening and brand development continuously refined. Looking ahead, the Group approaches the future with confidence and anticipation. Building upon its long-established strengths in professional expertise, brand reputation, and channel networks, the Group will enhance internal governance, proactively embrace transformative opportunities, and advance with steady strides to pioneer new horizons, driving sustained business growth and generating greater value for society.

**Zhou Xuzhou**

*Co-Chairman*

Hong Kong, 27 March 2026

# MANAGEMENT DISCUSSION AND ANALYSIS

## FINANCIAL REVIEW

Below is a summary of the financial information of the Group:

	2025 HK\$'000	2024 HK\$'000
Revenue	36,518	50,676
Gross profit	22,631	28,905
Gross profit margin	62.0%	57.0%
Other income and gains, net	25,419	53,339
Total operating expenses (Note)	31,172	31,600
Finance costs	9,290	10,294
Profit before tax	30,537	45,401
Profit after tax	37,998	32,045
Profit attributable to owners of the Company	37,983	32,480

Note: Total operating expenses included (i) selling and distribution expenses; and (ii) administrative expenses.

### Revenue

Revenue for the year ended 31 December 2025 was approximately HK\$36.5 million (2024: HK\$50.7 million), mainly generated by (i) healthcare-related business; (ii) trading business; and (iii) property-related business.

Revenue decreased by approximately 28.0% from approximately HK\$50.7 million for the year ended 31 December 2024 to approximately HK\$36.5 million for the year ended 31 December 2025. The decrease in revenue of approximately HK\$14.2 million was mainly due to (i) a decrease in sale of construction materials of approximately HK\$10.5 million; (ii) a decrease in healthcare management service income of approximately HK\$3.2 million; and (iii) a decrease in provide aesthetic medical services of approximately HK\$2.2 million, as a result of adverse market condition.

### Gross Profit and Gross Profit Margin

The Group's gross profit for the year ended 31 December 2025 was approximately HK\$22.6 million (2024: approximately HK\$28.9 million), representing a decrease of approximately 21.8% as compared to that for the year ended 31 December 2024. The gross profit margin for the year ended 31 December 2025 increased to approximately 62.0% from approximately 57.0% for the year ended 31 December 2024.

The decrease in gross profit of approximately HK\$6.3 million was mainly due to (i) a decrease in gross profit of the healthcare-related business of HK\$7.7 million, mainly resulting from a decrease in the provide aesthetic medical services; and such decrease was partially offset by (ii) an increase in gross profit of the property-related business of HK\$2.0 million, mainly resulting from an increase in rental income.

On the other hand, the increase in gross profit margin was mainly due to a decrease in the proportion of the revenue derived from the trading business to the Group's total revenue for the year ended 31 December 2025 as compared to that for the year ended 31 December 2024, as the trading business has a lower gross profit margin as compared to that of other business segments of the Group.

# MANAGEMENT DISCUSSION AND ANALYSIS

## Other Income and Gains, Net

Other income and gains, net for the year ended 31 December 2025 was approximately HK\$25.4 million (2024: approximately HK\$53.3 million), representing a decrease of approximately HK\$27.9 million or approximately 52.3% as compared to that for the year ended 31 December 2024. Such decrease was mainly due to (i) an increase in fair value loss on investments at FVTPL of approximately HK\$12.8 million as a result of the decrease in revenue from and loss of equity-invested entities; such decrease was partially offset by (ii) a positive financial impact arising from foreign exchange gain, which increased from approximately HK\$4.0 million for the year ended 31 December 2024 to approximately HK\$8.3 million for the year ended 31 December 2025; and (iii) the interest income increased from approximately HK\$22.0 million for the year ended 31 December 2024 to approximately HK\$29.3 million for the year ended 31 December 2025.

## Total Operating Expenses

Total operating expenses for the year ended 31 December 2025 were approximately HK\$31.2 million (2024: approximately HK\$31.6 million), representing a decrease of approximately HK\$0.4 million or approximately 1.3% as compared to that for the year ended 31 December 2024. Such decrease was mainly due to a decrease in commission expenses for the pre-sale of residential property development project in Australia and rental expenses of approximately HK\$0.4 million.

## Finance Costs

Finance costs for the year ended 31 December 2025 were approximately HK\$9.3 million (2024: approximately HK\$10.3 million), representing a decrease of approximately HK\$1.0 million or approximately 9.7% as compared to that for the year ended 31 December 2024. Such decrease was mainly due to a decrease in interest on bank loans of approximately HK\$1.0 million, primarily resulting from a decrease in the interest rate of bank borrowings in PRC during the year ended 31 December 2025 as compared to that for the year ended 31 December 2024.

## Profit After Tax

Profit after tax for the year ended 31 December 2025 was approximately HK\$38.0 million (2024: HK\$32.0 million), representing an increase of approximately HK\$6.0 million or approximately 18.8% as compared to that for the year ended 31 December 2024. Such increase was mainly due to:

- (i) an increase in revenue from and profit of property-related business of the Group as a result of an increase in rental income from approximately HK\$17.2 million for the year ended 31 December 2024 to approximately HK\$19.2 million for the year ended 31 December 2025;
- (ii) the interest income increased from approximately HK\$22.0 million for the year ended 31 December 2024 to approximately HK\$29.3 million for the year ended 31 December 2025;
- (iii) gains on partial and deemed disposal of investment in a joint venture of approximately HK\$8.3 million; and
- (iv) a decrease in impairment loss of assets of approximately HK\$19.4 million.

Such increase was partially offset by an unfavourable financial impact arising from movements of fair value changes on investments at FVTPL, which changed from a fair value gain on investments at FVTPL of approximately HK\$20.2 million for the year ended 31 December 2024 to a fair value loss on investments at FVTPL of approximately HK\$12.8 million for the year ended 31 December 2025, and decrease in fair value gains on investment properties of approximately HK\$2.1 million.

# MANAGEMENT DISCUSSION AND ANALYSIS

## BUSINESS REVIEW

### Healthcare-related Business

The revenue derived from the healthcare-related business for the year ended 31 December 2025 was approximately HK\$16.1 million, representing a decrease of approximately 17.9% as compared to approximately HK\$19.6 million for the year ended 31 December 2024. The loss derived from this segment for the year ended 31 December 2025 was approximately HK\$4.2 million, representing a decrease of approximately 78.2% as compared to approximately HK\$19.3 million for the year ended 31 December 2024. Such decrease was mainly due to (i) a favourable financial impact arising from movements of loss allowance for trade and other receivables, which changed from an impairment loss of approximately HK\$1.6 million for the year ended 31 December 2024 to reversal of impairment loss of approximately HK\$2.5 million for the year ended 31 December 2025, and (ii) no impairment loss of goodwill recorded for the year ended 31 December 2025, as compared to a significant decrease in the impairment loss of goodwill approximately HK\$18.5 million for the year ended 31 December 2024. Such changes were partially offset by a decrease in gross profit of approximately HK\$7.7 million, primarily resulting from a decrease in the Healthcare management service income and aesthetic medical service income.

### Trading Business

The revenue derived from the trading business for the year ended 31 December 2025 was approximately HK\$1.2 million, representing a decrease of approximately 91.3% as compared to approximately HK\$13.8 million for the year ended 31 December 2024. The result for this segment changed from a profit of approximately HK\$7.2 million for the year ended 31 December 2024 to a loss of approximately HK\$4.3 million for the year ended 31 December 2025. Such change was mainly due to an unfavourable financial impact arising from movements of loss allowance for trade and other receivables, which changed from a reversal of impairment loss of approximately HK\$6.7 million for the year ended 31 December 2024 to an impairment loss of approximately HK\$4.0 million for the year ended 31 December 2025.

### Property-related Business

The revenue derived from the property-related business for the year ended 31 December 2025 was approximately HK\$19.2 million, representing an increase of approximately 11.6% as compared to approximately HK\$17.2 million for the year ended 31 December 2024.

The profit derived from this segment for the year ended 31 December 2025 was approximately HK\$31.8 million, representing a decrease of approximately 19.7% as compared to approximately HK\$39.6 million for the year ended 31 December 2024, which was mainly due to (i) a decrease in other income and gains, net of approximately HK\$6.3 million mainly resulting from a decrease in compensation from construction contract; and (ii) a decrease in fair value gains on investment properties of HK\$2.1 million.

The Group has a 100% interest in a residential development project located at Lot A & B, 626 Heidelberg Road, Alphington, VIC, 3078, Australia. The project covers a total site area of approximately 11,488 sq.m.. Advantageously located just 6.5 kilometres from Melbourne's central business district, the site provides a gross floor area of approximately 18,752 sq.m. to be developed into 109 residential units of townhouses.

As at 31 December 2025, the project was still in progress. As at the date of this Annual Report, the project's civil works have already been completed. The pre-sale of part of the project commenced in November 2022, which is expected to rapidly realise the value of the land reserve, deliver business growth for the Group and boost the Group's brand value.

# MANAGEMENT DISCUSSION AND ANALYSIS

## Equity Investment Business

The result for this segment changed from a gain of approximately HK\$15.6 million for the year ended 31 December 2024 to a loss of approximately HK\$9.7 million for the year ended 31 December 2025. Such change was mainly due to an unfavourable financial impact arising from movements of fair value changes on investments at FVTPL, which changed from a fair value gain on investments at FVTPL of approximately HK\$20.2 million for the year ended 31 December 2024 to a fair value loss on investments at FVTPL of approximately HK\$12.8 million for the year ended 31 December 2025. Such changes were partially offset by gains on partial and deemed disposal of investment in a joint venture of approximately HK\$8.2 million.

## REVIEW OF FINANCIAL POSITION

	2025 HK\$'000	2024 HK\$'000
<b>Non-current Assets</b>		
Investment properties	663,388	610,292
Investments at FVTPL	35,970	47,023
Investments in a joint venture	46,407	49,889
Investments in associates	4,011	4,907
Prepayments, loans and other receivables	6,785	226,571
Equity investments at FVTOCI	8,499	6,122
Others	34,759	35,552
<b>Total Non-current Assets</b>	<b>799,819</b>	980,356
<b>Current Assets</b>		
Bank and cash balances	13,079	29,944
Properties held for sale under development	373,072	255,086
Prepayments, loans and other receivables	605,198	367,612
Trade receivables	16,099	27,241
Restricted bank deposit	7,105	6,550
Others	1,214	1,862
<b>Total Current Assets</b>	<b>1,015,767</b>	688,295
<b>Total Assets</b>	<b>1,815,586</b>	1,668,651
<b>Liabilities</b>		
Bank borrowings	380,395	301,821
Deferred tax liabilities	96,484	89,494
Accruals and other payables	41,217	36,555
Contract liabilities	33,362	21,838
Others	15,885	17,579
<b>Total Liabilities</b>	<b>567,343</b>	467,287
<b>Net Assets</b>	<b>1,248,243</b>	1,201,364

# MANAGEMENT DISCUSSION AND ANALYSIS

Non-current assets of the Group as at 31 December 2025 were approximately HK\$799.8 million (2024: approximately HK\$980.4 million), representing a decrease of approximately HK\$180.6 million, which was mainly due to (i) a decrease in prepayments, loans and other receivables of approximately HK\$219.8 million; (ii) a decrease in investment in joint ventures of approximately HK\$3.5 million; and (iii) a decrease in equity investments at FVTPL of approximately HK\$11.0 million. Such decreases were partially offset by an increase in investment properties of approximately HK\$53.1 million.

Current assets were approximately HK\$1,015.8 million (2024: approximately HK\$688.3 million), representing an increase of approximately HK\$327.5 million, which was mainly due to (i) an increase in land held for development of approximately HK\$118.0 million, and (ii) an increase in prepayments, loans and other receivables of approximately HK\$237.6 million. Such increases were partially offset by (i) a decrease in bank and cash balances of approximately HK\$16.8 million and (ii) a decrease in trade receivables of approximately HK\$11.1 million.

As at 31 December 2025, the Group's total liabilities were approximately HK\$567.3 million (2024: approximately HK\$467.3 million), representing an increase of approximately HK\$100.0 million mainly due to (i) an increase in contract liabilities of approximately HK\$11.6 million; (ii) an increase in deferred tax liabilities of approximately HK\$7 million; (iii) an increase in other payables and accrued expenses of approximately HK\$4.6 million; and (iv) an increase in bank borrowings of approximately HK\$78.6 million as compared to the year ended 31 December 2024.

## NET ASSET VALUE

As at 31 December 2025, the Group's total net assets amounted to approximately HK\$1,248.3 million (2024: approximately HK\$1,201.4 million), representing an increase of approximately HK\$46.8 million, mainly due to (i) the exchange gains arising from the translation of foreign operations of approximately HK\$45.5 million and (ii) the profit recorded for the year ended 31 December 2025 of approximately HK\$38.0 million. Such increases were partially offset by (i) the payment of dividend of approximately HK\$22.5 million during the year ended 31 December 2025; (ii) the fair value losses of equity investments at FVTOCI, net of HK\$5.8 million; and (iii) the repurchases of shares of approximately HK\$8.9 million.

## LIQUIDITY AND FINANCIAL RESOURCES

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
Net cash (used in)/generated from operating activities	<b>(50,019)</b>	185,996
Net cash generated from/(used in) investing activities	<b>14,636</b>	(253,977)
Net cash generated from/(used in) financing activities	<b>18,072</b>	(6,390)
Net decrease in cash and cash equivalents	<b>(17,311)</b>	(74,371)
Effect of foreign exchange rate changes	<b>446</b>	(1,994)
Cash and cash equivalents as at 1 January	<b>29,944</b>	106,309
Cash and cash equivalents as at 31 December	<b>13,079</b>	29,944

As at 31 December 2025, the total cash and cash equivalents of the Group were approximately HK\$13.1 million (2024: approximately HK\$29.9 million), of which approximately 49.4% was denominated in HKD, approximately 39.1% was denominated in RMB, approximately 10.3% was denominated in AUD, approximately 0.6% was denominated in CHF, approximately 0.4% was denominated in EUR and approximately 0.2% was denominated in USD (2024: approximately 85.2% was denominated in AUD, approximately 7.9% was denominated in RMB, approximately 4.8% was denominated in HKD, approximately 1.4% was denominated in EUR, approximately 0.6% was denominated in CHF and approximately 0.1% was denominated in USD).

## MANAGEMENT DISCUSSION AND ANALYSIS

Net cash used in operating activities for the year ended 31 December 2025 was approximately HK\$50 million, which was mainly the net cash used in the Group's daily operation during the year ended 31 December 2025.

Net cash generated from investing activities was approximately HK\$14.6 million, which was mainly attributable to (i) the receipt of repayment of short-term interest-bearing loans advanced to certain independent third parties of approximately HK\$65.2 million; (ii) the receipt of repayment of interest bearing revolving loan advanced to a related party of approximately HK\$13.8 million; (iii) proceeds received from partial disposal of investment in a joint venture of HK\$9.9 million; (iv) proceeds received from sales of investment properties of approximately HK\$3.7 million and (v) the deposit received from disposal of investment properties of HK\$6.9 million. Such increase was partially offset by the short-term interest-bearing loans advanced to certain independent third parties of approximately HK\$84.7 million.

Net cash generated from financing activities was approximately HK\$18.1 million, which mainly represented a net amount of (i) proceeds received from new bank borrowings of approximately HK\$137.0 million; (ii) repayment of bank borrowings of approximately HK\$77.9 million; (iii) payment of loan interest of approximately HK\$9.2 million; (iv) repurchase of shares of approximately HK\$8.9 million; and (v) payment of dividend of approximately HK\$22.5 million.

As at 31 December 2025, the total bank borrowings of the Group were approximately HK\$380.4 million (2024: approximately HK\$301.8 million), which are mainly used as working capital of the Group. The Group had no unutilised banking facilities as at 31 December 2025 and 2024.

The following table illustrates the composition of the Group's bank borrowings:

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
Floating rate RMB bank loan	<b>57,663</b>	74,834
Floating rate AUD bank loan	<b>185,133</b>	90,123
Fixed rate RMB bank loan	<b>137,599</b>	136,864
	<b>380,395</b>	301,821

The following table illustrates the maturity profile of the Group's bank borrowings:

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
Within one year	<b>271,317</b>	83,176
In the second year	<b>33,429</b>	120,969
In the third to fifth years, inclusive	<b>51,281</b>	66,983
Beyond five years	<b>24,368</b>	30,693
	<b>380,395</b>	301,821

Based on the Group's steady cash flow, coupled with sufficient bank and cash balances, the Group has adequate liquidity and financial resources to meet its future capital expenditures, daily operations and working capital requirements in the next financial year.

# MANAGEMENT DISCUSSION AND ANALYSIS

## CAPITAL STRUCTURE OF THE GROUP

The capital structure of the Group consists equity attributable to owners of the Company (i.e. issued share capital and reserves).

## TREASURY POLICIES

The Group has adopted a prudent financial management approach towards its treasury policies and thus maintained a healthy liquidity position throughout the year ended 31 December 2025. The Group strives to reduce exposure to credit risk by performing ongoing credit assessments and evaluations of the financial status of its customers. To manage liquidity risk, the Board closely monitors the Group's liquidity position to ensure that the liquidity structure of the Group's assets, liabilities and other commitments can meet its funding requirements from time to time.

## GEARING RATIO

The Group's gearing ratio, expressed as the percentage of net debt (includes bank borrowings, trade payables, contract liabilities, accruals and other payables and amounts due to related parties, less bank and cash balances and restricted bank deposit) over the sum of equity attributable to owners of the Company and net debt, was approximately 26.4% (2024: approximately 21.6%).

As at 31 December 2025, the Group had a net debt of approximately HK\$447.1 million (2024: approximately HK\$331.1 million), while the equity attributable to owners of the Company amounted to approximately HK\$1,248.5 million (2024: approximately HK\$1,201.6 million).

## CAPITAL EXPENDITURE

During the year ended 31 December 2025, the expenditure on purchasing property, plant and equipment amounted to approximately HK\$583,000 (2024: approximately HK\$132,000).

## CAPITAL COMMITMENTS

As at 31 December 2025, the Group had capital commitments of approximately HK\$22.9 million (2024: approximately HK\$96.2 million) in respect of capital contribution payable to associates and construction costs commitments for properties held for sale under development, which are contracted but not provided for in the consolidated financial statements.

## CHARGES ON GROUP ASSETS

The following table sets forth the net book value of assets under pledges for certain banking facilities as at the dates indicated:

	31 December	
	2025 HK\$'000	2024 HK\$'000
Investment properties	500,743	452,969
Properties held for sale under development	197,266	181,850
Restricted bank deposit	7,105	6,550
	<b>705,114</b>	641,369

# MANAGEMENT DISCUSSION AND ANALYSIS

## CONTINGENT LIABILITIES

As at 31 December 2025 and 2024, the Group did not have any significant contingent liabilities.

## GENERAL DESCRIPTION OF THE GROUP'S INVESTMENT STRATEGIES

The Group continues to believe in the substantial potential of the healthcare industry. The Group adheres to the corporate vision of "using technology and expertise to serve more people's health and beauty needs". Therefore, the Group manages its investment portfolio with an objective to capture market opportunities in the healthcare industry.

On the other hand, the Group allocates certain resources to various investments in order to maximise the return.

## MATERIAL ACQUISITIONS AND DISPOSALS

Save as disclosed in this Annual Report, there was no material acquisition or disposal of subsidiaries, associates and joint ventures during the year ended 31 December 2025.

## MATERIAL LENDING TRANSACTIONS

### **Business model and credit risk assessment policy**

In order to increase the rate of return of the Group's cash and cash equivalents which can improve the investment income and the profits of the Group, the Group provided short-term interest-bearing loans and long-term interest-bearing revolving facility to its customers and a related party.

Through the business and social networks of the management of the Company, the Group identifies potential customers, which are corporate customers and individual customers. The Group has established strict credit risk management and internal control procedures to regulate its lending transactions and only provides loans to customers with good credit standing and satisfactory results of operation as well as those in need of short-term financing. The credit risk management and internal control procedures mainly consist of the following stages, namely (i) due diligence and credit risk assessment of customers; (ii) assessment and approval processes; and (iii) post-loan monitoring and loan recovery:

### **(i) Due Diligence and Credit Risk Assessment of Customers**

The Corporate Treasury Department assesses the background and reputation of any new customers by taking into account the new customer's financial condition, the purpose of borrowing, ultimate beneficial owners' and shareholders' background and business reputation, etc. The Corporate Treasury Department also conducts due diligence, credit verification and repayment ability assessment on new customers. The Corporate Treasury Department researches and analyses customers' background information, including but not limited to their operating history, shareholders, ultimate beneficial owners, financial information, income proofs, bank statements, tax returns, independent professional credit reports, operational risks, legal risks, online media investigation reports, industry reports, etc.

# MANAGEMENT DISCUSSION AND ANALYSIS

## **(ii) Assessment and Approval Processes**

The Corporate Treasury Department would perform credit assessment and review of the loan applications as well as determine the loan terms (having taken into consideration factors such as the credit risks of the customers, their recoverability, the financing cost of the Group and the prevailing market interest rates, etc). The financial controller of the Group would review the relevant assessment reports and loan terms, and then report to Ms. Zhou Wen Chuan, our Chief Executive Officer and Executive Director. Ms. Zhou Wen Chuan will be responsible for the approval of loans in relatively small amounts.

If the potential loans are of larger amounts (i.e. by assessment of size tests under Chapter 14 of the Listing Rules, may constitute a disclosable transaction or above), in which case, such potential loans will be reported by Ms. Zhou Wen Chuan and she will elaborate to the Board such potential loans in contemplation and her recommendations therewith for discussion and approval, the Directors (including the Independent Non-Executive Directors) will then consider whether such loans are on normal commercial terms, fair and reasonable and in the interests of the Company and its shareholders as a whole. The requirements of reporting, announcement, circular and shareholders' approval under Chapter 14 of the Listing Rules will then be fulfilled (if applicable).

Moreover, for any potential loans which may involve connected person(s) as defined under Chapter 14A of the Listing Rules, such loans will be reported to the Board immediately for assessment with respect to size tests and assessments by the Board as elaborated above. The requirements of reporting, announcement, circular, independent financial advice and independent shareholders' approval under Chapter 14A of the Listing Rules will then be fulfilled (if applicable).

## **(iii) Post-loan Monitoring and Loan Recovery**

The Corporate Treasury Department would conduct regular review and carry out follow-up actions (on a monthly and continuing basis) in respect of overdue amounts to minimise the Group's exposure to credit risk and follow up closely with its customers as to the deadlines for payment of interest on the loans. Ageing analysis of the debtors is prepared on a monthly basis and is closely monitored to minimise any credit risk associated with these debtors. The Corporate Treasury Department will report the status of the loan portfolio to Ms. Zhou Wen Chuan on a monthly basis, such that Ms. Zhou Wen Chuan may closely monitor the loan portfolio to oversee the credit risk. Ms. Zhou Wen Chuan would report to the Board and discuss actions to be taken in case of any abnormal situations.

The Corporate Treasury Department has standard procedures for dealing with default in payment. In case there are any minor defaults, the Corporate Treasury Department will send reminder and/or demand letters to its customers. In case the default on loans persists, the collection procedure will commence and the Corporate Treasury Department will engage lawyers in advising on the recovery of the loan, and take appropriate enforcement action for overdue loans.

# MANAGEMENT DISCUSSION AND ANALYSIS

## Major terms of loan receivables

Details of outstanding loan receivables as at 31 December 2025 are as follows:

Customers	Maturity date	Security pledged or guarantee obtained	Interest rate per annum	As at 31 December 2025	
				Carrying amount HK\$'000	Approximate percentage of total outstanding loan receivables
U-light Energy	On or before 31 December 2026 (Note 1)	Personal guarantee from Mr. Zhou Xuzhou	one-year LPR plus 3.05%	221,780	45.1%
<i>Other Borrowers (Note 2)</i>					
Borrower A	On or before 30 June 2026	Nil	3.0%	11,089	2.3%
Borrower B	On or before 30 June 2026	Nil	6.0%	39,920	8.1%
Borrower C	On or before 31 December 2026	Nil	4.5%	37,703	7.7%
Borrower D	On or before 31 May 2026	Nil	8.0%	11,089	2.3%
Borrower E	On or before 30 June 2026	Nil	8.0%	11,089	2.3%
Borrower F	On or before 30 June 2026	Nil	8.0%	16,634	3.3%
Borrower G	On or before 30 June 2026	Nil	6.0%	44,356	9.0%
Borrower H	On or before 30 June 2026	Nil	8.0%	11,089	2.3%
Borrower I	On or before 30 March 2026	Nil	5.0%	44,356	9.0%
Borrower J	On or before 03 November 2026	Nil	5.3%	42,138	8.6%
				269,463	54.9%
				491,243	100%

Notes:

- On 27 November 2023, the Company and U-light Energy entered into the Facility Agreement, pursuant to which the Company agreed, by itself or through its designated lending subsidiary(ies), to grant to U-light Energy a revolving loan facility up to a maximum of RMB200,000,000 at an interest rate of one-year LPR plus 3.05% per annum for the Drawdown Period. On the same date, Mr. Zhou Xuzhou (as guarantor) executed a deed of guarantee to provide the personal guarantee in favour of the Company to secure U-light Energy's repayment obligations under the Facility Agreement. The transaction has been approved by the shareholders of the Company at the 2024 SGM held on 31 January 2024. Further details are set out in the announcement of the Company dated 27 November 2023 and the circular of the Company dated 17 January 2024.

# MANAGEMENT DISCUSSION AND ANALYSIS

2. As at 31 December 2025, the total outstanding loan receivables was HK\$269,463,000 from the 10 borrowers. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of the above borrowers was independent of and not connected with each other when entering into the above transactions.

## Impairment and write-off of loan receivables

The Group has recognised a loss allowance of approximately HK\$1,196,000 for the year ended 31 December 2025 (2024: HK\$1,104,000), which was arrived at on the basis of a valuation carried out by Roma Appraisals Limited, an independent professional valuer. The loss allowance was determined by using expected credit losses defined in Hong Kong Financial Reporting Standard – probability of default method. There was no write-off for loan receivables for the year ended 31 December 2025 (2024: Nil).

## SIGNIFICANT INVESTMENTS HELD

As at 31 December 2025, the investment portfolio of the Group amounted to approximately HK\$95.2 million (2024: approximately HK\$108.1 million) as recorded in the consolidated statement of financial position under various categories, including:

- investments in associates and a joint venture, which are accounted for by using the equity method;
- equity investments at FVTOCI;
- investments at FVTPL; and
- derivative financial assets.

There was no single investment in the Group's investment portfolio that was considered a significant investment, given that none of the investments had a carrying amount accounting for more than 5% of the Group's audited total assets as at 31 December 2025.

## FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Save as disclosed in the section "Capital Commitments" above, there were no other future plans authorised by the Board for material investments or acquisitions of capital assets as at 31 December 2025.

The Group will finance the future acquisitions through internally generated funds and other funding activities, including but not limited to bank borrowing.

## EXPOSURE TO FLUCTUATIONS IN EXCHANGE RATES AND RELATED HEDGE

The revenue, expenses and monetary assets and liabilities of the Group are mainly denominated in RMB, HKD, EUR, CHF and AUD.

The Group did not enter into any foreign currency forward contract during the year ended 31 December 2025. As at 31 December 2025 and 2024, the Group did not have any unrealised gain or loss in respect of the foreign currency forward contracts.

# MANAGEMENT DISCUSSION AND ANALYSIS

## EMPLOYEES AND REMUNERATION POLICIES

As at 31 December 2025, the Group had approximately 42 employees (2024: 46 employees). Staff costs (including Directors' emoluments) charged to profit or loss amounted to approximately HK\$12.5 million (2024: approximately HK\$13.7 million) for the year ended 31 December 2025.

The Group's remuneration policies are in line with prevailing market practices and formulated on the basis of the performance and experience of individual employees (including Directors). Apart from base salaries, other staff benefits included pension and medical schemes. The remuneration policies and remuneration packages of the Directors and members of the senior management of the Group are reviewed by the Remuneration Committee.

The Company adopted the 2019 Share Option Scheme pursuant to which eligible persons may be granted options to subscribe for the shares of the Company.

The Company believes that the ability to recruit and retain experienced and skilled labour is crucial to the Group's growth and development. The Group provides training to its new employees to familiarise them with the working environment and work culture. The Group also provides on-the-job training to the employees, which aims at developing their skills so as to meet the strategic goals and customer requirements. In addition to providing the Group's staff with the opportunities to receive on-the-job trainings, the Group strives to create a harmonious and warm working and living environment for the staff.



# DIRECTORS' REPORT

The Board is pleased to present this Annual Report together with the audited consolidated financial statements of the Group for the year ended 31 December 2025.

## **PRINCIPAL ACTIVITIES**

The Company acts as an investment holding company. Details of the principal activities of the principal subsidiaries are set out in note 22 to the consolidated financial statements.

## **BUSINESS REVIEW**

The business review and performance analysis of the Group for the year ended 31 December 2025 and a discussion on the Group's future business development are set out in the sections headed "Co-Chairman's Statement" and "Management Discussion and Analysis" on pages 3 to 8 and 9 to 20 in this Annual Report, respectively.

## **Key Risks and Uncertainties**

The Group's results and operations are subject to various factors, with the key risks summarised below:

### ***Macroeconomic Changes***

The Group's business is sensitive to the general economic conditions and other factors like consumer credit.

### ***Legal, Regulatory and Compliance Risks***

Changes in government policies, relevant regulations and guidelines established by the regulatory authorities would have an impact on the business operation of the Group. Failure to comply with the rules and requirements may lead to penalties or suspension of the business operation by the authorities.

### ***Reputation and Performance Risks***

The Group's business is dependent on the reputation and quality of its products and services, and the Group may lose potential business if its products and quality of services are called into question.

### ***Financial Risks***

The principal financial risks are set out in note 5 to the consolidated financial statements contained in this Annual Report.

### ***Environmental Policies and Performance***

The Group realised the importance of environmental protection in pursuing long-term sustainability. The Group is committed to improving environmental sustainability and will closely monitor its performance. In accordance with Rule 13.91 and the Environmental, Social and Governance ("ESG") Reporting Guide contained in Appendix C2 to the Listing Rules, the Company's ESG Report will be available on its website and the website of the Stock Exchange at the same time of publication of this Annual Report.

# DIRECTORS' REPORT

## **Compliance with Laws and Regulations**

The Group's operations are mainly carried out by the Company's subsidiaries in the PRC, Hong Kong, Australia and Switzerland, while the Company is a holding company incorporated in Bermuda with its shares listed on the Main Board of the Stock Exchange. Accordingly, our establishments and operations shall comply with relevant laws and regulations in the PRC, Hong Kong, Australia, Switzerland and Bermuda. In 2025, our businesses were in compliance with all the relevant laws and regulations in the PRC, Hong Kong, Australia, Switzerland and Bermuda in all material aspects.

## **Relationship with Key Stakeholders**

The Group fully understands that employees, customers and partners are the keys to our sustainable and stable development. We are committed to establishing a close relationship with our employees, enhancing cooperation with our partners and providing high-quality products/services to our customers so as to ensure the Group's sustainable development.

### ***Employees***

Our staff is regarded as the most important resource of the Group. The Group endeavours to provide our staff with a range of competitive compensation packages, attractive promotion opportunities, comprehensive training courses and a professional working environment. In order to assist us in attracting, retaining and motivating our key employees, the Group has adopted the 2019 Share Option Scheme, pursuant to which share options will be granted to eligible employees. The Group provides ongoing training to our employees.

### ***Customers***

We uphold the principle of providing high-quality products/services throughout our operation, which we believe is vital to achieving customer satisfaction and maintaining our reputation.

### ***Suppliers***

We firmly believe that our suppliers are equally important in providing high-quality products/services. When selecting suppliers, we consider, among other things, their product/service offerings, pricing, reputation, product/service quality and delivery schedule. We conduct regular reviews of our suppliers and screen out any suppliers who do not meet our supply standards or requirements from our list of approved suppliers. We usually have more than one supplier for each kind of our supply so as to ensure we maintain sufficient inventory levels and bargaining power to deal with price fluctuations. We had stable business relationships with our suppliers in 2025.

## **RESULTS**

The financial performance of the Group for the year ended 31 December 2025 and the Group's financial position as at that date are set out in the consolidated financial statements on pages 71 to 170.



# DIRECTORS' REPORT

## FINAL DIVIDEND

The Directors have resolved to recommend the payment of a final dividend of HK0.4 cents per Share for the year ended 31 December 2025 (2024: HK0.4 cents).

Subject to the approval of shareholders at the 2026 AGM, the final dividend will be payable on Friday, 28 August 2026 to shareholders whose names appear on the register of members of the Company on Wednesday, 5 August 2026.

There is no arrangement under which a Shareholder has waived or agreed to waive any dividend.

## ANNUAL GENERAL MEETING

The 2026 AGM will be held at 11:00 a.m. on Friday, 26 June 2026 at Portion 2, 12/F, The Center, 99 Queen's Road Central, Central, Hong Kong and a notice of AGM will be published and dispatched in due course.

## CLOSURE OF REGISTER OF MEMBERS TO ASCERTAIN SHAREHOLDERS' ENTITLEMENT TO ATTEND AND VOTE AT THE ANNUAL GENERAL MEETING

The register of members of the Company for the 2026 AGM will be closed from Monday, 22 June 2026, to Friday, 26 June 2026, both days inclusive, during which period no transfer of shares will be registered. In order to qualify for attendance at the 2026 AGM, all transfers accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration not later than 4:30 p.m. on Thursday, 18 June 2026.

Subject to the approval of shareholders at the 2026 AGM, the proposed final dividend will be payable to shareholders whose names appear on the register of members of the Company after the close of business at 4:30 p.m. on Wednesday, 5 August 2026 and the register of members of the Company will be closed from Tuesday, 4 August 2026 to Wednesday, 5 August 2026, both days inclusive, during which no transfer of shares of the Company will be registered. In order to be entitled to the proposed final dividend, completed transfer forms accompanied by the relevant share certificates must be lodged with the Company's Hong Kong branch share registrar and transfer office, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on Monday, 3 August 2026.

## FIVE YEAR FINANCIAL SUMMARY

A summary of the results and of the assets, liabilities and non-controlling interests of the Group for the last five financial years, as extracted from the published audited consolidated financial statements and restated/reclassified as appropriate, is set out on page 171 in this Annual Report. This summary does not form part of the audited consolidated financial statements.

## SHARE CAPITAL

Details of the movements in the share capital of the Company during the year are set out in note 40 to the consolidated financial statements contained in this Annual Report.

## EQUITY-LINKED AGREEMENTS

Save as disclosed in the subsection headed "Share Option Scheme" below, no equity-linked agreements were entered into by the Group or existed during the year ended 31 December 2025.

# DIRECTORS' REPORT

## SHARE OPTION SCHEME

In order to provide incentives and rewards to the eligible employees and participants, the Company approved and adopted a share option scheme at the 2020 SGM. The 2019 Share Option Scheme became effective on 28 June 2019, being the date on which the Stock Exchange approved the listing of, and permission to deal in, the shares falling to be issued pursuant to the exercise of options under the 2019 Share Option Scheme. The 2019 Share Option Scheme is subject to the requirements under Chapter 17 of the Listing Rules.

### Summary of terms

The following is a summary of the principal terms of the 2019 Share Option Scheme. The Directors confirm that the terms of the Share Option Scheme comply with the requirements under Chapter 17 of the Listing Rules.

#### (a) Purpose

The purpose of the 2019 Share Option Scheme is to provide incentive or reward to Eligible Persons (as defined in paragraph (b) below) for their contributions or potential contributions to the Group.

#### (b) Who may join

The Board may, at its discretion, offer to grant share option (the "**Share Option(s)**") to the Eligible Participants to subscribe for such number of new Shares as the Board may determine in accordance with the terms of the 2019 Share Option Scheme. Eligible participants (the "**Eligible Participants**") include any full-time or part-time employees, executives, officers or directors (including independent non-executive directors) of the Company, any of the subsidiaries, invested entities and substantial shareholders and any advisors, consultants, agents, suppliers, customers, distributors, contractors, business partners and joint venture partners of the Company and any of the subsidiaries who, in the sole opinion of the Board, will contribute or have contributed to the Company and/or any of the subsidiaries.

#### (c) Total number of Shares available for issue

The maximum number of Shares which may be issued upon exercise of all Share Options to be granted under the 2019 Share Option Scheme and under any other schemes of the Company must not in aggregate exceed 10% of the total number of Shares in issue as at the date of the passing of the resolution for the adoption of the 2019 Share Option Scheme (i.e. 427,175,263 Shares, representing 10% and approximately 10.4% of the total number of Shares in issue as at the date of passing the aforesaid resolution and the date of this Annual Report (in each case, excluding treasury shares), respectively). Subject to the issue of a circular by the Company and the approval of the Shareholders in general meeting and/or such other requirements prescribed under the Listing Rules from time to time, the Board may:

- (i) renew this limit at any time to 10% of the Shares in issue as at the date of the approval by the Shareholders in general meeting; and/or
- (ii) grant options beyond the 10% limit to Eligible Participants specifically identified by the Board.

The maximum number of Shares which may be issued upon exercise of all outstanding options granted and yet to be exercised under the 2019 Share Option Scheme and the other schemes of the Company at any time shall not exceed 30% of the Shares in issue (excluding treasury shares) from time to time. No options shall be granted under any schemes of the Company (including the 2019 Share Option Scheme) if this will result in the aforesaid 30% limit being exceeded.

**(d) Maximum number of options to any one individual**

The total number of Shares issued and may fall to be issued upon exercise of the Share Options granted under the 2019 Share Option Scheme and any other share option schemes of the Company (including both exercised and outstanding options) to each Eligible Participant in any 12-month period up to and including the date of grant shall not exceed 1% of the Shares in issue as at the date of grant. If the Board determines to offer Share Options to an Eligible Participant which would result in the Shares issued and to be issued upon exercise of all Share Options granted and to be granted to that Eligible Participant (including exercised, cancelled and outstanding Share Options) in the 12-month period up to and including the date of such grant exceeding this 1% limit, such grant shall be subject to (i) the issue of a circular by the Company to its Shareholders which shall comply with the relevant Listing Rules and/or such other requirements as prescribed under the Listing Rules from time to time; and (ii) the approval of the Shareholders in GM at which that Eligible Participant and his close associates (as defined in the Listing Rules) (or his associates if the Eligible Participant is a connected person (as defined in the Listing Rules)) shall abstain from voting.

**(e) Exercise Price**

The exercise price in relation to each Share Option offered to an Eligible Participant shall be such price as the Board in its absolute discretion shall determine, save that such price must be at least the higher of:

- (i) the official closing price of the Shares as stated in the daily quotation sheets of the Stock Exchange on the date of the grant, which must be a day on which the Stock Exchange is open for the business of dealing in securities;
- (ii) the average of the official closing price of the Shares as stated in the daily quotation sheets of the Stock Exchange for the 5 business days immediately preceding the date of grant; and
- (iii) the nominal value of a Share.

**(f) Time of exercise of share option**

Subject to the provisions of the Listing Rules and other applicable laws and regulations, the Board may in its absolute discretion when offering the grant of a Share Option impose any conditions, restrictions or limitations in relation thereto in addition to those set forth in the 2019 Share Option Scheme as the Board may think fit (to be stated in the offer letter) including (without prejudice to the generality of the foregoing) qualifying and/or continuing eligibility criteria, conditions, restrictions or limitations relating to the achievement of performance, operating or financial targets by the Company and/or the grantee, the satisfactory performance or maintenance by the grantee of certain conditions or obligations or the time or period before the right to exercise the Share Option in respect of all or any of the Shares shall vest provided that such terms or conditions shall not be inconsistent with any other terms or conditions of the 2019 Share Option Scheme. For the avoidance of doubt, subject to such terms and conditions as the Board may determine as aforesaid (including such terms and conditions in relation to their vesting, exercise or otherwise) there is no minimum period for which a Share Option must be held before it can be exercised and no performance target which need to be achieved by the grantee before the option can be exercised.

The period during which a Share Option may be exercised will be determined by the Board in its absolute discretion, save that no Option may be exercised more than 10 years after it has been granted and accepted. No Share Option may be granted more than 10 years after the date of approval of the 2019 Share Option Scheme. Subject to earlier termination by the Company in GM or by the Board, the 2019 Share Option Scheme shall be valid and effective for a period of 10 years from the date of its adoption.

# DIRECTORS' REPORT

## (g) Acceptance of Share Options

A Share Option shall be deemed to have been granted and accepted by the grantee and to have taken effect when the duplicate offer document constituting acceptance of the Share Option duly signed by the grantee, together with a remittance in favour of the Company of HK\$1.00 (or such other sum in any currency as the Board may determine) by way of consideration for the grant thereof is received by the Company on or before the relevant acceptance date. Such remittance shall in no circumstances be refundable.

The following table discloses movements in the Share Options held by each of the Directors, the employees of the Company, and other eligible participants in aggregate granted under the 2019 Share Option Scheme during the year ended 31 December 2025:

Category of participants	Date of grant (Note 1)	Exercise period	Exercise price HK\$	Number of Share Options					Outstanding as at 31.12.2025	Closing price per Share immediately before the date of grant HK\$
				Outstanding as at 1.1.2025	Granted during the year	Exercised during the year	Lapsed during the year	Cancelled during the year		
<b>(a) DIRECTORS</b>										
Dr. Zeng Wentao	12.5.2020 (Note 2)	12.5.2021 – 11.5.2030 (Note 4)	0.33	2,500,500	-	-	-	-	2,500,500	0.32
Ms. Zhou Wen Chuan	24.6.2020 (Note 3)	24.6.2021 – 23.6.2030 (Note 5)	0.33	4,500,000	-	-	-	-	4,500,000	0.345
<b>Total for Directors</b>				<b>7,000,500</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>7,000,500</b>	
<b>(b) EMPLOYEES</b>										
In aggregate	12.5.2020 (Note 2)	12.5.2021 – 11.5.2030 (Note 4)	0.33	501,000	-	-	-	-	501,000	0.32
	12.5.2020 (Note 2)	12.5.2022 – 11.5.2030 (Note 6)	0.33	501,000	-	-	(501,000)	-	-	0.32
	12.5.2020 (Note 2)	12.5.2021 – 11.5.2030 (Note 7)	0.33	5,418,000	-	-	(2,208,000)	-	3,210,000	0.32
	12.5.2020 (Note 2)	12.5.2020 – 11.5.2030 (Note 9)	0.33	996,000	-	-	(996,000)	-	-	0.32
<b>Total for Employees</b>				<b>7,416,000</b>	<b>-</b>	<b>-</b>	<b>(3,705,000)</b>	<b>-</b>	<b>3,711,000</b>	
<b>(c) OTHERS (Note 10)</b>										
In aggregate	12.5.2020 (Note 2)	12.5.2021 – 11.5.2030 (Note 4)	0.33	750,000	-	-	-	-	750,000	0.32
	12.5.2020 (Note 2)	12.5.2022 – 11.5.2030 (Note 8)	0.33	504,000	-	-	-	-	504,000	0.32
	12.5.2020 (Note 2)	N/A (Note 9)	0.33	5,004,000	-	-	-	-	5,004,000	0.32
<b>Total for Others</b>				<b>6,258,000</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>6,258,000</b>	
<b>Total for the 2019 Share Option Scheme</b>				<b>20,674,500</b>	<b>-</b>	<b>-</b>	<b>(3,705,000)</b>	<b>-</b>	<b>16,969,500</b>	

Notes:

- The vesting period of the Share Options is from the date of grant until the commencement of the exercise period.
- On 12 May 2020, the Company granted 61,248,000 Share Options to certain eligible participants pursuant to the 2019 Share Option Scheme. Further details are set out in the announcement of the Company dated 12 May 2020 and the circular of the Company dated 3 June 2020.
- On 12 May 2020, the Company proposed to grant 18,000,000 Share Options to Ms. Zhou Wen Chuan pursuant to the 2019 Share Option Scheme. At the 2020 SGM, the resolution in respect of approving the proposed grant of Share Options to Ms. Zhou Wen Chuan was duly passed by the independent shareholders of the Company by way of poll. Further details are set out in the announcements of the Company dated 12 May 2020 and 24 June 2020 and the circular of the Company dated 3 June 2020.

# DIRECTORS' REPORT

4. Subject to the fulfilment of certain annual performance targets as determined by the Board, the Share Options granted shall be vested during the relevant periods in 4 tranches: (i) 25% of which shall be vested after 12 months of the Date of Acceptance; (ii) another 25% of which shall be vested after 24 months of the Date of Acceptance; (iii) another 25% of which shall be vested after 36 months of the Date of Acceptance; and (iv) the remaining 25% of which shall be vested after 48 months of the Date of Acceptance.
5. Subject to the fulfilment of certain annual performance targets as determined by the Board, the Share Options granted shall be vested during the relevant periods in 4 tranches: (i) 25% of which shall be vested after 12 months of the date of 2020 SGM; (ii) another 25% of which shall be vested after 24 months of the date of 2020 SGM; (iii) another 25% of which shall be vested after 36 months of the date of 2020 SGM; and (iv) the remaining 25% of which shall be vested after 48 months of the date of 2020 SGM.
6. Subject to the fulfilment of certain annual performance targets as determined by the Board, the Share Options granted shall be vested during the relevant periods in 4 tranches: (i) 25% of which shall be vested after 24 months of the Date of Acceptance; (ii) another 25% of which shall be vested after 36 months of the Date of Acceptance; (iii) another 25% of which shall be vested after 48 months of the Date of Acceptance; and (iv) the remaining 25% of which shall be vested after 60 months of the Date of Acceptance.
7. The Share Options granted shall be vested during the relevant periods in 4 tranches: (i) 25% of which shall be vested after 12 months of the Date of Acceptance; (ii) another 25% of which shall be vested after 24 months of the Date of Acceptance; (iii) another 25% of which shall be vested after 36 months of the Date of Acceptance; and (iv) the remaining 25% of which shall be vested after 48 months of the Date of Acceptance.
8. The Share Options granted shall be vested during the relevant periods in 4 tranches: (i) 25% of which shall be vested after 24 months of the Date of Acceptance; (ii) another 25% of which shall be vested after 36 months of the Date of Acceptance; (iii) another 25% of which shall be vested after 48 months of the Date of Acceptance; and (iv) the remaining 25% of which shall be vested after 60 months of the Date of Acceptance.
9. The Share Options granted shall be vested immediately upon the fulfilment of certain vesting conditions, including the achievement of certain R&D milestones for certain pharmaceutical products, completion of designated tasks and satisfactory business performance of the relevant entities (subject to the Board's opinion). The Share Options are exercisable the date on which the Share Options are vested, which is 11 May 2030.
10. As at 31 December 2025, there were a total of 6,258,000 outstanding Share Options granted to 2 grantees, who are non-employees of the Group, pursuant to the 2019 Share Option Scheme. The 2 grantees can be divided into two categories. Details of the number of the Share Options granted to each category of grantees and the Board's reasons for granting the Share Options to each category of grantees are as follows:

**(i) Director of invested entity**

As at 31 December 2025, there were a total of 5,754,000 outstanding Share Options granted to Ms. Jiang Shu (姜舒), a director of an invested entity of the Group, namely Wingor Bio, who is a PRC national and oversees the operations of Wingor Bio.

To the best of the knowledge, information and belief of the Directors, Ms. Jiang Shu (姜舒) is a third party independent of the Company and its connected persons.

The Group has invested in Wingor Bio since February 2019. The size of the investment in Wingor Bio as calculated by the carrying amount of investment in Wingor Bio as at 31 December 2025, which is HK\$46,407,000, divided by the Group's total assets as at 31 December 2025, which is HK\$1,815,586,000, is approximately 2.56%, which the Board considers to be significant. In addition, the Group has a 27.51% stake in Wingor Bio as at 31 December 2025, and hence, the business performance of Wingor Bio could have a significant impact on the business performance of the Group. Wingor Bio is engaged in the R&D of stem cell products and the provision of health management consulting and medical treatment services. The Group and Wingor Bio may explore cross-selling opportunities, which would generate synergy for both parties. As such, the Company considers Wingor Bio to be an important investment with significant strategic value.

Wingor Bio is accounted for in the Company's accounts using the equity method of accounting.

# DIRECTORS' REPORT

Given the importance of Wingor Bio to the Group and the key roles and responsibilities performed by the grantee in Wingor Bio, the Board considers that it is desirable to grant Share Options to the grantee to incentivise her to improve her performance efficiency and align her interests with those of the Group.

All of the Share Options granted to Ms. Jiang Shu (姜舒) is subject to the satisfaction of certain performance targets of Wingor Bio, including annual performance targets for the years ending 31 December 2020, 2022 and 2023 of Wingor Bio and the achievement of certain R&D milestones for certain pharmaceutical products developed by Wingor Bio. Such pharmaceutical products are stem cell products, and the successful R&D and commercialisation of these products mark a significant breakthrough in the stem cell field. Ms. Jiang Shu (姜舒) could significantly improve the financial performance of Wingor Bio, thereby improving the financial performance of the Group. These performance targets tie the performance of the invested entity with the benefits to be received by the director thereby motivating her to improve the performance of the invested entity.

## (ii) Management consultant

As at 31 December 2025, there were a total of outstanding 504,000 Share Options granted to a management consultant of the Group, namely Mr. Jin Lei (金磊), who provides management consultancy services to the Group by the Board. Mr. Jin Lei (金磊) is a PRC national who lives in China.

Prior to his engagement as a management consultant by the Group, he worked as an employee of the invested entity. During such time, he was responsible for project procurement, business development, management of working teams and assisting the Chief Executive Officer in the accomplishment of strategic plans of the Company.

To the best of the knowledge, information and belief of the Directors, Mr. Jin Lei (金磊) is a third party independent of the Company and its connected persons.

Mr. Jin Lei (金磊) has expertise and skills in respect of the business operations of the Group, including strategic planning, financial management and control, financing, marketing, team management, internal coordination, and government relations. He has played an important role in enabling the Group to achieve smooth operations. The Board considers that it is desirable to grant Share Options to him as incentives to retain him and to motivate him to improve his performance for the benefit of the Group and to align his interests with that of the Group.

No performance target is set for Mr. Jin Lei (金磊). As Mr. Jin Lei (金磊) is responsible for overseeing certain aspects of the business operations of the Group, the Board considers that setting a performance target for him is not as meaningful as for employees of the Group. Notwithstanding this, the Board considers that the grant of Share Options to Mr. Jin Lei (金磊) is fair and reasonable to the Company and its shareholders as a whole, given that Mr. Jin Lei (金磊) contributions and potential contributions to the Group and considering the fact that the size of the grant is relatively insignificant given Mr. Jin Lei (金磊) roles and duties in the Group and the fact that the Share Options will be vested in four equal instalments in four years' time. Additionally, the Share Options will help align the interests of Mr. Jin Lei (金磊) with those of the Company and its shareholders.

The grant of Share Options to the management consultants can also meet the purpose of the 2019 Share Option Scheme, notwithstanding no performance target is set. The Share Options can serve as a reward for the management consultant's past contributions. As the Share Options granted to him will vest on his in four equal instalments in the next four years, the grant of Share Options will also help retain his services. It can align his interests with those of the Company and its shareholders; therefore, it can also serve as an incentive for the management consultant to improve his performance for the benefit of the Group.

The total number of shares of the Company that may be issued pursuant to the 2019 Share Option Scheme on the date of its adoption was 427,175,263 Shares, representing approximately 10.4% of the issued share capital of the Company (excluding treasury shares) as at the date of this Annual Report. The number of Share Options available for grant under the scheme mandate limit under the 2019 Share Option Scheme as at the beginning of the Reporting Period and the end of the Reporting Period were 15,043,500 and 11,965,500, respectively.

Save as disclosed above, for the year ended 31 December 2025, no other Share Option was granted, exercised, lapsed, forfeited or cancelled under the 2019 Share Option Scheme. Accordingly, the number of Shares that may be issued in respect of Share Options granted under the 2019 Share Option Scheme for the year ended 31 December 2025 divided by the weighted average number of Shares in issue (i.e. 4,063,776,115 Shares) (excluding treasury shares) is nil. The remaining life of the 2019 Share Option Scheme is approximately 3.5 years.

Further particulars of the 2019 Share Option Scheme of the Company are set out in note 44 to the consolidated financial statements contained in this Annual Report.

## **VALUATION OF SHARE OPTIONS**

The valuation of Share Options granted under the 2019 Share Option Scheme is set out in note 44 to the consolidated financial statements contained in this Annual Report.

## **RESERVES**

Details of the movements in the reserves of the Company and the Group during the year ended 31 December 2025 are set out in note 43(b) to the consolidated financial statements and the consolidated statement of changes in equity on page 75 in this Annual Report, respectively.

## **DISTRIBUTABLE RESERVES**

As at 31 December 2025, the aggregate amount of the Company's reserves available for distribution to its owners, calculated under the Companies Act 1981 of Bermuda (as amended), was HK\$238,247,000 (2024: HK\$233,366,000).

## **PRE-EMPTIVE RIGHTS**

There are no provisions for pre-emptive rights under the Bye-Laws or the applicable laws of Bermuda, which would oblige the Company to offer new shares on a pro-rata basis to the existing shareholders.

## **PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY OR SALE OF TREASURY SHARES**

During the year ended 31 December 2025, the Company repurchased (the "**Share Repurchases**") a total of 29,706,000 Shares on the Stock Exchange at an aggregate consideration (before expenses) of HK\$8,847,264. As at 31 December 2025, these 29,706,000 Shares repurchased for cancellation but have not been cancelled. Subsequent to the Reporting Period and as at the date of this Annual Report, the Company had no present intention to use or sell the Treasury Shares, save and except for its intention to use the Treasury Shares to satisfy any share awards to be granted under the 2026 share award scheme proposed to be adopted at the 2026 SGM. The Directors believe that the Share Repurchases would lead to an enhancement of the net assets value per share and/or earnings per share.

# DIRECTORS' REPORT

Save as disclosed above, during the Reporting Period and up to the date of this Annual Report, neither the Company nor its subsidiaries had purchased, sold or redeemed any of the securities of the Company listed on the Stock Exchange, nor sold any treasury shares of the company, if any.

Particulars of the Share Purchases during the Reporting Period are as follows:

Month of repurchase	Total number of Shares repurchased	Repurchased price per Share		Aggregate consideration (before expenses)
		Highest <i>HK\$</i>	Lowest <i>HK\$</i>	
Jan 2025	29,166,000	0.305	0.285	8,732,400
April 2025	540,000	0.225	0.209	114,864
	29,706,000			8,847,264

## PROPERTY, PLANT AND EQUIPMENT

The movements of property, plant and equipment of the Group for the year ended 31 December 2025 are set out in note 18 to the consolidated financial statements.

## DIRECTORS

The Directors during the year and up to the date of this Annual Report were as follows:

### Executive Directors

Mr. Zhou Xuzhou  
Dr. Zeng Wentao  
Ms. Zhou Wen Chuan

### Non-Executive Director

Dr. Mao Zhenhua

### Independent Non-Executive Directors

Professor Chau Chi Wai, Wilton  
Mr. Chen Shi  
Mr. Wu Peng

Pursuant to the Bye-law 87(1) of the Bye-Laws, each Director is required to retire by rotation once every three years, and that one-third (or the number nearest to one-third but not less than one-third) of the Directors shall retire from office by rotation at each AGM of the Company. Accordingly, Ms. Zhou Wen Chuan, Dr. Zeng Wentao and Mr. Wu Peng will retire and, being eligible, offer themselves for re-election at the forthcoming AGM.

## CHANGES IN INFORMATION OF DIRECTORS AND CHIEF EXECUTIVE

Pursuant to Rule 13.51B(1) of the Listing Rules, the changes in the information of the Directors up to the date of this Annual Report are set out as below:

- Mr. Zhou Xuzhou was appointed as a lifetime director of Wuhan University.
- Professional Chau Chi Wai, Wilton ceased to be the Co-Chairman of Business Innovation Education of City University of Hong Kong, and the adjunct professor of the Shenzhen Finance Institute.

Save as disclosed above, upon specific enquiry by the Company and confirmations from the Directors, there had been no other changes in the information of any Directors up to the date of this Annual Report that are required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

## DIRECTOR'S SERVICE CONTRACTS/LETTERS OF APPOINTMENT

Mr. Zhou Xuzhou and Ms. Zhou Wen Chuan have entered into service contracts with the Company both for a term of three years commencing on 30 August 2025. Such contracts are determinable by either party serving not less than three months' notice in writing to the other.

Dr. Zeng Wentao has been re-designated as an Executive Director since 27 May 2019. Dr. Zeng Wentao has entered into a service contract with the Company for a term of three years commencing on 27 May 2025. Such contract is determinable by either party serving not less than three months' notice in writing to the other.

Dr. Mao Zhenhua has been appointed as a Non-Executive Director since 5 October 2015. Dr. Mao Zhenhua entered into a service contract with the Company for a term of one year commencing on 5 October 2025, and such agreement is determinable by either party serving not less than three months' notice in writing to the other.

Professor Chau Chi Wai, Wilton has been appointed as an Independent Non-Executive Director since 30 August 2013. Professor Chau Chi Wai, Wilton entered into a letter of appointment with the Company for a term of one year commencing on 30 August 2025, and such letter is determinable by either party serving not less than two months' notice in writing to the other.

Mr. Wu Peng has been appointed as an Independent Non-Executive Director since 27 May 2019. Mr. Wu Peng entered into a letter of appointment with the Company for a term of one year commencing on 20 June 2025, and such letter is determinable by either party serving not less than two months' notice in writing to the other.

Mr. Chen Shi has been appointed as an Independent Non-Executive Director since 10 April 2024. Mr. Chen Shi entered into a letter of appointment with the Company for a term of one year commencing on 10 April 2025, and such letter is determinable by either party serving not less than two months' notice in writing to the other.

None of the Directors has entered into a service contract with the Company which is not determinable by the Group within one year without payment of compensation (other than statutory compensation).

# DIRECTORS' REPORT

## DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

The Directors and chief executive of the Company who held offices as at 31 December 2025 had the following interests and short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register maintained by the Company pursuant to Section 352 of the SFO or otherwise notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which were taken or deemed to have under such provisions of the SFO) or pursuant to the Model Code required to be disclosed in accordance with the Listing Rules:

### (a) Interests in Issued Shares

Name of Director	Capacity		Total number of Shares held (Note 1)	Approximate percentage of total issued Shares
	Beneficial owner (Note 1)	Interest in controlled corporation (Note 1)		
Mr. Zhou Xuzhou (Notes 2, 3)	139,856,470 (L)	2,384,798,291 (L)	2,524,654,761 (L)	61.67%
Dr. Zeng Wentao (Note 3)	75,000,000 (L)	–	75,000,000 (L)	1.83%
Ms. Zhou Wen Chuan (Note 3)	40,239,000 (L)	–	40,239,000 (L)	0.98%
Dr. Mao Zhenhua (Note 4)	–	113,890,000 (L)	113,890,000 (L)	2.78%

Notes:

- The letter "L" denotes the person's long position in the Shares.
- These Shares are held by U-Home Group International Limited and Zhongjia U-Home Investment Limited.
- Mr. Zhou Xuzhou, Dr. Zeng Wentao and Ms. Zhou Wen Chuan are Executive Directors.
- 113,890,000 shares are beneficially owned by Honour Goal Investments Limited. Honour Goal Investments Limited is wholly owned by Zhongchengxin (HK) Investment Services Limited, a company incorporated in Hong Kong with limited liability. Zhongchengxin (HK) Investment Services Limited is wholly owned by Zhongchengxin Investment Group Company Limited\* (中誠信投資集團有限公司), a company established in the PRC with limited liability. Zhongchengxin Investment Group Company Limited is owned as to 80% by Hubei East Asia Enterprise Company Limited\* (湖北東亞實業有限公司), a company established in the PRC with limited liability. Hubei East Asia Enterprise Company Limited is owned as to 80% by Wuhan Huabing Real Estate Company Limited\* (武漢華兵置業有限公司), a company established in the PRC with limited liability. Wuhan Huabing Real Estate Company Limited is owned as to 99% by Dr. Mao Zhenhua, a Non-Executive Director. Under the SFO, Dr. Mao Zhenhua is taken to be interested in the Shares held by Honour Goal Investments Limited.

\* For identification purposes only

# DIRECTORS' REPORT

## (b) Interests in Share Options

<b>Name of Director</b>	<b>Number of options directly beneficially owned</b> (Note 1)
Dr. Zeng Wentao (Note 2)	2,500,500 (L)
Ms. Zhou Wen Chuan (Note 2)	4,500,000 (L)

Notes:

1. The letter "L" denotes the person's long position in the underlying shares of the Share Options granted under the 2019 Share Option Scheme.
2. Dr. Zeng Wentao and Ms. Zhou Wen Chuan, Executive Directors, have been granted Share Options under the 2019 Share Option Scheme, details of which are set out in the section "Share Option Scheme" above.

Save as disclosed above, none of the Directors and chief executive of the Company or their respective associates had any interests and short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register maintained by the Company pursuant to Section 352 of the SFO or otherwise notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which were taken or deemed to have under such provisions of the SFO) or pursuant to the Model Code as at 31 December 2025.

## **SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES**

As at 31 December 2025, the Company had been notified by the following person (other than the Directors or chief executive of the Company) who had interests or short positions in the shares and underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or be directly or indirectly interested in 5% or more of the nominal value of any class of share capital (excluding treasury shares) carrying rights to vote in all circumstances of GMs or who were recorded in the register of substantial shareholders maintained by the Company pursuant to Section 336 of the SFO or had otherwise notified the Company:

# DIRECTORS' REPORT

## Interests in Issued Shares

Name of substantial shareholder	Capacity	Total interests (Note 1)	Approximate percentage of total issued Shares
U-Home Group International Limited (Note 2)	Beneficial owner	964,172,530 (L)	23.55%
Zhongjia U-Home Investment Limited (Note 3)	Beneficial owner	1,420,625,761 (L)	34.70%
Shunda Investment Limited (Notes 2, 3)	Interest in controlled corporation	2,384,798,291 (L)	58.25%
Mr. Zhou Xuzhou (Notes 2, 3)	Interest in controlled corporation	2,384,798,291 (L)	58.25%
	Beneficial owner	139,856,470 (L)	3.42%

Notes:

1. The letter "L" denotes the person's long position in the shares.
2. U-Home Group International Limited is wholly and beneficially owned by Shunda Investment Limited, which in turn is wholly and beneficially owned by Mr. Zhou Xuzhou. Under the SFO, Shunda Investment Limited and Mr. Zhou Xuzhou are taken to be interested in the Shares held by U-Home Group International Limited.
3. Zhongjia U-Home Investment Limited is wholly and beneficially owned by Shunda Investment Limited, which in turn is wholly and beneficially owned by Mr. Zhou Xuzhou. Under the SFO, Shunda Investment Limited and Mr. Zhou Xuzhou are taken to be interested in the Shares held by Zhongjia U-Home Investment Limited.

Save as disclosed above, the Company has not been notified by any person (other than the Directors or chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or be directly or indirectly interested in 5% or more of the nominal value of any class of share capital (excluding treasury shares) carrying rights to vote in all circumstances of GM or who were recorded in the register of substantial shareholders maintained by the Company pursuant to Section 336 of the SFO or had otherwise notified the Company as at 31 December 2025.

## CONNECTED TRANSACTIONS AND CONTINUING CONNECTED TRANSACTIONS

During the year ended 31 December 2025, the Company and the Group entered into the following agreements, which constituted connected transaction(s) and continuing connected transaction(s), subject to the reporting, announcement and independent shareholders' approval requirements under Chapter 14A of the Listing Rules, where applicable, certain details of which are disclosed in compliance with the requirements of Chapter 14A of the Listing Rules:

### Continuing Connected Transaction

#### *Provision of revolving facility*

In order to increase the rate of return of the Group's cash and cash equivalents which can improve the investment income and the profits of the Group, the Group has been providing short-term interest-bearing loans to its customers. For further details, please refer to the section headed "Material Lending Transactions" in the management discussion and analysis in this Annual Report. In view of such practice, on 27 November 2023, the Company and U-light Energy entered into the Facility Agreement, pursuant to which the Company agreed, by itself or through its designated lending subsidiary(ies), to grant to U-light Energy a revolving loan facility up to a maximum of RMB200,000,000 at an interest rate of one-year LPR plus 3.05% per annum for the Drawdown Period. On the same date, Mr. Zhou Xuzhou (as guarantor) executed a deed of guarantee to provide the personal guarantee in favour of the Company to secure U-light Energy's repayment obligations under the Facility Agreement. The transaction has been approved by the shareholders of the Company at the 2024 SGM. Unless otherwise defined in this Annual Report, capitalised terms used herein share have the same meanings as those defined in the circular of the Company dated 17 January 2024.

As at the date of this Annual Report, U-light Energy is owned as to 36.7238% in aggregate by Shenzhen Xiaozhou Investment Co., Ltd.\* (深圳市曉舟投資有限公司) and its wholly-owned subsidiary, Wuhu Yizhou Health Industry Investment Co., Ltd.\* (蕪湖懿舟健康產業投資有限公司), which in turn is controlled by Ms. Zhou Wen Chuan. Ms. Zhou Wen Chuan is an Executive Director and the chief executive officer of the Company. As such, each of U-light Energy and Shenzhen Xiaozhou Investment Co., Ltd.\* (深圳市曉舟投資有限公司) is an associate of Ms. Zhou Wen Chuan, and hence a connected person of the Company under Chapter 14A of the Listing Rules.

# DIRECTORS' REPORT

The principal terms of the Facility Agreement are as follows:

<b>Date:</b>	27 November 2023
<b>Parties:</b>	(a) The Company (and/or its designated lending subsidiary(ies), as the lender; and (b) U-light Energy, as the borrower.
<b>Facility Limit:</b>	A revolving loan facility in the principal amount of up to a maximum of RMB200,000,000 (the " <b>Facility Limit</b> ") at any time during the Drawdown Period
<b>Interest rate:</b>	The annual interest rate applicable to the loan is the annual LPR for one year term announced for each year on the day before the Drawing Date plus 3.05%.  Interest is calculated on the basis of the actual number of days elapsed on a 365-day year and is paid six-monthly in arrears, or such other interest payment date as may be mutually agreed between the Company and U-light Energy.
<b>Default interest:</b>	12% per annum, to be accrued on a day-to-day basis and calculated on the basis of the actual number of days elapsed over a year of 365 days
<b>Drawdown Period:</b>	The period commencing on 1 January 2024 (or a later date subject to the fulfilment of the conditions precedent as stipulated below) and ending on the date immediately prior to the earlier of (i) 31 December 2026; and (ii) the date on which the Revolving Facility is terminated upon the occurrence of an Event of Default under the provisions of the Facility Agreement.
<b>Term of the Revolving Facility:</b>	From 1 January 2024 (or a later date subject to the fulfilment of the conditions precedent as stipulated below) to 31 December 2026
<b>Repayment:</b>	U-light Energy may repay the whole or any part of the amount drawn under the Revolving Facility on or before 31 December 2026.
<b>Prepayment:</b>	U-light Energy may on any Business Day prepay the whole or any part of the amount drawn under the Revolving Facility together with interest accrued thereon by giving the Company not less than two business days' prior written notice specifying the date of prepayment and the amount to be prepaid.
<b>Security:</b>	Pursuant to the deed of guarantee dated 27 November 2023, Mr. Zhou Xuzhou has agreed to provide a personal guarantee in favour of the Company to secure all the repayment obligations of U-light Energy under the Facility Agreement.

# DIRECTORS' REPORT

## **Drawdown conditions:**

U-light Energy may draw under the Revolving Facility provided that:

- (a) no Event of Default or prospective Event of Default has occurred and all representations, warranties and undertakings given by U-light Energy under the Facility Agreement are true and correct as at the date of each drawing;
- (b) it gives the Company a notice of drawing (the **"Notice of Drawing"**) in the manner set out in the Facility Agreement;
- (c) it has received a written confirmation from the Company approving the Notice of Drawing and confirming the provision of the loan. Such confirmation may be withheld by the Company at its sole discretion subject to the availability of its internal financial resources from time to time, and the Company shall reply to U-light Energy for its decision within 5 business days upon receiving the Notice of Drawing; and
- (d) the amount of such drawing shall, when aggregated with the principal amount of then outstanding, not exceed the Facility Limit.

## **Conditions precedent:**

- (a) The provision of the Revolving Facility is subject to and conditional on the approval of the Independent Shareholders at the EGM; and
- (b) The execution of a deed of guarantee by Mr. Zhou Xuzhou guaranteeing all the repayment obligations of U-light Energy under the Facility Agreement in favour of the Company.

The Independent Non-Executive Directors have reviewed the continuing connected transactions set out above and have confirmed that the continuing connected transaction was entered into (i) in the ordinary and usual course of business of the Group; (ii) on normal commercial terms or better; and (iii) in accordance with the relevant agreement governing them on terms that are fair and reasonable and in the interests of the shareholders of the Company as a whole, for the year ended 31 December 2025.

ZHONGHUI ANDA CPA Limited, the Company's auditor, was engaged to report on the Group's continuing connected transaction in accordance with Hong Kong Standard on Assurance Engagements 3000 "Assurance Engagements Other Than Audits or Reviews of Historical Financial Information" and with reference to Practice Note 740 "Auditor's Letter on Continuing Connected Transactions under the Hong Kong Listing Rules" issued by the HKICPA. ZHONGHUI ANDA CPA Limited have issued their unqualified letter containing the findings and conclusions in respect of the continuing connected transactions disclosed above by the Group in accordance with Rule 14A.56 of the Listing Rules that nothing has come to their attention that causes them to believe that (i) the disclosed continuing connected transaction has not been approved by the Company's board of directors; (ii) the transaction was not entered into, in all material respects, in accordance with the relevant agreements governing such transactions; and (iii) the disclosed continuing connected transaction has exceeded the annual cap as set by the Company. Further details of the continuing connected transaction are included in note 47 to the consolidated financial statements in this Annual Report.

# DIRECTORS' REPORT

## Connected Transaction

### *Disposal of property*

On 10 January 2025, U-Home Oceania Pty Ltd. (the "**Vendor**"), a company established in Australia with limited liability and an indirect wholly-owned subsidiary of the Company, entered into the an agreement (the "**Agreement**") with Ms. Zhou Wen Chuan (the "**Purchaser**"), an Executive Director and the chief executive officer of the Company, pursuant to which the Vendor agreed to sell, and the Purchaser agreed to purchase, the property situated at Lot 6, Yarra Park, 100 La Trobe Avenue, Alphington, VIC, 3078, Australia (the "**Property**") at the consideration (the "**Consideration**") of AUD1,360,000 (equivalent to approximately HK\$6.6 million) (the "**Disposal**"). Ms. Zhou Wen Chuan subscribed for one of the townhouse units, being the Property.

The Consideration was determined after arm's length negotiations between the Company and the Vendor with reference to the current property market in Australia and the market price of similar properties near the Property.

The Board is of the view that the Disposal represents a good opportunity for the Group to realise the value of its land reserve and/or properties held by it, generate additional working capital strengthening the Group's liquidity and financial position. The Company intends to use the net proceeds from the Disposal for supplementing the Group's working capital.

For details of the Disposal, please refer to the announcement of the Company dated 10 January 2025.

Save as disclosed above, the Group had not entered into any other connected transactions and continuing connected transactions during the year ended 31 December 2025, which are required to be disclosed under Chapter 14A of the Listing Rules.

## RELATED PARTY TRANSACTIONS

Details of the related party transactions undertaken during the year ended 31 December 2025 are set out in note 47 to the consolidated financial statements contained in this Annual Report, which included the abovementioned continuing connected transactions of the Company.

Save for the transactions disclosed in the above section headed "Connected Transactions and Continuing Connected Transactions", none of the related party transactions as disclosed under note 47 to the consolidated financial statements contained in this Annual Report constitutes a connected transaction or continuing connected transaction that is subject to, among other things, reporting, announcement or independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

To the extent that the Group's related party transactions constituted connected transactions or continuing connected transactions as defined in the Listing Rules, the Company had complied with the relevant requirements under Chapter 14A of the Listing Rules during the year ended 31 December 2025.

# DIRECTORS' REPORT

## MAJOR CUSTOMERS AND SUPPLIERS

The information in respect of the Group's sales and purchases attributable to the major customers and suppliers respectively during the year is as follows:

	Approximate percentage of the Group's total	
	Sales	Purchases
The largest customer	21%	–
Five largest customers in aggregate	42%	–
The largest supplier	–	20%
Five largest suppliers in aggregate	–	70%

Other than property sale and consultancy service income paid by fellow subsidiaries of the Group and sales to the fellow subsidiaries of the Group as disclosed in note 47(a) to the consolidated financial statements, at no time during the year ended 31 December 2025 have the Directors, their associates or any shareholder of the Company (which to the knowledge of the Directors owns more than 5% of the Company's share capital (excluding treasury shares)) had any interests in these major customers and suppliers.

## PERMITTED INDEMNITY PROVISION

The Company has arranged for appropriate insurance cover for Director's and officers' liabilities in respect of legal actions against its Directors and senior management arising out of corporate activities. The permitted indemnity provision is in force for the benefit of the Directors as required by section 470 of the Companies Ordinance (Chapter 622, Laws of Hong Kong) when the Directors' Report prepared by the Directors is approved in accordance with section 391(1)(a) of the Companies Ordinance (Chapter 622, Laws of Hong Kong).

## RETIREMENT BENEFIT SCHEMES

Details of the Group's retirement benefit schemes for the year ended 31 December 2025 are set out in note 15 to the consolidated financial statements.

During the years ended 31 December 2024 and 2025, there were no contributions forfeited by the Group on behalf of its employees who left the plan prior to vesting fully in such contribution, nor had there been any utilisation of such forfeited contributions to reduce future contributions. As at 31 December 2024 and 2025, no forfeited contributions were available for utilisation by the Group to reduce the existing level of contributions as described in paragraph 26(2) of Appendix D2 to the Listing Rules.

# DIRECTORS' REPORT

## SUFFICIENCY OF PUBLIC FLOAT

Based on information publicly available to the Company and within the knowledge of the Directors, for the year ended 31 December 2025, the Company was in compliance with the minimum public float requirement under the Listing Rules by maintaining its public float at the level of at least 25% of its total issued Shares (excluding treasury shares) as required under Rules 13.32B of the Listing Rules. As at 31 December 2025, the Company had 4,093,756,636 issued ordinary shares of a single class, each carrying one vote per Share, and the Company's public float was approximately 31.98% of its total issued Shares (excluding treasury shares).

## DIRECTORS' INTERESTS IN COMPETING BUSINESS

As at the date of this Annual Report, save for Mr. Zhou Xuzhou, who held shareholding or other interests and/or directorships in U-Home Group Limited that engaged in the businesses of property investment and leasing in the PRC, and Ms. Zhou Wen Chuan, who is an associate of Mr. Zhou Xuzhou, none of the Directors or their respective associate(s) is considered to have interests in business which compete or are likely to compete, either directly or indirectly, with the business of the Group which require disclosure under the Listing Rules. The investment properties held by U-Home Group Limited comprise shops, parking spaces, residential buildings, office buildings and hotels, all of which are located in Yueyang, Changsha, Kunshan and Nanjing of the PRC. The annual rental income from these investment properties held by U-Home Group Limited amounted to approximately RMB75 million, with a carrying amount of approximately RMB3,400 million.

The power to make material business decisions for the Group is vested in the Board. Whenever the Board considers that there may be a conflict of interest between the Group and any Director, such Director and his/her associate will be required to abstain from voting. Therefore, the Board is capable of carrying on the Group's business independently of, and at arm's length, from the business of Mr. Zhou Xuzhou.

## DIRECTORS' RIGHT TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed in the section headed "Share Option Scheme" above, during the year ended 31 December 2025, there was no rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any of the Directors or their respective spouses or minor children, and there was no such rights exercised by them; and none of the Company, its holding company, or any of its subsidiaries or fellow subsidiaries is a party to any arrangement to enable the Directors to acquire such rights in any other body corporate.

## DIRECTORS' INTERESTS IN TRANSACTIONS, ARRANGEMENTS OR CONTRACT

Save as disclosed in the section headed "Connected Transactions and Continuing Connected Transactions" above, neither a Director nor a connected entity of a Director had a material interest, either directly or indirectly, in any transactions, arrangements or contracts of significance to the business of the Group to which the Company, the holding company of the Company, or any of the Company's subsidiaries or fellow subsidiaries was a party for the year ended 31 December 2025.

## MANAGEMENT CONTRACTS

No contracts concerning the management and administration of the whole or any substantial part of the businesses of the Company were entered into or existed during the year ended 31 December 2025.

## SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

On 8 January 2026, the Company as purchaser entered into an equity interest transfer agreement (the “**Equity Transfer Agreement**”) with U-Home Group Company Limited, a company established in the PRC with limited liability that is ultimately controlled by Mr. Zhou Xuzhou, and an independent third party as vendors (collectively, the “**Yide Vendors**”), pursuant to which, the Company agreed to acquire, and the Yide Vendors agreed to sell, the entire equity interest in Jiangsu Yide Investment Company Limited\* (江蘇懿德投資有限公司), a company established in the PRC with limited liability (the “**Proposed Acquisition**”) at an aggregate consideration of RMB124,766,500. On the same date, Mr. Zhou Xuzhou (as guarantor) executed a deed of guarantee to provide a personal guarantee in favour of the Company to secure the Yide Vendors’ obligations under the Equity Transfer Agreement.

As at the date of this Annual Report, the Proposed Acquisition has not yet been completed. The completion of the Proposed Acquisition shall take place on the completion date following the fulfillment of the conditions precedent under the Equity Transfer Agreement, including, but not limited to, the approval of shareholders at the 2026 SGM of the Company, which will be held on 21 April 2026.

The 2026 SGM will be held on 21 April 2026 to consider and approve, among other things, the Equity Transfer Agreement and the transactions contemplated thereunder and the proposed adoption of a share award scheme (the “**2026 Share Award Scheme**”). For details of the Proposed Acquisition and the proposed adoption of the 2026 Share Award Scheme, please refer to the circular of the Company dated 27 March 2026.

On 27 March 2026, the Company announced that the Company’s interim dividend for the six months ended 30 June 2017 of HK\$0.006 per share of the Company, payable on 31 October 2017 and remaining unclaimed on 31 October 2023, will be forfeited and will revert to the Company.

## MATERIAL LEGAL PROCEEDINGS

As at 31 December 2025, the Group was not involved in any material litigation or arbitration, and no material litigation or claim was pending or threatened or made against the Group as far as the Board was aware of.

## TAX RELIEF AND EXEMPTION

The Company is not aware of any tax relief and exemption available to shareholders by reason of their holding of the Company’s securities.

## CHANGE IN THE INDEPENDENT AUDITORS FOR THE PAST THREE YEARS

There was no changes in the independent auditor of the Company in the past three years.

# DIRECTORS' REPORT

## AUDITOR

The consolidated financial statements of the Group for the year ended 31 December 2025 have been audited by ZHONGHUI ANDA CPA Limited, who shall retire and, being eligible, offer themselves for re-appointment in the forthcoming AGM. A resolution for their re-appointment as auditor of the Company will be proposed at the forthcoming AGM.

On behalf of the Board

**Zhou Wen Chuan**

*Executive Director and Chief Executive Officer*

Hong Kong, 27 March 2026

# CORPORATE GOVERNANCE REPORT

## CORPORATE GOVERNANCE PRACTICES

The Board considers that good corporate governance practices are crucial to the effective management of the Group. The Company is committed to the transparency, accountability and independence highlighted by the principles of the code provisions in the Corporate Governance Code (the “CG Code”) as set out in Appendix C1 to the Listing Rules to protect the rights of shareholders and stakeholders, enhance shareholder value and ensure proper management of corporate assets.

The Board is of the opinion that during the year ended 31 December 2025, the Company had adopted the principles and complied with all the applicable code provisions of the Part 2 of the CG Code as set out in Appendix C1 to the Listing Rules.

## DIRECTOR’S SECURITIES TRANSACTIONS

The Company has adopted the Model Code contained in Appendix C3 to the Listing Rules as its own code of conduct regarding securities transactions by the Directors. After specific enquiries made by the Company with each of the Directors, all Directors have confirmed that, for the year ended 31 December 2025, they have complied with the required standard set out in the Model Code.

## BOARD OF DIRECTORS

### Composition of the Board

As at the date of this Annual Report, the Board comprised three Executive Directors, one Non-Executive Director and three Independent Non-Executive Directors.

Save as disclosed under the section headed “Biography of Directors and Senior Management” in this Annual Report, there is no other financial, business, family or other material/relevant relationship between the Directors and the Board, which comprised the following:

### ***Executive Directors***

Mr. Zhou Xuzhou (*Co-Chairman*)

Dr. Zeng Wentao (*Co-Chairman*)

Ms. Zhou Wen Chuan (*Vice-Chairman*)

### ***Non-Executive Director***

Dr. Mao Zhenhua

### ***Independent Non-Executive Directors***

Professor Chau Chi Wai, Wilton

Mr. Chen Shi

Mr. Wu Peng

# CORPORATE GOVERNANCE REPORT

Four board meetings were held for the year ended 31 December 2025. Details of Directors' attendance at the shareholders' GM and Board meetings held during the year ended 31 December 2025 are set out in the following table:

<b>Members of the Board</b>	<b>Meeting attendance/held</b>	
	<b>Board meeting</b>	<b>AGM<sup>1</sup></b>
<b>Executive Directors</b>		
Mr. Zhou Xuzhou ( <i>Co-Chairman</i> )	6/6	1/1
Dr. Zeng Wentao ( <i>Co-Chairman</i> )	6/6	1/1
Ms. Zhou Wen Chuan ( <i>Vice-Chairman</i> )	6/6	1/1
<b>Non-Executive Director</b>		
Dr. Mao Zhenhua	6/6	1/1
<b>Independent Non-Executive Directors</b>		
Professor Chau Chi Wai, Wilton	6/6	1/1
Mr. Chen Shi	6/6	1/1
Mr. Wu Peng	6/6	1/1

Note:

1. The 2025 AGM was held on 27 June 2025.

Apart from the Board meetings above, consent and/or approvals of the Board were also obtained by way of written resolutions on a number of matters.

The Company has appointed sufficient numbers of Independent Non-Executive Directors in accordance with the Listing Rules, including those with appropriate professional qualifications or accounting or related financial management expertise. They have dedicatedly provided the Company with professional advice with respect to the steady operation and development of the Company. They also exercise supervision and coordination to safeguard the interests of the Company and its shareholders.

The Company has received written annual confirmations for the year ended 31 December 2025 from each of the Independent Non-executive Directors of his independence pursuant to Rule 3.13 of the Listing Rules. Based on the aforesaid confirmations received and with reference to the independence criteria as set out in Rule 3.13 of the Listing Rules, the Company considers that the Independent Non-executive Directors remain to be independent in accordance with independence criteria set out in the Listing Rules.

## The operation of the Board

The Board oversees the Group's strategic development and determines the objectives, strategies and policies of the Group. The Board also monitors and controls operating and financial performance in pursuit of the Group's strategic objectives. All Board members have access to appropriate business documents and information about the Group on a timely basis. All Directors and members of Board committees have access to external legal counsel and other professionals for independent advice at the Group's expense if they require it.

# CORPORATE GOVERNANCE REPORT

Four Board committees, namely the Audit Committee, Remuneration Committee, Nomination Committee and Strategic Committee, have been established to oversee particular aspects of the Group's affairs. The Board has delegated the day-to-day management and operations of the Group's businesses to the management of the Company and its subsidiaries.

The Board had met four times during the year ended 31 December 2025 to discuss and formulate overall strategies for the Group, review the financial performance, as well as other significant matters when Board decisions were required.

## CORPORATE GOVERNANCE FUNCTIONS

No corporate governance committee has been established, and the Board is responsible for performing the following corporate governance duties:

- (i) to develop and review the Company's policies and practices on corporate governance and make recommendations;
- (ii) to review and monitor the training and continuous professional development of Directors and senior management;
- (iii) to review and monitor the Company's policies and practices in compliance with legal and regulatory requirements;
- (iv) to develop, review and monitor the code of conduct and compliance manual (if any) applicable to employees and Directors; and
- (v) to review the Company's compliance with the CG Code and disclosures in the corporate governance report of the Company (the "**Corporate Governance Report**").

The major work performed by the Board included the following:

1. reviewed and monitored the Company's policies and practices in compliance with legal and regulatory requirements;
2. reviewed the terms of reference of the Audit Committee, the Nomination Committee, the Strategic Committee and the Remuneration Committee;
3. reviewed the Company's compliance with the CG Code and disclosures in this Corporate Governance Report;

# CORPORATE GOVERNANCE REPORT

4. reviewed the dividend policy (the “**Dividend Policy**”);
5. arranged suitable training for Directors, placing an appropriate emphasis on the roles, functions and duties of a listed company director;
6. reviewed and approved the financial results of the Company and announcements thereof; and
7. reviewed the board diversity policy (the “**Board Diversity Policy**”).

## CO-CHAIRMEN AND CHIEF EXECUTIVE OFFICER

Mr. Zhou Xuzhou and Dr. Zeng Wentao are the Co-Chairmen and are mainly responsible for the management of the Board. Ms. Zhou Wen Chuan is the Chief Executive Officer and is delegated with authority and is responsible for the day-to-day management of the Group’s businesses and the implementation of the approved strategies in achieving the overall business objectives.

## MECHANISMS FOR THE BOARD TO OBTAIN INDEPENDENT VIEWS

The Company adopted a mechanism for obtaining independent views (the “**Mechanism**”) with the aim of ensuring the strong independence of the Board and improving the working efficiency and the independence of decision-making of the Board. The Board will review the implementation and effectiveness of the Mechanism annually. The Mechanism specifies that all Directors have the right to obtain sufficient resources provided by the Company to perform their duties, and Directors have the right to make a request to the Company for independent professional advice at the expense of the Company if they believe that the advice is relevant and necessary for performing their duties.

The Board has reviewed the implementation and effectiveness of the Mechanism for the year ended 31 December 2025, and considers it to be adequate and effective.

## TERM OF APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Non-Executive Director has entered into a letter of appointment with the Company for a term of one year or till retirement by rotation in accordance with the Bye-Laws, whichever is earlier.

## PROFESSIONAL DEVELOPMENT

To assist the Directors’ continuing professional development, the Company encouraged the Directors to attend relevant seminars to develop and refresh their knowledge and skills. All Directors also participate in continuous professional development programmes such as external seminars organised by qualified professionals to develop and refresh their knowledge and skills in relation to their contribution to the Board. A record of the training received by the respective Directors is kept and updated by the company secretary or joint company secretaries of the Company, as the case may be.

All the Directors understand the importance of continuous professional development and are committed to participating in any suitable training to develop and refresh their knowledge and skills. During the year ended 31 December 2025, the Directors participated in training as follows to develop and refresh their knowledge so as to ensure their contributions to the Board:

# CORPORATE GOVERNANCE REPORT

	Reading regulatory updates	Attending expert briefings/seminars/conferences relevant to the business or Directors' duties
<b>Executive Directors</b>		
Mr. Zhou Xuzhou	✓	✓
Dr. Zeng Wentao	✓	✓
Ms. Zhou Wen Chuan	✓	✓
<b>Non-Executive Director</b>		
Dr. Mao Zhenhua	✓	✓
<b>Independent Non-Executive Directors</b>		
Professor Chau Chi Wai, Wilton	✓	✓
Mr. Chen Shi	✓	✓
Mr. Wu Peng	✓	✓

## REMUNERATION COMMITTEE

As at 31 December 2025, the Remuneration Committee comprised one Executive Director and two Independent Non-Executive Directors, namely Dr. Zeng Wentao, Mr. Chen Shi and Professor Chau Chi Wai, Wilton. Mr. Chen Shi is the chairman of the Remuneration Committee.

The terms of reference of the Remuneration Committee have been reviewed with reference to the CG Code. The terms of reference of the Remuneration Committee are posted on the websites of the Company and the Stock Exchange and are also available from the company secretary or joint company secretaries of the Company, as the case may be, on request.

The primary duty of the Remuneration Committee is to make recommendations to the Board on the remuneration packages of individual Executive Directors and senior management. The remuneration packages include benefits in kind, pension rights and compensation payments, including any compensation payable for loss or termination of their office or appointment.

The main functions of the Remuneration Committee include:

1. to make recommendations to the Board on the Company's policy and structure for all Directors and senior management remuneration and on the establishment of a formal and transparent procedure for developing remuneration policy;
2. to review and approve the management's remuneration proposals with reference to the Board's corporate goals and objectives;
3. to make recommendations to the Board on the remuneration packages of individual Executive Directors and senior management, which include benefits in kind, pension rights and compensation payments (including any compensation payable for loss or termination of their office or appointment);

# CORPORATE GOVERNANCE REPORT

4. to make recommendations to the Board on the remuneration of Non-Executive Directors;
5. to review the proposals for the award of share options to Executive Directors and senior management based on their performance and contribution to the Company from time to time;
6. to review and approve compensation arrangements relating to dismissal or removal of Directors for misconduct to ensure they are consistent with contractual terms and are otherwise reasonable and appropriate;
7. to consider salaries paid by comparable companies, time commitment and responsibilities and employment conditions elsewhere in the Group;
8. to review and approve compensation payable to the Executive Directors and the senior management for any loss or termination of office or appointment to ensure that it is consistent with contractual terms and is otherwise fair and not excessive;
9. to ensure that no Director or any of his/her associates is involved in deciding his/her own remuneration;
10. to review and/or approve matters relating to share schemes under Chapter 17 of the Listing Rules; and
11. to recommend to the Board the structure of long-term incentive plans for Executive Directors and certain senior management.

The details of the remuneration payable to the Directors are set out in note 13 to the consolidated financial statements in this Annual Report.

During the year ended 31 December 2025, the Remuneration Committee held one meeting. Attendance of each individual member was as follows:

<b>Committee member</b>	<b>Meeting attended/held</b>
Mr. Chen Shi	1/1
Professor Chau Chi Wai, Wilton	1/1
Dr. Zeng Wentao	1/1

The major work performed by the Remuneration Committee included the following:

1. reviewed and recommended the remuneration and bonus of Executive Directors and senior management;
2. conducted an annual review of the remuneration packages for Executive Directors, Non-Executive Director and senior management based on their performance; and
3. reviewed the terms of reference of the Remuneration Committee.

# CORPORATE GOVERNANCE REPORT

## NOMINATION COMMITTEE

As at 31 December 2025, the Nomination Committee comprised two Executive Directors and three Independent Non-Executive Directors, namely Mr. Zhou Xuzhou, Ms. Zhou Wen Chuan, Professor Chau Chi Wai, Wilton, Mr. Chen Shi and Mr. Wu Peng. Mr. Zhou Xuzhou is the chairman of the Nomination Committee. It has one Director of a different gender and comprises a majority of independent non-executive Directors.

Each of Ms. Zhou Wen Chuan and Mr. Chen Shi have been appointed as a member of the Nomination Committee with effect from 31 December 2025.

The terms of reference of the Nomination Committee have been reviewed with reference to the CG Code. The terms of reference of the Nomination Committee are posted on the websites of the Company and the Stock Exchange and are also available from the company secretary or joint company secretaries of the Company, as the case may be, on request.

The primary duties of the Nomination Committee are to develop and maintain a formal and transparent process for the appointment and re-appointment of members of the Board. The Nomination Committee also reviews and assesses Board composition and its effectiveness on an annual basis.

The main functions of the Nomination Committee include:

1. to review the structure, size and composition (including the skills, knowledge and experience) of the Board at least annually and make recommendations on any proposed changes to the Board to complement the Company's corporate strategy;
2. to identify individuals suitably qualified to become Board members and select or make recommendations to the Board on the selection of individuals nominated for directorships;
3. to establish a policy concerning the diversity of Board members;
4. to make recommendations to the Board on the appointment or re-appointment of Directors and succession planning for Directors, in particular, the chairman and the chief executive; and
5. to assess the independence of the Independent Non-Executive Directors.

During the year ended 31 December 2025, the Nomination Committee held one meeting. Attendance of each individual member was as follows:

<b>Committee member</b>	<b>Meeting attended/held</b>
Mr. Zhou Xuzhou	1/1
Ms. Zhou Wen Chuan (appointed on 31 December 2025)	N/A
Professor Chau Chi Wai, Wilton	1/1
Mr. Chen Shi (appointed on 31 December 2025)	N/A
Mr. Wu Peng	1/1

# CORPORATE GOVERNANCE REPORT

The major work performed by the Nomination Committee included the following:

1. reviewed and updated the Board Diversity Policy;
2. reviewed and assessed the structure, size and composition (including the skills, knowledge and experience) of the Board and its effectiveness;
3. assessed the independence of Independent Non-Executive Directors and confirmed that all Independent Non-Executive Directors are considered independent;
4. reviewed the terms of reference of the Nomination Committee;
5. proposed the Directors for re-election at the 2025 AGM; and
6. reviewed the nomination policy (the “**Nomination Policy**”).

## AUDIT COMMITTEE

As at 31 December 2025, the Audit Committee comprised one Non-Executive Director and two Independent Non-Executive Directors, namely Dr. Mao Zhenhua, Professor Chau Chi Wai, Wilton and Mr. Chen Shi. Professor Chau Chi Wai, Wilton is the chairman of the Audit Committee. None of the members of the Audit Committee is a member of the former or external auditor of the Company.

The terms of reference of the Audit Committee have been reviewed with reference to the CG Code. The terms of reference of the Audit Committee are posted on the websites of the Company and the Stock Exchange and are also available from the company secretary or joint company secretaries of the Company, as the case may be, on request.

The primary duties of the Audit Committee are to review and supervise the financial reporting process and internal control procedures of the Group.

The main functions of the Audit Committee include:

1. to be primarily responsible for making recommendations to the Board on the appointment, re-appointment and removal of the external auditor, and to approve the remuneration and terms of engagement of the external auditor, any questions of its resignation or dismissal;
2. to develop and implement policy on engaging an external auditor to supply non-audit services;
3. to review the Group’s financial and accounting policies and practices;
4. to consider major investigation findings on risk management and internal control matters as delegated by the Board or on its own initiative and management’s response to these findings;

# CORPORATE GOVERNANCE REPORT

5. to review the Group's financial controls, and unless expressly addressed by a separate board risk committee or by the Board itself, to review the Group's risk management and internal control systems;
6. to discuss the risk management and internal control system with management to ensure that management has performed its duty to have an effective system;
7. where an internal audit function exists, to ensure coordination between the internal and external auditors, and to ensure that the internal audit function is adequately resourced and has appropriate standing within the Group, and to review and monitor its effectiveness;
8. to monitor the integrity of the Company's financial statements and Annual Report and accounts, half-year report and, if prepared for publication, quarterly reports, and to review significant financial reporting judgments contained in them;
9. to review and monitor the external auditor's independence, objectivity and the effectiveness of the audit process in accordance with applicable standards. The Audit Committee should discuss with the auditor the nature and scope of the audit and reporting obligations before the audit commences;
10. to consider other topics, as defined by the Board;
11. to ensure that the Board will provide a timely response to the issues raised in the external auditor's management letter;
12. to report to the Board on the matters contained in the code provision of the CG Code;
13. to review the external auditor's management letter, any material queries raised by the auditor to management about accounting records, financial accounts or systems of control and management's response;
14. to review arrangements employees of the Company can use, in confidence, to raise concerns about possible improprieties in financial reporting, internal control or other matters; and
15. to act as the key representative body for overseeing the Company's relations with the external auditor.

During the year ended 31 December 2025, the Audit Committee held three meetings. Attendance of each individual member was as follows:

<b>Committee member</b>	<b>Meeting attended/held</b>
Professor Chau Chi Wai, Wilton	3/3
Dr. Mao Zhenhua	3/3
Mr. Chen Shi	3/3

Apart from the meetings above, consent and/or approvals of the Audit Committee were also obtained by way of written resolutions on a number of matters.

# CORPORATE GOVERNANCE REPORT

The major work performed by the Audit Committee included the following:

1. reviewed the Group's draft annual audited financial statements for the year ended 31 December 2024 and the interim financial statements for the six months ended 30 June 2025, including the accounting principles and accounting standards adopted with recommendations for presentation to the Board for its consideration and approval;
2. reviewed the enhancements to the 2025 audit planning process;
3. approved the audit and non-audit services provided by ZHONGHUI ANDA CPA Limited;
4. reviewed the fees proposal of ZHONGHUI ANDA CPA Limited for the 2025 audit work for the Group;
5. discussed, examined and reviewed annual accounting and financial reporting issues for the year ended 31 December 2025;
6. reviewed and monitored the external auditor's independence, objectivity and the effectiveness of the audit process;
7. reviewed the terms of reference of the Audit Committee;
8. discussed, assessed and reviewed the reports of internal control and risk management system as well as its effectiveness and significant risks faced by the Group for the year;
9. reviewed the remuneration and terms of engagement of the auditor of the Company for the year ended 31 December 2025, and made recommendations to the Board on the re-appointment of the auditor of the Company; and
10. reviewed the policies and practices of the Company's corporate governance and training and continuous professional development of the Directors.

## STRATEGIC COMMITTEE

As at 31 December 2025, the Strategic Committee comprised two Executive Directors and one Non-Executive Director, namely Mr. Zhou Xuzhou, Dr. Zeng Wentao and Dr. Mao Zhenhua. Dr. Mao Zhenhua is the chairman of the Strategic Committee.

The terms of reference of the Strategic Committee are posted on the websites of the Company and the Stock Exchange and are also available from the company secretary or joint company secretaries of the Company, as the case may be, on request.

The primary function of the Strategic Committee is to conduct research and submit proposals to the Board concerning the long-term developing strategic and material investment decisions of the Company.

During the year ended 31 December 2025, the Strategic Committee did not hold any meeting.

# CORPORATE GOVERNANCE REPORT

## REMUNERATION OF SENIOR MANAGEMENT

Pursuant to code provision E.1.5 of the CG Code, the remuneration of the members of the senior management (other than the Directors) whose particulars are contained in the section headed “Biography of Directors and Senior Management” in this Annual Report for the year ended 31 December 2025 by band is set out below:

<b>Remuneration band</b>	<b>Number of individuals</b>
HK\$1,500,001 to HK\$2,000,000	1

## AUDITOR’S REMUNERATION

For the year ended 31 December 2025, the Group engaged ZHONGHUI ANDA CPA Limited, auditor of the Company, to perform audit services. The services provided by ZHONGHUI ANDA CPA Limited and the fees thereof were as follows:

<b>Nature of services</b>	<b>For the year ended 31 December 2025</b> HK\$'000
Audit services	1,260
Non-audit services (Note a)	100
	1,360

Note:

- (a) Fees for non-audit services in 2025 consisted of fees incurred to ZHONGHUI ANDA CPA Limited in connection with the review of the annual results announcement and the Continuing Connected Transaction of the Group.

## RESPONSIBILITY FOR FINANCIAL REPORTING

The management of the Group provides financial information with explanations to the Board to assist the Board in assessing the financial position of the Group.

The Board acknowledges its responsibility to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Group and to present a balanced, clear and understandable assessment in the Company’s annual and interim reports, other price-sensitive announcements and other financial disclosures required under the Listing Rules and reports to the regulators as well as to information required to be disclosed pursuant to the statutory requirements. The Board is not aware of any material uncertainties that may cast significant doubt upon the Group’s ability to continue as a going concern.

A discussion and analysis of the Group’s performance, an explanation of the basis on which the Company generates or preserves value over the longer term and the strategy for delivering the Company’s objectives have been prepared and included in the sections headed “Co-Chairman’s Statement” and “Management Discussion and Analysis” on pages 3 to 8 and 9 to 20 in this Annual Report.

# CORPORATE GOVERNANCE REPORT

The reporting responsibilities of ZHONGHUI ANDA CPA Limited, the Company's auditor, are stated in the Independent Auditor's Report on pages 67 to 70 in this Annual Report.

## NOMINATION POLICY

### 1. Purpose

The Nomination Policy sets out the process and criteria for identifying potential candidates for the Company. The Nomination Committee should ensure that the Board has a balance of skills, experience and diversity of perspectives appropriate to the requirements of the Group's businesses.

### 2. Selection Criteria

The Nomination Committee shall consider the following selection criteria in evaluating and selecting candidates for directorships:

- character and integrity;
- qualifications including professional qualifications, skills, knowledge and experience that are relevant to the Company's businesses and corporate strategy;
- willingness to devote adequate time to discharge duties as a Board member and other directorships and significant commitments;
- requirement for the Board to have Independent Non-Executive Directors in accordance with the Listing Rules and whether the candidates would be considered independent with reference to the independence criteria set out in the Listing Rules;
- succession planning or strategies for the ongoing effective performance of the Board as a whole;
- the Board Diversity Policy and any measurable objectives adopted by the Nomination Committee for achieving diversity on the Board; and
- such other perspectives appropriate to the Group's businesses.

These factors are for reference only and are not meant to be exhaustive and decisive. The Nomination Committee has the discretion to nominate any person as it considers appropriate.

### 3. Nomination Process

#### 3.1 Appointment of New Director

- 3.1.1 The Nomination Committee shall, upon receipt of the proposal for the appointment of a new director and the biographical information (or relevant details) of the candidate, evaluate and assess such candidate based on the selection criteria as set out in section 2 to determine whether such candidate is qualified for directorship.

# CORPORATE GOVERNANCE REPORT

3.1.2 If there are one or more desirable candidates, the Nomination Committee shall rank them by order of preference based on the needs of the Company and reference check of each candidate (where applicable).

3.1.3 The Nomination Committee shall then recommend appointing the appropriate candidate for directorship.

3.1.4 For any person that is nominated by a shareholder for election as a director at the GM of the Company, the Nomination Committee shall evaluate such candidate based on the selection criteria as set out in section 2 to determine whether such candidate is qualified for directorship and where appropriate, the Nomination Committee and/or the Board shall make a recommendation to shareholders in respect of the proposed election of director at the GM.

## **4. Re-Election of Director at General Meeting**

4.1 The Nomination Committee shall review the overall contribution and service to the Company of the retiring director, including his/her attendance of Board meetings and, where applicable, GM and the level of participation and performance on the Board.

4.2 The Nomination Committee shall also review and determine whether the retiring director continues to meet the selection criteria as set out in section 2.

4.3 The Board, with the recommendation from Nomination Committee, shall then make a recommendation to shareholders in respect of the proposed re-election of the director at the GM.

## **5. Ultimate Responsibility for Selection and Appointment**

The nomination of directors is also subject to any restrictions under the Bermuda law and the Bye-Laws. The Board shall have the final decision on all matters relating to its recommendation of candidates to stand for election at any GM.

## **6. Monitoring and Reporting**

The Nomination Committee will disclose the Nomination Policy and the progress made towards achieving the objectives set out in the Nomination Policy in the Corporate Governance Report in the Annual Report.

## **BOARD DIVERSITY POLICY**

### **1. Vision**

The Company sees diversity at the Board level as an important element in maintaining a high standard of corporate governance. The Company is committed to a diverse Board, so Directors from diverse backgrounds could present the Company effectively to various constituencies and bring different and inspiring perspectives into the Board.

# CORPORATE GOVERNANCE REPORT

## 2. Policy Statement

- 2.1 The Company aspires to maintain an appropriate range and balance of skills, experience and background on the Board. In determining the optimum composition of the Board, differences in the skills, regional and industry experience, background, ethnicity, gender and other qualities of Directors shall be considered. All Board appointments are made on merits, in the context of the skills and experience the Board as a whole requires to be effective, with due regard for the benefits of diversity on the Board.
- 2.2 The Nomination Committee will review and assess Board composition and its effectiveness on an annual basis. When there is a vacancy on Board, the Nomination Committee will recommend suitable candidates for appointment to the Board on merits, based on the terms of reference of the Nomination Committee, with due regard to the Company's own circumstances.

## 3. Measurable Objectives

The selection of candidates will be based on a range of diverse perspectives, including but not limited to gender, age, cultural and educational background, professional experience, skills, knowledge and length of service. The ultimate decision will be based on merit and contribution that the selected candidates will bring to the Board.

## 4. Monitoring and Reporting

- 4.1 The Nomination Committee will report annually in the Corporate Governance Report contained in the Annual Report on the composition of the Board (including gender, age, length of service, education background, working experience) and monitor the implementation of the Board Diversity Policy.
- 4.2 The Nomination Committee will monitor the implementation of the Board Diversity Policy by conducting a review of the Board's composition at least once annually, taking into account the benefits of all relevant diversity aspects, and adhering to the Board Diversity Policy when making recommendations any Board appointments.

The Nomination Committee reviewed the Board's composition and considered the Board Diversity Policy during the year ended 31 December 2025. The Board currently comprises experts from diversified professions such as accounting, finance and management, and was diversified in terms of gender, age, duration of service, which effectively improved the ability of the Board in decision making and strategic management. The Board reviews the implementation of the Board Diversity Policy on an annual basis, and considers that the Board Diversity Policy was effective for the year ended 31 December 2025.

To ensure gender diversity of the Board, including senior management of the Company, the Nomination Committee reviews the Board composition, including senior management of the Company, from time to time and identify suitable Director candidates of both genders to the Board, including senior management of the Company, for consideration where appropriate.

Based on the current composition of the Board, the Company is of the view that the Board has achieved gender diversity. Among the workforce, the gender ratio is 20 male employees (including senior management) to 22 female employees (including senior management). Accordingly, the Company considers that gender diversity is also achieved in its workforce generally.

# CORPORATE GOVERNANCE REPORT

## DIVIDEND POLICY

1. The Dividend Policy sets out the structure of dividend payout to the shareholders of the Company.
2. Under the Companies Act 1981 of Bermuda (as amended), the contributed surplus account of the Company is available for distribution. However, the Company cannot declare or pay a dividend or make a distribution out of contributed surplus if:
  - (a) it is, or would after the payment be, unable to pay its liabilities as they become due; or
  - (b) the realisable value of its assets would thereby be less than the aggregate of its liabilities and its issued share capital and share premium accounts.
3. The Company may distribute dividends by way of (1) cash; and (2) Shares.
4. The Board may, from time to time, pay to the shareholders such interim dividends as appear to the Board to be justified by the position of the Company.
5. According to the Bye-Laws, the Company in GM may declare dividends in any currency, but no dividends shall exceed the amount recommended by the Board.
6. The Company's ability to pay dividends is also subject to the requirements of the Listing Rules and all relevant applicable laws, rules and regulations in Bermuda, Hong Kong and the Bye-Laws.
7. In proposing any dividend payout, the Board shall also take into account, inter alia:
  - (a) the Company's actual and expected financial performance;
  - (b) retained earnings of the Company and each of the members of the Group;
  - (c) the level of the Group's debts to equity ratio, return on equity and the relevant financial covenants;
  - (d) any restrictions on the payment of dividends that may be imposed by the Group's lenders, if any;
  - (e) the Group's expected working capital requirements and future expansion plans;
  - (f) general economic conditions and other internal or external factors that may have an impact on the business or financial performance and position of the Company; and
  - (g) any other factors that the Board deem appropriate.
8. Any final dividend for a financial year will be subject to shareholders' approval.

# CORPORATE GOVERNANCE REPORT

## JOINT COMPANY SECRETARIES

Mr. Li Shu Pai resigned as the Company Secretary on 31 December 2025. Ms. Chu Mei Yi and Mr. Tsoi Kwai Kwan are appointed as Joint Company Secretaries with effect from 31 December 2025.

The Joint Company Secretaries are responsible for advising the Board on governance matters and also facilitates induction and professional development of the Directors. The Joint Company Secretaries report to the Co-Chairman. All Directors have access to the advice and services of the Joint Company Secretaries to ensure that Board procedures, all applicable laws, rules and regulations are followed. The biographies of the Joint Company Secretaries are set out in the section headed "Biography of Directors and Senior Management" in this Annual Report. Ms. Zhou Wen Chuan, an Executive Director, is the principal contact person of Ms. Chu in the Company.

Mr. Li Shu Pai has taken no less than 15 hours of relevant professional training to comply with Rule 3.29 of the Listing Rules for the year ended 31 December 2025.

## ANTI-CORRUPTION AND BRIBERY POLICY AS WELL AS WHISTLEBLOWING POLICY

The Group has established (i) policy and measures that promote and support anti-corruption and bribery laws and regulations; and (ii) whistleblowing policy and measures for employees, suppliers and business partners to raise concerns, in confidence and anonymity, with the Audit Committee about possible improprieties in any matter related to the Group. For further details of the Group's anti-corruption and bribery policy, and whistleblowing policy and/or measures, please refer to the ESG Report 2025 published on the websites of the Company and the Stock Exchange.

## RISK MANAGEMENT AND INTERNAL CONTROL

The Board is responsible for maintaining a sound and effective internal control system in order to safeguard the Group's assets and shareholders' interests and reviewing the effectiveness of the Company's internal control and risk management systems on a regular basis so as to ensure that internal control and risk management systems in place are effective and adequate.

The Group's internal control system includes a well-established organisational structure with clearly defined lines of responsibility and authority. The day-to-day departmental operations are entrusted to the individual department which is accountable for its own conduct and performance and is required to operate its own department's business within the scope of the delegated authority and to implement and strictly adhere to the strategies and policies set by the Board from time to time. Each department is also required to keep the Board informed of material developments of the department's business and the implementation of the policies and strategies set by the Board on a regular basis.

Our risk management activities are performed by management on an ongoing process. The effectiveness of our risk management framework will be evaluated at least annually, and periodic management meeting is held to update the progress of risk monitoring efforts. The management of the Group is committed to ensuring that risk management forms part of the daily business operation processes in order to align risk management with corporate goals in an effective manner.

Pursuant to D.2.1 of the CG Code, the Group engages an independent professional advisor to conduct an annual review of the effectiveness of the Group's risk management and internal control system in various material aspects, including financial, operational and compliance controls. The risk management report and internal control report are submitted and reviewed by the Audit Committee at least once a year. Summary of findings and recommendations are discussed at the Audit Committee meeting with a view to improving the Group's operations.

# CORPORATE GOVERNANCE REPORT

There is currently no internal audit function within the Group. The Board has reviewed the need for an internal audit function and is of the view that there is no immediate need to set up an internal audit function within the Group in light of the relatively simple corporate and operation structure of the Group, it is adequate for the Group to appoint independent external professionals to perform the internal audit function for the Group in order to meet its needs currently. Nevertheless, the Board will continue to review at least annually the need for an internal audit function. The Board has conducted a review of the effectiveness the systems of risk management and internal control for the year ended 31 December 2025. Such review is conducted annually. The Board considers that our risk management and internal control systems were effective and adequate for the year ended 31 December 2025.

## **Main features of the risk management and internal control systems**

Highlights of the Group's internal control measures include the following:

the Group has improved the existing internal control framework by adopting a set of internal control manual and policies, which cover corporate governance, risk management, operation and legal matters:

- the Directors have received trainings conducted by the Company's legal advisor as to Hong Kong laws on the continuing obligations, duties and responsibilities of directors of publicly listed companies under the applicable laws of Hong Kong;
- each of the Directors is aware of the fiduciary duties as a director which require, among other things, that he or she must act for the benefit and in the best interest of the Company and must not allow any conflict between his duties as a director and his personal interests. In the event that there is a potential conflict of interest arising out of any transaction to be entered into between the Company and Directors or their respective associates, any interested Director will be abstained from voting at the relevant meeting of the Board in respect of such transaction and shall not be counted in the quorum;
- the Group has adopted various policies to ensure compliance with the Listing Rules, including those in relation to risk management and information disclosure;
- the Group has appointed external legal advisor to advise on the compliance requirements of the Listing Rules and ensure the compliance with relevant regulatory requirements and applicable laws, where necessary;
- the Group will assess and monitor the implementation of the internal control manual and policies by the relevant departments and companies in the Group through regular audits and inspections;
- the Group will provide internal training to employees as appropriate in order to enable them to follow the internal control and corporate governance procedures;
- the Group will provide anti-corruption and anti-bribery compliance policies in the manual and implement a whistle-blower program under which the employees are encouraged to report instances of bribes directly to the finance department; and
- the Group will keep implementing updated policies to the extent necessary to ensure future compliance with applicable laws and regulations.

# CORPORATE GOVERNANCE REPORT

## **The process used to identify, evaluate and manage significant risks**

The Company has established a risk management system consisting of relevant policies and procedures that the Company believes are appropriate for our business operations. Pursuant to the Company's risk management policy, the key risk management objectives include: (i) identifying different types of risks; (ii) assessing and prioritizing the identified risks; (iii) developing appropriate risk management strategies for different types of risks; (iv) identifying, monitoring and managing risks and risk tolerance level; and (v) execution of risk response measures.

## **Internal audit function**

For the year ended 31 December 2025, the Board appoint an independent external professional to perform the internal audit function for the Group. The internal auditor has carried out an overview on the effectiveness of the risk management and internal control systems of the Group. Based on the risk-based approach, the internal auditor review the adequacy and effectiveness of the risk control measures of material business unit of the Group and to examine if relevant measures have been implemented. The internal auditor attended the Audit Committee meeting to explain the results of the internal audit and responded to the questions of the members of the Audit Committee. The Company considers its risk management and internal control systems to be effective and adequate.

## **Handling and dissemination of inside information**

The Group regulates the handling and dissemination of inside information according to the inside information policy of the Company and the "Guidelines on Disclosure of Inside Information" published by the Securities and Future Commission in June 2012 to ensure inside information remains confidential until the disclosure of such information is appropriately approved, and the dissemination of such information is efficiently and consistently made. The Company regularly reminds the Directors and employees about due compliance with all policies regarding the inside information. Also, the Company keeps Directors, senior management and employees apprised of the latest regulatory updates. The Company shall prepare or update appropriate guidelines or policies to ensure the compliance with regulatory requirements.

## **SHAREHOLDERS' RIGHTS**

Shareholder(s) holding at the date of deposit of the requisition not less than one-tenth of the paid-up capital of the Company carrying the right of voting at GM shall at all times have the right, by written requisition sent to the Joint Company Secretaries, to require a SGM to be called by the Board for the transaction of any business specified in such requisition; and such meeting shall be held within two months after the deposit of such requisition.

(i) Shareholder(s) of the Company holding not less than one-twentieth of the total voting rights of all shareholders having the right to vote at the GM; or (ii) not less than 100 shareholders can submit a written request to the Joint Company Secretaries stating the resolution intended to be moved at the GM or a statement of not more than 1,000 words with respect to the matter referred to in any proposed resolution or the business to be dealt with at a particular GM.

The above procedures are subject to the Bye-Laws, the Bermuda Companies Act 1981 and applicable legislation and regulation (as amended from time to time). Shareholders who have enquiries about the above procedures or have enquiries to put to the Board may write to the Joint Company Secretaries at the principal place of business of the Company at Unit 2906, Tower 1, Lippo Centre, 89 Queensway, Admiralty, Hong Kong or by e-mail to [info@meilleure.com.cn](mailto:info@meilleure.com.cn) for the attention of the Joint Company Secretaries.

# CORPORATE GOVERNANCE REPORT

## COMMUNICATION WITH SHAREHOLDERS

To enhance transparency and effectively communicate with the investment community, the Executive Directors and senior management of the Company actively maintain close communications with various institutional investors, financial analysts and financial media. Investors are welcome to share their views with the Board by sending enquiries to [info@meilleure.com.cn](mailto:info@meilleure.com.cn).

The Company has in place a Shareholders' communication policy. The policy aims at promoting effective communication with Shareholders and other stakeholders, encouraging Shareholders to engage actively with the Company and enabling Shareholders to exercise their rights as Shareholders effectively. The Company has established a number of channels for maintaining an on-going dialogue with its Shareholders as follows:

### (a) Corporate Communication

Corporate communication will be provided to Shareholders and non-registered holders of the Company's securities in both English and Chinese versions or where permitted, in a single language, in a timely manner as required by the Listing Rules using electronic means. Shareholders and non-registered holders of the Company's securities shall have the right to choose the language (either English or Chinese) or means of receipt of the Corporate communication (in printed form or through electronic means).

### (b) Announcements and Other Documents pursuant to the Listing Rules

The Company shall publish announcements (on inside information, corporate actions and transactions etc.) and other documents (e.g. Memorandum and Articles of Association) on the Stock Exchange's website in a timely manner in accordance with the Listing Rules.

### (c) Corporate website

Any information or documents of the Company published on the website of HKExnews ([www.hkexnews.hk](http://www.hkexnews.hk)) will also be published on the Company's website ([www.meilleure.com.cn](http://www.meilleure.com.cn)). Other corporate information about the Company's business developments, goals and strategies, corporate governance and risk management will also be available on the website of the Company.

# CORPORATE GOVERNANCE REPORT

## **(d) Shareholders' Meetings**

The AGM and other GMs of the Company are primary forum for communication between the Company and its Shareholders. The Company shall provide Shareholders with relevant information on the resolution(s) proposed at a GM in a timely manner in accordance with the Listing Rules. The information provided shall be reasonably necessary to enable Shareholders to make an informed decision on the proposed resolution(s). Shareholders are encouraged to participate in GM or to appoint proxies to attend and vote at the meetings for and on their behalf if they are unable to attend the meetings. Where appropriate or required, the Chairman of the Board and other Board members, the chairmen of board committees or their delegates, and the external auditors should attend general meetings of the Company to answer Shareholders' questions (if any).

## **(e) Shareholders' Enquiries**

For enquires about shareholding, Shareholders should direct their enquiries about their shareholdings to the Company's branch share registrar and transfer office, Tricor Investor Services Limited, or call its hotline at (852) 2980-1333, or go in person to its public counter at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong.

For enquiries about corporate governance or other Matters to be put to the Board and the Company, the Company will not normally deal with verbal or anonymous enquiries. Shareholders may send any enquiries by email to [info@meilleure.com.cn](mailto:info@meilleure.com.cn) or by post to Unit 2906, Tower 1, Lippo Center, 89 Queensway, Admiralty, Hong Kong for the attention of Ms. Chu Mei Yi and Mr. Tsoi Kwai Kwan, Joint Company Secretaries.

Having considered and reviewed the various existing channels of communication, the Company considers that the Shareholders' communication policy has been properly implemented and effective for the year ended 31 December 2025.

## **CHANGE IN CONSTITUTIONAL DOCUMENTS**

There were no changes in constitutional documents of the Company during the year ended 31 December 2025.

# BIOGRAPHY OF DIRECTORS AND SENIOR MANAGEMENT

## EXECUTIVE DIRECTORS

**Mr. Zhou Xuzhou**, aged 70, was appointed as an Executive Director on 30 August 2013, was appointed as the chairman of the Board on 23 September 2013 and was re-designated as a Co-Chairman on 20 June 2019. He is the chairman of the Nomination Committee and a member of the Strategic Committee.

Mr. Zhou obtained a master's degree from Wuhan University in 1985. Mr. Zhou was appointed as a lifetime director of Wuhan University with effect from November 2025. Mr. Zhou is primarily responsible for leading the strategic planning and financial planning of the Group. Mr. Zhou is the father of Ms. Zhou Wen Chuan.

**Dr. Zeng Wentao**, aged 62, was appointed as an Independent Non-Executive Director on 18 October 2017, was re-designated as an Executive Director on 27 May 2019 and was appointed as a Co-Chairman on 20 June 2019. He is a member of the Remuneration Committee and the Strategic Committee.

Dr. Zeng graduated from Wuhan University with a doctoral degree in Economics. Dr. Zeng founded Hainan Sanyou Real Estate Company Limited (海南三友房地產有限公司) in Hainan in 1990 and acted as its general manager. In 1995, he founded Wuhan Yin Hai Property Company Limited (武漢銀海置業有限公司), which was principally engaged in real estate development and technology investment, and acted as its chief executive officer. He has been the chief executive officer of Zhongjia Capital (Wuhan) Investment Management Company Limited (中珈資本(武漢)投資管理有限公司) since March 2017. He is a part-time professor of Zhongnan University of Economics and Law, a member of Zhongnan University of Economics and Law Educational Development Fund and a standing council member of Dong Fureng Foundation (董輔弼基金會). He was the vice-chairman of the 12th and 13th Federation of Industry and Commerce of Wuhan City (武漢市工商聯) and a member of the 11th and 12th People's Consultative Conference of Wuhan City. Dr. Zeng has been a Counselor of the Healthcare Industry Union of Wuhan University Alumni Entrepreneur Association (武漢大學校友企業家聯誼會健康產業聯盟), an organisation dedicated to the promotion of co-operations in the healthcare industry among entrepreneurs who are alumni of Wuhan University, since July 2017. By taking this position, Dr. Zeng has gained an understanding of the healthcare business and has built good relationships with certain entrepreneurs and market players in the healthcare industry. In 2018, Dr. Zeng was appointed as a researcher in health economics of Dong Fureng Economic & Social Development School of Wuhan University, which demonstrated the recognition of Dr. Zeng's knowledge in health economics by the said organisation and has enabled Dr. Zeng to use his managerial experience to contribute to the research work in the health economics area.

**Ms. Zhou Wen Chuan**, aged 42, was appointed as an Executive Director on 30 August 2013 and the Chief Executive Officer on 23 September 2013. She is a member of the Nomination Committee.

Ms. Zhou obtained a master's degree in Business Administration from the Chinese University of Hong Kong in 2011. Also, she obtained a master's degree in Science and a dual bachelor's degree in Food Nutrition and Health from the University of British Columbia in 2008 and 2007, respectively. Ms. Zhou is currently a PhD student. Ms. Zhou is the daughter of Mr. Zhou Xuzhou.

# BIOGRAPHY OF DIRECTORS AND SENIOR MANAGEMENT

## NON-EXECUTIVE DIRECTOR

**Dr. Mao Zhenhua**, aged 62, was appointed as a Non-Executive Director on 5 October 2015. He is the chairman of the Strategic Committee and a member of the Audit Committee.

Dr. Mao is currently the chairman of China Chengxin Credit Management Co., Ltd. ("**China Chengxin**"), professor of the Renmin University of China, chairman of the Institute of Economic Research of the Renmin University of China, professor of Wuhan University, Dean of Dong Fureng Economic & Social Development School of Wuhan University and professor of Business School at the University of Hong Kong. Dr. Mao graduated from Wuhan University with a doctoral degree in Economics. Dr. Mao had carried out economic analysis and policies research for the Hubei Provincial Government, Hainan Provincial Government and Research Office of the State Council.

Dr. Mao founded China Chengxin in 1992. Since then, he acted as its general manager, chairman as well as general manager, chief executive officer, and chairman. He was the major shareholder and controller of China Cheng Xin International Credit Rating Co., Ltd. Under the leadership of Dr. Mao, China Chengxin has become a company specialising in credit services and a comprehensive enterprise group principally engaging in the business of investing in finance, real estate and industries.

Dr. Mao is currently an independent non-executive director of China Infrastructure & Logistics Group Ltd (a company listed on the Stock Exchange, stock code: 1719), China SCE Group Holdings Ltd (a company listed on the Stock Exchange, stock code: 1966), Airstar Bank Limited and Gravitation Fintech HK Limited. Dr. Mao was appointed as a member of the Research Strategy Expert Group of the Policy Unit of the Chief Executive of the Hong Kong Special Administrative Region on 30 May 2023.

## INDEPENDENT NON-EXECUTIVE DIRECTORS

**Professor Chau Chi Wai, Wilton**, aged 64, was appointed as an Independent Non-Executive Director on 30 August 2013. He is the chairman of the Audit Committee, a member of the Remuneration Committee and a member of the Nomination Committee.

Professor Chau obtained a doctoral degree in business administration, a master's degree in business administration, a bachelor's degree in laws and a bachelor's degree in science. He is a fellow member of the Chartered Association of Certified Accountants (UK). Professor Chau is currently the chairman of Pan Asia Venture Development Platform and a vice-chairman of Hong Kong Biotechnology Organisation. He is also an adjunct professor of the Chinese University of Hong Kong, City University of Hong Kong and National University of Singapore. Professor Chau is currently an independent non-executive director of China Three Gorges International Limited and Digital Hollywood Interactive Limited (a company listed on the Stock Exchange, stock code: 2022). Professor Chau has over 30 years of experience in direct investment and venture capital.

## BIOGRAPHY OF DIRECTORS AND SENIOR MANAGEMENT

**Mr. Chen Shi**, aged 64, was appointed as an Independent Non-Executive Director on 10 April 2024. He is the chairman of the Remuneration Committee, a member of the Audit Committee and a member of the Nomination Committee.

Mr. Chen obtained a bachelor's degree and a master's degree in Economics from Wuhan University in August 1982 and July 1985, respectively. He later obtained a doctorate in Economics from the Graduate School of Chinese Academy of Social Sciences in July 1989. Mr. Chen has over 30 years of working experience. Mr. Chen served as deputy head and then the head of the Policy Division of Social and Economic Development Research Center of the People's Government of Hainan Province from July 1989 to November 1994. He served as a deputy general manager of Yat Chau Holdings Limited from December 1994 to February 1998. He then served as a deputy general manager of Cityford Dyeing & Printing Industrial Limited from March 1998 to December 2001. From January 2002 to February 2013, Mr. Chen served as the president of Caricom Limited. He was previously a director of Partners Financial Holdings Limited from November 2012 to July 2013 and a non-executive director of LDK Solar Co., Ltd. (a company listed on the New York Stock Exchange Inc.) from March 2014 to May 2016. He has been a director of Mountain China Resorts (Holdings) Limited (a former company listed on the TSX Venture Exchange in Canada and delisted on 19 January 2023) since February 2012 and an executive director and chief executive office of Good Resources Holdings Limited (a former company listed on the Main Board of the Stock Exchange, stock code: 109 and delisted on 4 May 2022) since July 2019. Mr. Chen was first appointed as a non-executive director of Shunfeng International Clean Energy Limited (stock code: 1165), a company listed on the Stock Exchange, from March 2013 to September 2013 and has later been appointed as an executive director from 1 August 2017 to 31 December 2024.

**Mr. Wu Peng**, aged 44, was appointed as an Independent Non-Executive Director on 27 May 2019. He is a member of the Nomination Committee.

Mr. Wu graduated from Tsinghua University with a bachelor's degree in information systems in July 2004 and a doctoral degree (with supply chain management as a key research area) in January 2010. From September 2005 to January 2010, Mr. Wu worked as a research assistant in the Humanities Key Research Base of the Ministry of Education (教育部人文社科重點研究基地) of the PRC and the Research Centre for Contemporary Management Tsinghua University (清華大學現代管理研究中心), where he participated in the study of pharmaceutical products supply chain management strategies. In this position, Mr. Wu conducted investigations and research on the production and operation processes of a number of large-sized pharmaceutical companies in the PRC and gained a good understanding of their supply chain management. From March 2010 to November 2012, Mr. Wu was a lecturer at the school of Business Administration of South China University of Technology and was mainly involved in teaching and researching green supply chain management. During this period, from November 2010 to April 2012, Mr. Wu was also a postdoctoral researcher at The Martin Centre for Architectural and Urban Studies of the University of Cambridge, where he was engaged in low-carbon supply chain and low-carbon urban planning and design research work. Since December 2012, Mr. Wu has been teaching green supply chain management and engaging in the research work in this area in the Business School of Sichuan University, first as an associate professor from December 2012 to September 2017 and subsequently as a professor since September 2017. During a five-year period from 2012 to 2017, Mr. Wu was involved in an industrial chain optimisation consulting project, through which he further gained experience in the supply chain management research area. Mr. Wu has been a Counselor of the Society of Management Science and Engineering of China (中國管理科學與工程學會理事) since October 2018. Mr. Wu is currently an independent director of LightInTheBox Holding Co., Ltd. (a company listed on the New York Stock Exchange, stock code: LITB).

# BIOGRAPHY OF DIRECTORS AND SENIOR MANAGEMENT

## SENIOR MANAGEMENT

**Mr. Li Shu Pai**, aged 49, was appointed as the Chief Financial Officer and the Company Secretary on 30 July 2019 and resigned both positions with effect from 31 December 2025.

## JOINT COMPANY SECRETAIRES

**Ms. Chu Mei Yi**, aged 33, was appointed as the Joint Company Secretaries on 31 December 2025. Ms. Chu is the Company Secretarial Manager of Bird & Bird. She has extensive experience in delivering comprehensive company secretarial services to listed companies across a diverse range of industries, including property development, property management, financial services, and e-commerce. Ms. Chu has held positions at international law firms and prominent corporate service providers.

Ms. Chu obtained a Bachelor of Laws from University of London and a Bachelor of Business Administration in Accounting from Hong Kong Metropolitan University. She is an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

**Mr. Tsoi Kwai Kwan**, aged 34, was appointed as the Joint Company Secretaries on 31 December 2025. Mr. Tsoi has over 10 years of experience in auditing, accounting and company secretary experience and currently serves as senior finance manager in Meilleure Enterprise Development Company Limited, a wholly-owned subsidiary of the Company, and is mainly responsible for the group finance and other company secretarial related works. Mr. Tsoi had worked for an audit firm.

Mr. Tsoi obtained a Bachelor of Professional Accounting from Hong Kong Metropolitan University. Mr. Tsoi is a member of the Hong Kong Institute of Certified Public Accountants.

# INDEPENDENT AUDITOR'S REPORT



**TO THE SHAREHOLDERS OF  
MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED**

*(Incorporated in Bermuda with limited liability)*

## OPINION

We have audited the consolidated financial statements of Meilleure Health International Industry Group Limited (the “**Company**”) and its subsidiaries (collectively referred to as the “**Group**”) set out on pages 71 to 170, which comprise the consolidated statement of financial position as at 31 December 2025, and the consolidated statement of profit or loss, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2025, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with HKFRS Accounting Standards issued by the Hong Kong Institute of Certified Public Accountants (“**HKICPA**”) and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

## BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing (“**HKSAs**”) issued by the HKICPA. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the HKICPA’s Code of Ethics for Professional Accountants (the “**Code**”), as applicable to and its of financial statements of public interest entities. We have also fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

### Valuation of investment properties

Refer to Note 20 to the consolidated financial statements.

The Group measured its investment properties at fair value with the changes in fair value recognised in the consolidated profit or loss. This fair value measurement is significant to our audit because the balance of investment properties of HK\$663,388,000 as at 31 December 2025 and the fair value gains of HK\$21,727,000 for the year then ended are material to the consolidated financial statements. In addition, the Group’s fair value measurement involves application of judgement and is based on assumptions and estimates.

# INDEPENDENT AUDITOR'S REPORT

Our audit procedures included, among others:

- Assessing the competence, independence and integrity of the external valuer engaged by the Company;
- Obtaining the external valuation reports and meeting with the external valuer to discuss and challenge the valuation process, methodologies used and market evidence to support significant judgments and assumptions applied in the valuation model;
- Checking key assumptions and input data in the valuation model to supporting evidence;
- Checking arithmetical accuracy of the valuation model; and
- Assessing the disclosure of the fair value measurement in the consolidated financial statements.

We consider that the Group's fair value measurement of the investment properties is supported by the available evidence.

## **Net realisable value of properties held for sale under development**

Refer to Note 28 to the consolidated financial statements.

The net realisable value of properties held for sale under development is significant to our audit because the balance of properties held for sale under development of HK\$373,072,000 as at 31 December 2025 is material to the consolidated financial statements. In addition, the management's assessment of net realisable value involves application of judgement and is based on estimates.

Our audit procedures included, among others:

- Understanding and evaluating the Group's assessment of the net realisable values of properties held for sale under development;
- Assessing the reasonableness of estimated selling prices by comparing management's estimated selling price to the recent contracted price or the prevailing market price of comparable properties; and
- Assessing the reasonableness and appropriateness of the estimated costs to completion by comparing the latest estimated costs to complete to the budget approved by management and examining the supporting evidence.

We consider that the Group's assessment's of net realisable value for properties held for sale under development is supported by the available evidence.

# INDEPENDENT AUDITOR'S REPORT

## **Impairment assessment of loan and interest receivables**

Refer to Note 30 to the consolidated financial statements.

The Group assessed the amount of loan and interest receivables for impairment under the expected credit loss model. This impairment assessment is significant to our audit because the balance of loan and interest receivables of approximately HK\$522,011,000 as at 31 December 2025 is material to the consolidated financial statements. In addition, the Group's impairment assessment involves application of judgement and is based on estimates.

## **Our audit procedures included, among others:**

- Obtaining an understanding of and evaluating the Group's credit policies and methodology for impairment assessment in relation to the application of expected credit loss ("ECL") model;
- Assessing the reasonableness and appropriateness of input and assumptions used in calculating the ECL;
- Evaluating the reasonableness of the forward-looking adjustments made to reflect the current and forecast general economic condition against public available information; and
- Assessing the disclosure of the Group's exposure to credit risk in the consolidated financial statements.

We consider that the Group's impairment assessment for loan and interest receivables is supported by the available evidence.

## **OTHER INFORMATION**

The directors of the Company are responsible for the other information. The other information comprises all the information in the Company's annual report, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

# INDEPENDENT AUDITOR'S REPORT

## RESPONSIBILITIES OF DIRECTORS FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRS Accounting Standards issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors of the Company determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors of the Company are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors of the Company either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

## AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. We report our opinion solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSA's will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

A further description of our responsibilities for the audit of the consolidated financial statements is located at the HKICPA's website at:

<https://www.hkicpa.org.hk/en/Standards-setting/Standards/Our-views/auditre>

This description forms part of our auditor's report.

### **ZHONGHUI ANDA CPA Limited**

*Certified Public Accountants*

#### **Sze Lin Tang**

Audit Engagement Director

Practising Certificate Number P03614

Hong Kong, 27 March 2026

# CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the year ended 31 December 2025

	Notes	2025 HK\$'000	2024 HK\$'000
<b>Revenue</b>	8	<b>36,518</b>	50,676
Cost of goods sold and service rendered		<b>(13,887)</b>	(21,771)
<b>Gross profit</b>		<b>22,631</b>	28,905
Fair value gains on investment properties	20	<b>21,727</b>	23,813
Gain on disposals of investment properties	20	<b>270</b>	–
Gain on partial disposal of investment in a joint venture		<b>1,207</b>	–
Gain on deemed partial disposal of investment in a joint venture		<b>7,081</b>	–
Other income and gains, net	9	<b>25,419</b>	53,339
Selling and distribution expenses		<b>(3,622)</b>	(6,985)
Administrative expenses		<b>(27,550)</b>	(24,615)
Impairment losses of assets	12	<b>(854)</b>	(20,224)
(Impairment losses)/reversal of impairment losses of receivables, net	12	<b>(2,366)</b>	4,478
Finance costs	10	<b>(9,290)</b>	(10,294)
Share of losses of associates		<b>(225)</b>	(205)
Share of losses of joint ventures		<b>(3,891)</b>	(2,811)
<b>Profit before tax</b>		<b>30,537</b>	45,401
Income tax credit/(expense)	11	<b>7,461</b>	(13,356)
<b>Profit for the year</b>	12	<b>37,998</b>	32,045
<b>Attributable to:</b>			
Owners of the Company		<b>37,983</b>	32,480
Non-controlling interests		<b>15</b>	(435)
		<b>37,998</b>	32,045
<b>Earnings per share</b>	17		
Basic and diluted		<b>HK0.93 cents</b>	HK0.79 cents

# CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the year ended 31 December 2025

	Notes	2025 HK\$'000	2024 HK\$'000
<b>Profit for the year</b>	12	<b>37,998</b>	32,045
<b>Other comprehensive income/(loss) for the year, after tax:</b>			
<i>Item that will not be reclassified to profit or loss:</i>			
Fair value changes of equity investments at FVTOCI, net of tax		<b>(5,782)</b>	(15,082)
<i>Items that may be reclassified to profit or loss:</i>			
Exchange differences on translating foreign operations:			
– Subsidiaries		<b>43,817</b>	(52,810)
– Associates and joint ventures		<b>1,715</b>	(1,900)
		<b>45,532</b>	(54,710)
<b>Other comprehensive income/(loss) for the year, net of tax</b>		<b>39,750</b>	(69,792)
<b>Total comprehensive income/(loss) for the year</b>		<b>77,748</b>	(37,747)
<b>Attributable to:</b>			
Owners of the Company		<b>77,768</b>	(37,341)
Non-controlling interests		<b>(20)</b>	(406)
		<b>77,748</b>	(37,747)

# CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2025

	Notes	2025 HK\$'000	2024 HK\$'000
<b>Non-current assets</b>			
Property, plant and equipment	18	2,635	2,678
Right-of-use assets	19	643	1,245
Investment properties	20	663,388	610,292
Other intangible assets	21	–	–
Investments in associates	23	4,011	4,907
Investments in a joint venture	24	46,407	49,889
Investments at FVTPL	31	35,970	47,023
Equity investments at FVTOCI	25	8,499	6,122
Derivative financial assets	26	266	165
Prepayments, loans and other receivables	30	6,785	226,571
Deferred tax assets	39	31,215	31,464
		<b>799,819</b>	980,356
<b>Current assets</b>			
Inventories	27	1,214	1,862
Properties held for sale under development	28	373,072	255,086
Trade receivables	29	16,099	27,241
Prepayments, loans and other receivables	30	605,198	367,612
Restricted bank deposit	32	7,105	6,550
Bank and cash balances	32	13,079	29,944
		<b>1,015,767</b>	688,295
<b>Current liabilities</b>			
Trade payables	33	251	10
Contract liabilities	34	33,362	21,838
Accruals and other payables	35	41,217	36,555
Amounts due to related parties	36	11,953	7,353
Bank borrowings	37	271,317	83,176
Lease liabilities	38	302	437
Current tax liabilities		3,118	8,973
		<b>361,520</b>	158,342
<b>Net current assets</b>		<b>654,247</b>	529,953
<b>Total assets less current liabilities</b>		<b>1,454,066</b>	1,510,309

# CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2025

	Notes	2025 HK\$'000	2024 HK\$'000
<b>Non-current liabilities</b>			
Bank borrowings	37	<b>109,078</b>	218,645
Lease liabilities	38	<b>261</b>	806
Deferred tax liabilities	39	<b>96,484</b>	89,494
		<b>205,823</b>	308,945
<b>NET ASSETS</b>		<b>1,248,243</b>	1,201,364
<b>Capital and reserves</b>			
Share capital	40	<b>40,938</b>	40,938
Treasury shares	41	<b>(9,199)</b>	(335)
Reserves	43(a)	<b>1,216,764</b>	1,161,001
Equity attributable to owners of the Company		<b>1,248,503</b>	1,201,604
Non-controlling interests		<b>(260)</b>	(240)
<b>TOTAL EQUITY</b>		<b>1,248,243</b>	1,201,364

The consolidated financial statements on pages 71 to 170 were approved and authorised for issue by the Board on 27 March 2026 and are signed on its behalf by:

**Zhou Xuzhou**  
Director

**Zhou Wen Chuan**  
Director

# CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the year ended 31 December 2025

	Attributable to owners of the Company												
	Share capital	Treasury shares	Share premium account	Contributed surplus account	Share-based payment reserve	Statutory surplus reserve	Equity investment revaluation reserve	Other reserve	Foreign currency translation reserve	Retained profits	Total	Non-controlling interests	Total equity
	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
As at 1 January 2024	40,938	(335)	572,574	409,712	3,953	25,016	(10,237)	4,305	(76,728)	284,957	1,254,155	166	1,254,321
Total comprehensive loss for the year	-	-	-	-	-	-	(15,082)	-	(54,739)	32,480	(37,341)	(406)	(37,747)
Provision for equity-settled share-based payments,	-	-	-	-	190	-	-	-	-	-	190	-	190
Release of share-based payment reserve	-	-	-	-	(34)	-	-	-	-	34	-	-	-
Share of reserve of a joint venture	-	-	-	-	-	-	-	975	-	-	975	-	975
Dividend recognised as a distribution	-	-	-	-	-	-	-	-	-	(16,375)	(16,375)	-	(16,375)
Changes in equity for the year	-	-	-	-	156	-	(15,082)	975	(54,739)	16,139	(52,551)	(406)	(52,957)
As at 31 December 2024	40,938	(335)	572,574	409,712	4,109	25,016	(25,319)	5,280	(131,467)	301,096	1,201,604	(240)	1,201,364
As at 1 January 2025	<b>40,938</b>	<b>(335)</b>	<b>572,574</b>	<b>409,712</b>	<b>4,109</b>	<b>25,016</b>	<b>(25,319)</b>	<b>5,280</b>	<b>(131,467)</b>	<b>301,096</b>	<b>1,201,604</b>	<b>(240)</b>	<b>1,201,364</b>
Total comprehensive income for the year	-	-	-	-	-	-	(5,782)	-	45,567	37,983	77,768	(20)	77,748
Provision for equity-settled share-based payments	-	-	-	-	54	-	-	-	-	-	54	-	54
Release of share-based payment reserve	-	-	-	-	(1,252)	-	-	-	-	1,252	-	-	-
Share of reserve of a joint venture	-	-	-	-	-	-	-	457	-	-	457	-	457
Repurchases of shares (note 41)	-	(8,864)	-	-	-	-	-	-	-	-	(8,864)	-	(8,864)
Release of equity invested revaluation reserve	-	-	-	-	-	-	31,156	-	-	(31,156)	-	-	-
Dividend recognised as a distribution	-	-	-	-	-	-	-	-	-	(22,516)	(22,516)	-	(22,516)
Changes in equity for the year	-	(8,864)	-	-	(1,198)	-	25,374	457	45,567	(14,437)	46,899	(20)	46,879
As at 31 December 2025	<b>40,938</b>	<b>(9,199)</b>	<b>572,574</b>	<b>409,712</b>	<b>2,911</b>	<b>25,016</b>	<b>55</b>	<b>5,737</b>	<b>(85,900)</b>	<b>286,659</b>	<b>1,248,503</b>	<b>(260)</b>	<b>1,248,243</b>

# CONSOLIDATED STATEMENT OF CASH FLOWS

For the year ended 31 December 2025

	Notes	2025 HK\$'000	2024 HK\$'000
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit before tax		<b>30,537</b>	45,401
Adjustments for:			
Finance costs	10	<b>9,290</b>	10,294
Share of losses of associates		<b>225</b>	205
Share of losses of a joint venture		<b>3,891</b>	2,811
Interest income	9	<b>(29,303)</b>	(22,045)
Dividend income from investments at FVTPL	9	<b>-</b>	(456)
Gain on disposals of investment properties	20	<b>(270)</b>	-
Gain on partial disposal of investment in a joint venture		<b>(1,207)</b>	-
Gain on deemed partial disposal of investment in a joint venture		<b>(7,081)</b>	-
Depreciation of property, plant and equipment	18	<b>737</b>	1,189
Depreciation of right-of-use assets	19	<b>360</b>	442
Provision for equity-settled share options expenses, net		<b>54</b>	190
Fair value gains on investment properties	20	<b>(21,727)</b>	(23,813)
Fair value (gains)/losses on derivative financial instruments	9	<b>(92)</b>	711
Fair value losses/(gains) on investments at FVTPL	9	<b>12,752</b>	(20,170)
Impairment losses of assets	12	<b>854</b>	20,224
Impairment losses of trade receivables, net	29	<b>1,170</b>	204
Impairment losses/(reversal of impairment losses) of other receivables	30	<b>1,196</b>	(4,682)
Gain on lease termination	9	<b>(30)</b>	-
Gain on disposal of property, plant and equipment	9	<b>(1)</b>	(57)
Loss on written off of inventories	9	<b>-</b>	26
Net foreign exchange gains		<b>(12,024)</b>	(3,393)
Operating profit before working capital changes		<b>(10,669)</b>	7,081
Decrease in inventories		<b>774</b>	1,316
Increase in properties held for sale under development		<b>(92,443)</b>	(27,427)
Decrease in trade receivables, prepayments, deposits and other receivables		<b>44,146</b>	199,499
Increase in trade payables, contract liabilities, accruals and other payables		<b>5,525</b>	19,983
Increase/(decrease) in amounts due to related parties		<b>4,150</b>	(4,375)
Cash (used in)/generated from operations		<b>(48,517)</b>	196,077
Income taxes paid		<b>(1,502)</b>	(10,081)
Net cash (used in)/generated from operating activities		<b>(50,019)</b>	185,996

# CONSOLIDATED STATEMENT OF CASH FLOWS

For the year ended 31 December 2025

	Notes	2025 HK\$'000	2024 HK\$'000
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Capital injected to an associate		–	(379)
Considerations received in respect of partial disposal of investment in an associate in prior years		–	433
Proceeds from partial disposal of investment in a joint venture		<b>9,867</b>	–
Advances of loans to third parties		<b>(84,715)</b>	(308,356)
Advances of loans to a related party		–	(228,940)
Repayment of loans from third parties		<b>65,165</b>	265,077
Repayment of loans from a related party		–	12,550
Interest received		<b>13,792</b>	12,558
Dividend received from investments at FVTPL		–	456
Purchases of property, plant and equipment		<b>(583)</b>	(132)
Net proceeds from disposal of investment properties		<b>3,698</b>	–
Proceeds from disposal of property, plant and equipment		<b>1</b>	173
Considerations received in respect of disposal of investment properties in prior years		–	93
Deposit received from disposal of investment properties		<b>6,868</b>	3,554
Proceeds from disposal of equity investments at FVTOCI		<b>543</b>	–
Acquisition of investment properties		–	(15,659)
Decrease in restricted deposit		–	4,595
Net cash generated from/(used in) investing activities		<b>14,636</b>	(253,977)
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Proceeds from bank borrowings	45(b)	<b>137,008</b>	126,510
Repayment of bank borrowings	45(b)	<b>(77,861)</b>	(105,672)
Interest paid	45(b)	<b>(9,245)</b>	(10,262)
Repayment of lease liabilities	45(b)	<b>(450)</b>	(591)
Payments of shares repurchase		<b>(8,864)</b>	–
Dividend paid		<b>(22,516)</b>	(16,375)
Net cash generate from/(used in) financing activities		<b>18,072</b>	(6,390)
<b>NET DECREASE IN CASH AND CASH EQUIVALENTS</b>		<b>(17,311)</b>	(74,371)
Effect of foreign exchange rate changes		<b>446</b>	(1,994)
<b>CASH AND CASH EQUIVALENTS AS AT 1 JANUARY</b>		<b>29,944</b>	106,309
<b>CASH AND CASH EQUIVALENTS AS AT 31 DECEMBER</b>		<b>13,079</b>	29,944
<b>ANALYSIS OF CASH AND CASH EQUIVALENTS</b>			
Bank and cash balances	32	<b>13,079</b>	29,944

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 1. GENERAL INFORMATION

The Company was incorporated in Bermuda with limited liability. The address of its registered office is Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. The address of its principal place of business is Unit 2906, Tower 1, Lippo Centre, 89 Queensway, Admiralty, Hong Kong. The Company's shares are listed on the Main Board of the Stock Exchange.

The principal activities of the Group are operations of healthcare-related business, trading of construction materials and renewable energy products, provision of real estate agency services, property investment and leasing, development of residential properties and provision of procurement service of renewable energy products. The particulars of the subsidiaries are set out in note 22 to the consolidated financial statements.

In the opinion of the Directors, as at 31 December 2025, Shunda Investment Limited, a company incorporated in the British Virgin Islands ("**BVI**"), is the ultimate parent of the Company; and Mr. Zhou Xuzhou, a Co-Chairman and the Executive Director, is the ultimate controlling party of the Company.

## 2. ADOPTION OF NEW AND REVISED HKFRS ACCOUNTING STANDARDS

In the current year, the Group has adopted all the new and revised HKFRS Accounting Standards issued by the HKICPA that are relevant to its operations and effective for its accounting year beginning on 1 January 2025. HKFRS Accounting Standards comprise Hong Kong Financial Reporting Standards ("**HKFRS**"); Hong Kong Accounting Standards ("**HKAS**"); and Interpretations. The adoption of these new and revised HKFRS Accounting Standards did not result in significant changes to the Group's accounting policies, presentation of the Group's consolidated financial statements and amounts reported for the current year and prior years.

The Group has not early applied any new or revised HKFRS Accounting Standards that is not yet effective for the current accounting year.

The application of the new or revised HKFRS Accounting Standards that have been issued but are not yet effective and have not been early adopted by the Group will not have material impacts on the consolidated financial statements of the Group.

## 3. MATERIAL ACCOUNTING POLICIES

These consolidated financial statements have been prepared in accordance with HKFRS Accounting Standards issued by the HKICPA, accounting principles generally accepted in Hong Kong and the applicable disclosures required by the Listing Rules and by the Hong Kong Companies Ordinance.

These consolidated financial statements have been prepared under the historical cost convention, as modified by the revaluation of investment properties, derivatives and investments which are carried at their fair values.

The preparation of consolidated financial statements in conformity with HKFRS Accounting Standards requires the use of certain key assumptions and estimates. It also requires the Directors to exercise their judgements in the process of applying the accounting policies. The areas involving critical judgements and areas where assumptions and estimates are significant to these consolidated financial statements, are disclosed in note 4 to the consolidated financial statements.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

The material accounting policies applied in the preparation of these consolidated financial statements are set out below:

### (a) Consolidation

The consolidated financial statements include the financial statements of the Company and its subsidiaries made up to 31 December. Subsidiaries are entities over which the Group has control. The Group controls an entity when it is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The Group has power over an entity when the Group has existing rights that give it the current ability to direct the relevant activities, i.e. activities that significantly affect the entity's returns.

When assessing control, the Group considers its potential voting rights as well as potential voting rights held by other parties, to determine whether it has control. A potential voting right is considered only if the holder has the practical ability to exercise that right. Subsidiaries are consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date the control ceases.

The gain or loss on the disposal of a subsidiary that results in a loss of control represents the difference between (i) the fair value of the consideration of the sale plus the fair value of any investment retained in that subsidiary and (ii) the Company's share of the net assets of that subsidiary plus any remaining goodwill relating to that subsidiary and any related accumulated foreign currency translation reserve.

Intragroup transactions, balances and unrealised profits are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

Non-controlling interests represent the equity in subsidiaries not attributable, directly or indirectly, to the Company. Non-controlling interests are presented in the consolidated statement of financial position and consolidated statement of changes in equity within equity. Non-controlling interests are presented in the consolidated statement of profit or loss and the consolidated statement of comprehensive income as an allocation of profit or loss and total comprehensive loss for the year between the non-controlling shareholders and owners of the Company.

Profit or loss and each component of other comprehensive loss are attributed to the owners of the Company and to the non-controlling shareholders even if this results in the non-controlling interests having a deficit balance.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (b) Business combination and goodwill

The acquisition method is used to account for the acquisition of a subsidiary in a business combination. The cost of acquisition is measured at the acquisition-date fair value of the assets given, equity instruments issued, liabilities incurred and contingent consideration. Acquisition-related costs are recognised as expenses in the periods in which the costs are incurred and the services are received. Identifiable assets and liabilities of the subsidiary in the acquisition are measured at their acquisition-date fair values.

The excess of the cost of acquisition over the Company's share of the net fair value of the subsidiary's identifiable assets and liabilities is recorded as goodwill. Any excess of the Company's share of the net fair value of the identifiable assets and liabilities over the cost of acquisition is recognised in consolidated profit or loss as a gain on bargain purchase which is attributed to the Company.

In a business combination achieved in stages, the previously held equity interest in the subsidiary is remeasured at its acquisition-date fair value and the resulting gain or loss is recognised in consolidated profit or loss. The fair value is added to the cost of acquisition to calculate the goodwill.

If the changes in the value of the previously held equity interest in the subsidiary were recognised in other comprehensive income (for example, equity investments at FVTOCI), the amount that was recognised in other comprehensive income is recognised on the same basis as would be required if the previously held equity interest were disposed of.

Goodwill is tested annually for impairment or more frequently if events or changes in circumstances indicate that it might be impaired. Goodwill is measured at cost less accumulated impairment losses. The method of measuring impairment losses of goodwill is the same as that of other assets as stated in the accounting policy (ae) below. Impairment losses of goodwill are recognised in consolidated profit or loss and are not subsequently reversed. Goodwill is allocated to cash-generating units ("**CGU(s)**") that are expected to benefit from the synergies of the acquisition for the purpose of impairment testing.

The non-controlling interests in the subsidiary are initially measured at the non-controlling shareholders' proportionate share of the net fair value of the subsidiary's identifiable assets and liabilities at the acquisition date.

### (c) Associates

Associates are entities over which the Group has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of an entity, but is not control or joint control over those policies. The existence and effect of potential voting rights that are currently exercisable or convertible, including potential voting rights held by other entities, are considered when assessing whether the Group has significant influence. In assessing whether a potential voting right contributes to significant influence, the holder's intention and financial ability to exercise or convert that right is not considered.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (c) Associates *(Continued)*

Investment in an associate is accounted for in the consolidated financial statements by the equity method and is initially recognised at cost. Identifiable assets and liabilities of the associate in an acquisition are measured at their fair values at the acquisition date. The excess of the cost of acquisition over the Group's share of the net fair value of the associate's identifiable assets and liabilities is recorded as goodwill. The goodwill is included in the carrying amount of the investment and is tested for impairment together with the investment at the end of each reporting period when there is objective evidence that the investment is impaired. Any excess of the Group's share of the net fair value of the identifiable assets and liabilities over the cost of acquisition is recognised in consolidated profit or loss.

The Group's share of an associate's post-acquisition profits or losses is recognised in consolidated profit or loss, and its share of the post-acquisition movements in reserves is recognised in the consolidated reserves. The cumulative post-acquisition movements are adjusted against the carrying amount of the investment. When the Group's share of losses in an associate equals or exceeds its interest in the associate, including any other unsecured receivables, the Group does not recognise further losses, unless it has incurred obligations or made payments on behalf of the associate. If the associate subsequently reports profits, the Group resumes recognising its share of those profits only after its share of the profits equals the share of losses not recognised.

The gain or loss on the disposal of an associate that results in a loss of significant influence represents the difference between (i) the fair value of the consideration of the sale plus the fair value of any investment retained in that associate and (ii) the Group's share of the net assets of that associate plus any remaining goodwill relating to that associate and any related accumulated foreign currency translation reserve. If an investment in an associate becomes an investment in a joint venture, the Group continues to apply the equity method and does not remeasure the retained interest.

Unrealised profits on transactions between the Group and its associates are eliminated to the extent of the Group's interests in the associates. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of associates have been changed where necessary to ensure consistency with the policies adopted by the Group.

### (d) Joint arrangements

A joint arrangement is an arrangement of which two or more parties have joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control. Relevant activities are activities that significantly affect the returns of the arrangement. When assessing joint control, the Group considers its potential voting rights as well as potential voting rights held by other parties, to determine whether it has joint control. A potential voting right is considered only if the holder has the practical ability to exercise that right.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (d) Joint arrangements *(Continued)*

A joint arrangement is either a joint operation or a joint venture. A joint operation is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the assets, and obligations for the liabilities, relating to the arrangement. A joint venture is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement.

In relation to its interest in a joint operation, the Group recognises in its consolidated financial statements, its assets, including its share of any assets held jointly; its liabilities, including its share of any liabilities incurred jointly; its revenue from the sale of its share of the output arising from the joint operation; its share of the revenue from the sale of the output by the joint operation; and its expenses, including its share of any expenses incurred jointly, in accordance with the HKFRSs applicable to the particular assets, liabilities, revenues and expenses.

Investment in a joint venture is accounted for in the consolidated financial statements by the equity method and is initially recognised at cost. Identifiable assets and liabilities of the joint venture in an acquisition are measured at their fair values at the acquisition date. The excess of the cost of acquisition over the Group's share of the net fair value of the joint venture's identifiable assets and liabilities is recorded as goodwill. The goodwill is included in the carrying amount of the investment and is tested for impairment together with the investment at the end of each reporting period when there is objective evidence that the investment is impaired. Any excess of the Group's share of the net fair value of the identifiable assets and liabilities over the cost of acquisition is recognised in consolidated profit or loss.

The Group's share of a joint venture's post-acquisition profits or losses is recognised in consolidated profit or loss, and its share of the post-acquisition movements in reserves is recognised in the consolidated reserves. The cumulative post-acquisition movements are adjusted against the carrying amount of the investment. When the Group's share of losses in a joint venture equals or exceeds its interest in the joint venture, including any other unsecured receivables, the Group does not recognise further losses, unless it has incurred obligations or made payments on behalf of the joint venture. If the joint venture subsequently reports profits, the Group resumes recognising its share of those profits only after its share of the profits equals the share of losses not recognised.

The gain or loss on the disposal of a joint venture that results in a loss of joint control represents the difference between (i) the fair value of the consideration of the sale plus the fair value of any investment retained in that joint venture and (ii) the Group's share of the net assets of that joint venture plus any remaining goodwill relating to that joint venture and any related accumulated foreign currency translation reserve. If an investment in a joint venture becomes an investment in an associate, the Group continues to apply the equity method and does not remeasure the retained interest.

Unrealised profits on transactions between the Group and its joint ventures are eliminated to the extent of the Group's interests in the joint ventures. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of joint ventures have been changed where necessary to ensure consistency with the policies adopted by the Group.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (e) Foreign currency translation

#### (i) **Functional and presentation currency**

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the "**functional currency**"). The consolidated financial statements are presented in HK\$, which is the Company's functional and presentation currency.

#### (ii) **Transactions and balances in each entity's financial statements**

Transactions in foreign currencies are translated into the functional currency on initial recognition using the exchange rates prevailing on the transaction dates. Monetary assets and liabilities in foreign currencies are translated at the exchange rates at the end of each reporting period. Gains and losses resulting from this translation policy are recognised in profit or loss.

Non-monetary items that are measured at fair values in foreign currencies are translated using the exchange rates at the dates when the fair values are determined.

When a gain or loss on a non-monetary item is recognised in other comprehensive income, any exchange component of that gain or loss is recognised in other comprehensive income. When a gain or loss on a non-monetary item is recognised in profit or loss, any exchange component of that gain or loss is recognised in profit or loss.

#### (iii) **Translation on consolidation**

The results and financial position of all the Group's entities that have a functional currency different from the Company's presentation currency are translated into the Company's presentation currency as follows:

- Assets and liabilities for each statement of financial position presented are translated at the closing rate at the date of that statement of financial position;
- Income and expenses are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the exchange rates on the transaction dates); and
- All resulting exchange differences are recognised in the foreign currency translation reserve.

On consolidation, exchange differences arising from the translation of the net investment in foreign entities and of borrowings are recognised in the foreign currency translation reserve. When a foreign operation is sold, such exchange differences are recognised in consolidated profit or loss as part of the gain or loss on disposal.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (e) Foreign currency translation *(Continued)*

#### (iii) Translation on consolidation *(Continued)*

Goodwill and fair value adjustments arising from the acquisition of a foreign entity are treated as assets and liabilities of the foreign entity and translated at the closing rate.

### (f) Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other repairs and maintenance are recognised in profit or loss during the period in which they are incurred.

Depreciation of property, plant and equipment is calculated at rates sufficient to write off their cost less their residual values over the estimated useful lives on a straight-line basis. The principal annual rates are as follows:

Furniture, fixtures and equipment	10% to 33%
Leasehold improvements	over the shorter of lease terms or 20%

The residual values, useful lives and depreciation method are reviewed and adjusted, if appropriate, at the end of each reporting period.

The gain or loss on disposal of property, plant and equipment is the difference between the net sales proceeds and the carrying amount of the relevant asset, and is recognised in profit or loss.

### (g) Investment properties

Investment properties are land and/or buildings held to earn rentals and/or for capital appreciation. An investment property is measured initially at its cost including all direct costs attributable to the property.

After initial recognition, the investment property is stated at its fair value based on valuation by an external independent valuer. Gains or losses arising from changes in fair value of the investment property are recognised in profit or loss for the year in which they arise.

If an item of property, plant and equipment becomes an investment property because its use has changed, any difference between the carrying amount and the fair value of this item at the date of transfer is recognised as a revaluation of property, plant and equipment.

The gain or loss on disposal of an investment property is the difference between the net sales proceeds and the carrying amount of the property, and is recognised in profit or loss.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (h) Leases

#### ***The Group as lessee***

Leases are recognised as right-of-use assets and corresponding lease liabilities when the leased assets are available for use by the Group. Right-of-use assets are stated at cost less accumulated depreciation and impairment losses. Depreciation of right-of-use assets is calculated at rates to write off their cost over the shorter of the asset's useful life and the lease term on a straight-line basis. The principal annual rate is as follows:

Leased properties	Over the term of leases
-------------------	-------------------------

Right-of-use assets are measured at cost comprising the amount of the initial measurement of the lease liabilities, lease payments prepaid, initial direct costs and the restoration costs. Lease liabilities include the net present value of the lease payments discounted using the interest rate implicit in the lease if that rate can be determined, or otherwise the Group's incremental borrowing rate. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease term so as to produce a constant periodic rate of interest on the remaining balance of the lease liability.

Payments associated with short-term leases and leases of low-value assets are recognised as expenses in profit or loss on a straight-line basis over the lease terms. Short-term leases are leases with an initial lease term of 12 months or less. Low-value assets are assets of value below USD5,000.

#### ***The Group as lessor***

##### *Operating leases*

Leases that do not substantially transfer to the lessees all the risks and rewards of ownership of assets are accounted for as operating leases. Rental income from operating leases is recognised on a straight-line basis over the term of the relevant lease.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (i) Properties held for sale under development

Properties held for sale under development are stated at the lower of cost and net realisable value. Costs include acquisition costs, prepaid land lease payments, construction costs, borrowing costs capitalised and other direct costs attributable to such properties. Net realisable value is determined by reference to sale proceeds received after the reporting period less selling expenses, or by estimates based on prevailing market condition. On completion, the properties are reclassified to properties held for sale at the then carrying amount.

### (j) Properties held for sale

Properties held for sale are stated at the lower of cost and net realisable value. Costs of properties include acquisition costs, prepaid land lease payments, construction costs, borrowing costs capitalised and other direct costs attributable to such properties. Net realisable value is determined by reference to sale proceeds received after the reporting period less selling expenses, or by estimates based on prevailing market condition.

### (k) Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined using the weighted average basis. The cost of finished goods and work in progress comprises raw materials, direct labour and an appropriate proportion of all production overhead expenditure, and where appropriate, subcontracting charges. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.

### (l) Recognition and derecognition of financial instruments

Financial assets and financial liabilities are recognised in the consolidated statement of financial position when the Group becomes a party to the contractual provisions of the instruments.

Financial assets are derecognised when the contractual rights to receive cash flows from the assets expire; the Group transfers substantially all the risks and rewards of ownership of the assets; or the Group neither transfers nor retains substantially all the risks and rewards of ownership of the assets but has not retained control on the assets. On derecognition of a financial asset, the difference between the asset's carrying amount and the sum of the consideration received is recognised in profit or loss.

Financial liabilities are derecognised when the obligation specified in the relevant contract is discharged, cancelled or expires. The difference between the carrying amount of the financial liability derecognised and the consideration paid is recognised in profit or loss.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (m) Financial assets

Financial assets are recognised and derecognised on a trade date basis where the purchase or sale of an asset is under a contract whose terms require delivery of the asset within the timeframe established by the market concerned, and are initially recognised at fair value, plus directly attributable transaction costs except in the case of financial assets at FVTPL. Transaction costs directly attributable to the acquisition of financial assets at FVTPL are recognised immediately in profit or loss.

Financial assets of the Group are classified under the following categories:

- Financial assets at amortised cost;
- Equity investments at FVTOCI; and
- Financial assets at FVTPL.

#### (i) **Financial assets at amortised cost**

Financial assets (including trade receivables, financial assets included in prepayments, deposits and other receivables, restricted bank deposit and bank and cash balances) are classified under this category if they satisfy both of the following conditions:

- the assets are held within a business model whose objective is to hold assets in order to collect contractual cash flows; and
- the contractual terms of the assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal (“**SPPI**”) amount outstanding.

They are subsequently measured at amortised cost using the effective interest method less loss allowance for expected credit losses.

#### (ii) **Equity investments at FVTOCI**

On initial recognition, the Group can make an irrevocable election (on an instrument-by-instrument basis) to designate investments in equity instruments that are not held for trading as at FVTOCI.

Equity investments at FVTOCI are subsequently measured at fair value with gains and losses arising from changes in fair values recognised in other comprehensive income and accumulated in the equity investment revaluation reserve. On derecognition of an investment, the cumulative gains or losses previously accumulated in the equity investment revaluation reserve are not reclassified to profit or loss.

Dividends on these investments are recognised in profit or loss, unless the dividends clearly represent a recovery of part of the cost of the investment.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (m) Financial assets *(Continued)*

#### (iii) Financial assets at FVTPL

Financial assets are classified under this category if they do not meet the conditions to be measured at amortised cost and the conditions of debt investments at FVTOCI unless the Group designates an equity investment that is not held for trading as at FVTOCI on initial recognition.

Financial assets at FVTPL include derivative financial assets and investments at FVTPL.

Financial assets at FVTPL are subsequently measured at fair value with any gains or losses arising from changes in fair values recognised in profit or loss. The fair value gains or losses recognised in profit or loss are net of any interest income and dividend income. Interest income and dividend income are recognised in profit or loss.

### (n) Loss allowances for expected credit losses

The Group recognises loss allowances for expected credit losses on financial assets at amortised cost. Expected credit losses are the weighted average of credit losses with the respective risks of a default occurring as the weights.

At the end of each reporting period, the Group measures the loss allowance for a financial instrument at an amount equal to the expected credit losses that result from all possible default events over the expected life of that financial instrument ("**lifetime expected credit losses**") for trade receivables, or if the credit risk on that financial instrument has increased significantly since initial recognition.

If, at the end of the reporting period, the credit risk on a financial instrument (other than trade receivables) has not increased significantly since initial recognition, the Group measures the loss allowance for that financial instrument at an amount equal to the portion of lifetime expected credit losses that represents the expected credit losses that result from default events on that financial instrument that are possible within 12 months after the reporting period.

The amount of expected credit losses or reversal to adjust the loss allowance at the end of the reporting period to the required amount is recognised in profit or loss as an impairment gain or loss.

### (o) Cash and cash equivalents

For the purpose of the consolidated statement of cash flows, cash and cash equivalents represent cash at bank and on hand, demand deposits with banks and other financial institutions, and short-term highly liquid investments which are readily convertible into known amounts of cash and subject to an insignificant risk of change in value. Bank overdrafts which are repayable on demand and form an integral part of the Group's cash management are also included as a component of cash and cash equivalents.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### **(p) Financial liabilities and equity instruments**

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument under HKFRSs. An equity instrument is any contract that evidences a residual interest in the assets of the Group after deducting all of its liabilities. The accounting policies adopted for specific financial liabilities and equity instruments are set out in accounting policies 3(q) to (t) below.

### **(q) Borrowings**

Borrowings are initially recognised at fair value, net of transaction costs incurred, and subsequently measured at amortised cost using the effective interest method.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period.

### **(r) Trade payables and financial liabilities included in accruals and other payables**

Trade payables and financial liabilities included in accruals and other payables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method unless the effect of discounting would be immaterial, in which case they are stated at cost.

### **(s) Equity instruments**

Equity instruments issued by the Company are recorded at the proceeds received, net of direct issue costs.

### **(t) Treasury shares**

Own equity instruments which are repurchased and held by the Company of the Group (treasury shares) are recognised directly in equity at cost. No gain or loss is recognised in profit or loss on the purchase, sale issue or cancellation of the Group's own equity instruments.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (u) Revenue from contracts with customers

Revenue is measured based on the consideration specified in a contract with a customer with reference to the customary business practices and excludes amounts collected on behalf of third parties. For a contract where the period between the payment by the customer and the transfer of the promised product or service exceeds one year, the consideration is adjusted for the effect of a significant financing component.

The Group recognises revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. Depending on the terms of a contract and the laws that apply to that contract, a performance obligation can be satisfied over time or at a point in time. A performance obligation is satisfied over time if:

- the customer simultaneously receives and consumes the benefits provided by the Group's performance;
- the Group's performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or
- the Group's performance does not create an asset with an alternative use to the Group and the Group has an enforceable right to payment for performance completed to date.

If a performance obligation is satisfied over time, revenue is recognised by reference to the progress towards complete satisfaction of that performance obligation. Otherwise, revenue is recognised at a point in time when the customer obtains control of the product or service.

In determining whether revenue of the Group should be reported gross or net is based on a continuing assessment of various factors. When determining whether the Group is acting as the principal or agent in offering goods or services to the customer, the Group needs to first identify who controls the specified goods or services before they are transferred to the customer. The Group is a principal who obtains control any of the following: (i) a good or another asset from the other party that the Group then transfers to the customer; (ii) a right to a service to be performed by the other party, which gives the Group the ability to direct that party to provide the service to the customer on the Group's behalf; (iii) a good or service from the other party that the Group then consolidates with other goods or services in providing the specified good or service to the customer. If control is unclear, when the Group is primarily obligated in a transaction, is subject to inventory risk, has latitude in establishing prices, or has several but not all of these indicators, the Group records revenues on a gross basis. Otherwise, the Group records the net amount earned as commissions from products sold or services provided.

### (v) Other revenue

Interest income is recognised using the effective interest method.

Dividend income is recognised when the shareholders' rights to receive payment are established.

Rental income is recognised on a straight-line basis over the lease term.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (w) Employee benefits

#### (i) *Employee leave entitlements*

Employee entitlements to annual leave and long service leave are recognised when they accrue to employees. A provision is made for the estimated liability for annual leave and long service leave as a result of services rendered by employees up to the end of the reporting period. Employee entitlements to sick leave and maternity leave are not recognised until the time of leave.

#### (ii) *Pension obligations*

The Group contributes to defined contribution retirement schemes which are available to all employees. Contributions to the schemes by the Group and employees are calculated as a percentage of employees' basic salaries. The retirement benefit scheme cost charged to profit or loss represents contributions payable by the Group to the funds.

#### (iii) *Termination benefits*

Termination benefits are recognised at the earlier of the dates when the Group can no longer withdraw the offer of those benefits and when the Group recognises restructuring costs and involves the payment of termination benefits.

### (x) Share-based payments

The Group issues equity-settled share-based payments to certain directors, employees and consultants.

Equity-settled share-based payments to directors and employees are measured at the fair value (excluding the effect of non-market-based vesting conditions) of the equity instruments at the date of grant. The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on the Group's estimate of shares that will eventually vest and adjusted for the effect of non-market-based vesting conditions.

Equity-settled share-based payments to consultants are measured at the fair value of the services rendered or if the fair value of the services rendered cannot be reliably measured, at the fair value of the equity instruments granted. The fair value is measured at the date the Group receives the services and is recognised as an expense.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (y) Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are capitalised as part of the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation.

To the extent that funds are borrowed generally and used for the purpose of obtaining a qualifying asset, the amount of borrowing costs eligible for capitalisation is determined by applying a capitalisation rate to the expenditures on that asset. The capitalisation rate is the weighted average of the borrowing costs applicable to the borrowings of the Group that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset.

All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

### (z) Government grants

A government grant is recognised when there is reasonable assurance that the Group will comply with the conditions attaching to it and that the grant will be received.

Government grants relating to income are deferred and recognised in profit or loss over the period to match them with the costs they are intended to compensate.

Government grants that become receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Group with no future related costs are recognised in profit or loss in the period in which they become receivable.

Government grants relating to the purchase of assets are deducted from the carrying amount of the assets. The grant is recognised in profit or loss over the life of a depreciable asset by way of a reduced depreciation charge.

Repayment of a grant related to income is applied first against any unamortised deferred income set up in respect of the grant. To the extent that the repayment exceeds any such deferred income, or where no deferred income exists, the repayment is recognised immediately in profit or loss. Repayment of a grant related to an asset is recorded by increasing the carrying amount of the asset or reducing the deferred income by the amount repayable. The cumulative additional depreciation that would have been recognised in profit or loss to date in the absence of the grant is recognised immediately in profit or loss.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (aa) Taxation

Income tax represents the sum of the current tax and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit recognised in profit or loss because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Group's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences, unused tax losses or unused tax credits can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

Deferred tax liabilities are recognised for taxable temporary differences arising from investments in subsidiaries and associates, and interests in joint ventures, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised, based on tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred tax is recognised in profit or loss, except when it relates to items recognised in other comprehensive income or directly in equity, in which case the deferred tax is also recognised in other comprehensive income or directly in equity.

The measurement of deferred tax assets and liabilities reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### (aa) Taxation *(Continued)*

For the purposes of measuring deferred tax for investment properties that are measured using the fair value model, the carrying amounts of such properties are presumed to be recovered through sale, unless the presumption is rebutted. The presumption is rebutted when the investment property is depreciable and is held within a business model of the Group whose business objective is to consume substantially all of the economic benefits embodied in the investment property over time, rather than through sale. If the presumption is rebutted, deferred tax for such investment properties are measured based on the expected manner as to how the properties will be recovered.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis.

### (ab) Dividends

Final dividends are recognised as a liability when they are approved by the shareholders in a general meeting. Proposed final dividends are disclosed in the note 16 to the consolidated financial statements.

### (ac) Segment reporting

Operating segments and the amounts of each segment item reported in the financial statements are identified from the financial information provided regularly to the Group's most senior executive management for the purposes of allocating resources and assessing the performance of the Group's various lines of business.

Individually material operating segments are not aggregated for financial reporting purposes unless the segments have similar economic characteristics and are similar in respect of the nature of products and services, the nature of production processes, the type or class of customers, the methods used to distribute the products or provide the services, and the nature of the regulatory environment. Operating segments which are not individually material may be aggregated if they share a majority of these criteria.

### (ad) Related parties

A related party is a person or entity that is related to the Group.

(A) A person or a close member of that person's family is related to the Group if that person:

- (i) has control or joint control over the Group;
- (ii) has significant influence over the Group; or
- (iii) is a member of the key management personnel of the Company or of a parent of the Company.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### **(ad) Related parties** *(Continued)*

- (B) An entity is related to the Group if any of the following conditions applies:
- (i) The entity and the Company are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others).
  - (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member).
  - (iii) Both entities are joint ventures of the same third party.
  - (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity.
  - (v) The entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group. If the Group is itself such a plan, the sponsoring employers are also related to the Group.
  - (vi) The entity is controlled or jointly controlled by a person identified in (A).
  - (vii) A person identified in (A)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity).
  - (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the Company or to a parent of the Company.

### **(ae) Impairment of assets**

At the end of each reporting period, the Group reviews the carrying amounts of its tangible and intangible assets except goodwill, investment properties that are measured using the fair value model, deferred tax assets, investments, inventories and receivables to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of any impairment loss. Where it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the CGU to which the asset belongs.

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 3. MATERIAL ACCOUNTING POLICIES *(Continued)*

### **(ae) Impairment of assets** *(Continued)*

If the recoverable amount of an asset or CGU is estimated to be less than its carrying amount, the carrying amount of the asset or CGU is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or CGU) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined (net of amortisation or depreciation) had no impairment loss been recognised for the asset or CGU in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

### **(af) Provisions and contingent liabilities**

Provisions are recognised for liabilities of uncertain timing or amount when the Group has a present legal or constructive obligation arising as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made. Where the time value of money is material, provisions are stated at the present value of the expenditures expected to settle the obligation.

Where it is not probable that an outflow of economic benefits will be required, or the amount cannot be estimated reliably, the obligation is disclosed as a contingent liability, unless the probability of outflow is remote. Possible obligations, whose existence will only be confirmed by the occurrence or non-occurrence of one or more future events are also disclosed as contingent liabilities unless the probability of outflow is remote.

### **(ag) Events after the reporting period**

Events after the reporting period that provide additional information about the Group's position at the end of the reporting period or those that indicate the going concern assumption is not appropriate are adjusting events and are reflected in the consolidated financial statements. Events after the reporting period that are not adjusting events are disclosed in the notes to the consolidated financial statements when material.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 4. CRITICAL JUDGEMENTS AND KEY ESTIMATES

### Critical judgements in applying accounting policies

In the process of applying the accounting policies, the Directors have made the following judgements that have the most significant effect on the amounts recognised in the consolidated financial statements (apart from those involving estimations, which are dealt with below).

#### **(a) Property lease classification – Group as lessor**

The Group has entered into commercial property leases on its investment property portfolio. The Group has determined, based on an evaluation of the terms and conditions of the arrangements, such as the lease term not constituting a major part of the economic life of the commercial property and the present value of the minimum lease payments not amounting to substantially all the fair value of the commercial property, that it retains substantially all the significant risks and rewards incidental to ownership of these properties which are leased out and accounts for the contracts as operating leases.

#### **(b) Deferred tax for investment properties**

For the purposes of measuring deferred tax for investment properties that are measured using the fair value model, the Directors have reviewed the Group's investment property portfolios and concluded that the Group's investment properties are held under a business model whose objective is to consume substantially all of the economic benefits embodied in the investment properties over time, rather than through sale. Therefore, in determining the Group's deferred tax for investment properties, the Directors have rebutted the presumption that investment properties measured using the fair value model are recovered through sale.

### Key sources of estimation uncertainty

The key assumptions concerning the future, and other key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are discussed below:

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 4. CRITICAL JUDGEMENTS AND KEY ESTIMATES *(Continued)*

### Key sources of estimation uncertainty *(Continued)*

#### **(a) Net realisable value of properties held for sale under development**

The Group's properties held for sale under development is stated at the lower of cost and net realisable value, which is the estimated selling price in the ordinary course of business, less estimated costs of completion and selling expense. These estimates are based on the current market condition and the historical experience of constructing and selling properties of similar nature. It could change significantly as a result of changes in customer taste and competitor actions. The Group will reassess the estimates by the end of each reporting period.

#### **(b) Fair values of investment properties**

The Group appointed an independent professional valuer to assess the fair values of the investment properties. In determining the fair values, the valuer has utilised a method of valuation that involves certain estimates. The Directors have exercised their judgement and are satisfied that the method of valuation is reflective of the current market conditions.

#### **(c) Fair values of financial instruments**

The best evidence of fair value is the published price quotations in an active market. In the absence of such information, the fair value is determined by an independent professional valuer. Such valuation is subject to limitations of the valuation models adopted and the uncertainty in estimates used by the management of the Group in the assumptions. Should the estimates and the relevant parameters of the valuation models be changed, there would be material changes in the fair value of certain financial instruments without quoted prices. Further details are given in note 6 to the consolidated financial statements.

#### **(d) Allowance for expected credit loss for financial assets at amortised cost**

The Group makes loss allowance on financial assets at amortised cost based on various factors, including the ageing of the receivables, historical write-off experience and forward-looking information. The identification of impairment of financial assets at amortised cost requires the use of judgement and estimates. Where the expectations are different from the original estimates, such differences will impact the carrying amounts of the financial assets, and the allowance for credit losses on financial assets is recognised in the years in which such estimates have been changed. See note 5(b) to the consolidated financial statements for further discussion.

#### **(e) Income taxes**

The Group is subject to income taxes in several jurisdictions. Significant estimates are required in determining the provision for income taxes. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the year in which such determination is made.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 5. FINANCIAL RISK MANAGEMENT

The Group's activities expose it to a variety of financial risks: foreign currency risk, credit risk, liquidity risk and interest rate risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial performance.

### (a) Foreign currency risk

The Group has certain exposure to foreign currency risk as part of its business transactions, assets and liabilities are denominated in AUD, RMB, USD, EUR and CHF which are currencies other than the functional currencies of the group entities. The Group currently does not have a foreign currency hedging policy in respect of foreign currency transactions, assets and liabilities. The Group will monitor its foreign currency exposure closely and will consider hedging significant foreign currency exposure should the need arise.

The following table details the sensitivity of the Group to a 5% increase and decrease in HK\$ against the relevant foreign currencies. 5% represents management's assessment of the reasonably possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currencies denominated monetary items and adjusts their translation at the reporting date on a 5% change in foreign currency rates. A positive/negative number below indicates an increase/decrease in consolidated profit after tax for the year where HK\$ strengthens 5% against the relevant foreign currencies. For a weakening of HK\$ against the relevant foreign currency, there would be an equal but opposite impact on consolidated profit after tax for the year.

	2025 HK\$'000	2024 HK\$'000
USD*	(372)	(361)
AUD	(6,157)	(221)
RMB	(889)	(858)
CHF	(77)	(127)
EUR	54	74

\* HK\$ is pegged with USD between the range of 7.75 to 7.85 (USD: HK\$). The above analysis on 5% change in HK\$ against USD is for illustrative purposes only.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 5. FINANCIAL RISK MANAGEMENT *(Continued)*

### **(b) Credit risk**

The carrying amounts of trade receivables and non-trade receivables, including bank and cash balances, restricted bank deposit and financial assets included in prepayments, deposits, and other receivables included in the consolidated statement of financial position represent the Group's maximum exposure to credit risk in relation to the Group's financial assets.

The Group does not hold any collateral or other credit enhancements to cover its credit risks associated with its financial assets.

The Group limits its exposure to credit risk by rigorously selecting the counterparties. Credit risk on receivables is minimised as the Group performs ongoing evaluation on the financial condition of its debtors and tightly monitors the ageing of its receivable balances. Follow-up action is taken in the case of overdue balances. In addition, the management of the Group reviews the recoverability of receivables individually and collectively at each reporting date to ensure that adequate impairment losses are made for irrecoverable amounts.

### **(i) Trade receivables**

In order to minimise credit risk, the Directors have delegated a team to be responsible for the determination of credit limits, credit approvals and other monitoring procedures. In addition, the Directors review the recoverable amount of each individual trade debt regularly to ensure that adequate impairment losses are recognised for irrecoverable debts. In this regard, the Directors consider that the Group's credit risk is significantly reduced.

The Group has no significant concentration of credit risk, with exposure spread over a number of customers.

For trade receivables to which the Group applies the simplified approach for impairment, information based on the provision matrix and details of the quantitative data in respect of the Group's exposure to credit risk arising from trade receivables are disclosed in note 29 to the consolidated financial statements.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 5. FINANCIAL RISK MANAGEMENT *(Continued)*

### (b) Credit risk *(Continued)*

#### (ii) **Non-trade receivables**

At the end of each reporting period, the Group measures the loss allowance for non-trade receivables at an amount equal to the lifetime expected credit losses if the credit risk on that non-trade receivables has increased significantly since initial recognition.

The Group considers whether there has been a significant increase in credit risks of non-trade receivables on an ongoing basis throughout each reporting period by comparing the risk of a default occurring as at the reporting date with the risk of default as at the date of initial recognition. It considers available reasonable and supportive forwarding-looking information. Especially the following information is used:

- internal credit rating;
- external credit rating (if available);
- actual or expected significant adverse changes in business, financial or economic conditions that are expected to cause a significant change to the borrower's ability to meet its obligations;
- actual or expected significant changes in the operating results of the borrower;
- significant increases in credit risk on other financial instruments of the same borrower;
- significant changes in the value of the collateral or in the quality of guarantees or credit enhancements; and
- significant changes in the expected performance and behaviour of the borrower, including changes in the payment status of borrowers.

A significant increase in credit risk is presumed if a debtor is more than 30 days past due in making a contractual payment. A default on a financial asset is when the counterparty fails to make contractual payments within 60 days of when they fall due.

Non-trade receivables are written off when there is no reasonable expectation of recovery, such as a debtor failing to engage in a repayment plan with the Group. The Group normally categorises a non-trade receivable for write off when a debtor fails to make contractual payments greater than 360 days past due. Where non-trade receivables have been written off, the Group, if practicable and economical, continues to engage in enforcement activity to attempt to recover the receivable due.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 5. FINANCIAL RISK MANAGEMENT *(Continued)*

### (b) Credit risk *(Continued)*

#### (ii) **Non-trade receivables** *(Continued)*

##### *Restricted bank deposit and bank and cash balances*

The Group has concentrations of credit risk comprising deposits placed at two financial institutions of HK\$7,248,000 (2024: HK\$32,275,000), which represents approximately 36% (2024: 81%) of the aggregate balance of restricted bank deposit and bank and cash balances. The Directors considered that the credit risk on restricted bank deposit and bank and cash balances is limited because the counterparties are banks with high credit ratings assigned by international credit-rating agencies.

##### *Financial assets included in prepayments, deposits and other receivables*

For financial assets included in prepayments, deposits and other receivables, the Directors make periodic individual assessments on the recoverability of such financial assets based on historical settlement records, past experience, and also quantitative and qualitative information that is reasonable and supportive forward-looking information. The Directors believe that there are no significant increases in credit risks of these amounts since initial recognition, and the Group provided impairment based on 12-month expected credit losses. During the year ended 31 December 2025, impairment losses of financial assets included in prepayments, deposits and other receivables amounting to HK\$1,196,000 (2024: reversal of impairment losses of HK\$4,682,000) was recognised in the profit or loss.

The Group had a concentration of credit risk as 39% (2024: 39%) of the total financial assets included in prepayments, deposits and other receivables as at 31 December 2025 was due from one counterparty.

The Group uses three categories for non-trade receivables, which reflect their credit risk and how the loss provision is determined for each of the categories. In calculating the expected credit loss rates, the Group considers historical loss rates for each category and adjusts for forward-looking data.

<b>Category</b>	<b>Definition</b>	<b>Loss provision</b>
Low risk	Low risk of default and strong capacity to pay	12-month expected losses
Doubtful	Significant increase in credit risk	Lifetime expected losses
Loss	Credit-impaired	Lifetime expected losses

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 5. FINANCIAL RISK MANAGEMENT *(Continued)*

### (b) Credit risk *(Continued)*

#### (ii) *Non-trade receivables* *(Continued)*

	<b>Financial assets included in prepayments, deposits and other receivables</b> HK\$'000	<b>Restricted bank deposit</b> HK\$'000	<b>Bank and cash balances</b> HK\$'000	<b>Total</b> HK\$'000
<b>As at 31 December 2025</b>				
Gross carrying amounts	<b>568,943</b>	<b>7,105</b>	<b>13,079</b>	<b>589,127</b>
Provision for loss allowance	<b>(2,671)</b>	–	–	<b>(2,671)</b>
Net carrying amounts	<b>566,272</b>	<b>7,105</b>	<b>13,079</b>	<b>586,456</b>
<b>As at 31 December 2024</b>				
Gross carrying amounts	560,204	6,550	29,944	596,698
Provision for loss allowance	(8,864)	–	–	(8,864)
Net carrying amounts	551,340	6,550	29,944	587,834

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 5. FINANCIAL RISK MANAGEMENT *(Continued)*

### (b) Credit risk *(Continued)*

#### (ii) **Non-trade receivables** *(Continued)*

All of these non-trade receivables are considered to have low risk and are under the 'Low risk' category because they have a low risk of default and have strong abilities to meet their obligations.

	<b>Financial assets included in prepayments, deposits and other receivables</b> HK\$'000	<b>Restricted bank deposit</b> HK\$'000	<b>Bank and cash balances</b> HK\$'000	<b>Total</b> HK\$'000
Weighted average expected credit loss rate				
2025	<b>0.47%</b>	<b>0%</b>	<b>0%</b>	<b>0.45%</b>
2024	1.58%	0%	0%	1.49%
Loss allowance as at				
1 January 2024	13,917	–	–	13,917
Decrease in provision in 2024	(4,682)	–	–	(4,682)
Exchange differences	(371)	–	–	(371)
Loss allowance as at				
31 December 2024 and				
1 January 2025	<b>8,864</b>	–	–	<b>8,864</b>
Written off	<b>(7,615)</b>	–	–	<b>(7,615)</b>
Increase in provision in 2025	<b>1,196</b>	–	–	<b>1,196</b>
Exchange differences	<b>226</b>	–	–	<b>226</b>
Loss allowance as at				
31 December 2025	<b>2,671</b>	–	–	<b>2,671</b>

The decrease in loss allowance for financial assets included in prepayments, deposits and other receivables is due to a decrease in expected credit loss rates.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 5. FINANCIAL RISK MANAGEMENT *(Continued)*

### (c) Liquidity risk

The Group's policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves of cash to meet its liquidity requirements in the short and longer terms.

The maturity analysis, based on undiscounted cash flows, of the Group's financial liabilities is as follows:

	<b>Less than 1 year or on demand</b> HK\$'000	<b>Between 1 and 5 years</b> HK\$'000	<b>Over 5 years</b> HK\$'000	<b>Total</b> HK\$'000
<b>As at 31 December 2025</b>				
Bank borrowings	<b>278,027</b>	<b>108,740</b>	<b>30,058</b>	<b>416,825</b>
Lease liabilities	<b>340</b>	<b>255</b>	–	<b>595</b>
Trade payables	<b>251</b>	–	–	<b>251</b>
Financial liabilities included in accruals and other payables	<b>30,210</b>	–	–	<b>30,210</b>
Amounts due to related parties	<b>11,953</b>	–	–	<b>11,953</b>
	<b>320,781</b>	<b>108,995</b>	<b>30,058</b>	<b>459,834</b>
<b>As at 31 December 2024</b>				
Bank borrowings	88,769	204,880	38,387	332,036
Lease liabilities	495	854	–	1,349
Trade payables	10	–	–	10
Financial liabilities included in accruals and other payables	24,642	–	–	24,642
Amounts due to related parties	7,353	–	–	7,353
	121,269	205,734	38,387	365,390

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 5. FINANCIAL RISK MANAGEMENT *(Continued)*

### (d) Interest rate risk

The Group's exposure to interest-rate risk arises from its bank deposits, bank borrowings and lease liabilities.

The Group's bank deposits and bank borrowings, which bear interests at fixed interest rates, as well as lease liabilities, are subject to fair value interest rate risks.

The Group's bank deposits and bank borrowings, which bear interests at variable rates varied with the then prevailing market condition, are subject to cash flow interest rate risks. However, such exposure of bank deposits is minimal to the Group as these bank deposits are all short-term in nature.

At 31 December 2025, if interest rates at that date had been 1% lower with all other variables held constant, consolidated profit after tax for the year would have been HK\$2,428,000 (2024: HK\$1,650,000) higher, arising mainly as a result of lower interest expense on bank borrowings. If interest rates had been 1% higher, with all other variables held constant, consolidated profit after tax for the year would have been HK\$2,428,000 (2024: HK\$1,650,000) lower, arising mainly as a result of higher interest expense on bank borrowings.

### (e) Categories of financial instruments

	2025 HK\$'000	2024 HK\$'000
<b>Financial assets:</b>		
Financial assets at FVTPL:		
– Mandatorily measured	266	165
– Designated as such upon initial recognition	35,970	47,023
Equity investments at FVTOCI:		
– Designated as such upon initial recognition	8,499	6,122
Financial assets at amortised cost (including cash and cash equivalents)	602,555	615,075
<b>Financial liabilities:</b>		
Financial liabilities at amortised cost	423,372	335,069

### (f) Fair values

Except as disclosed in note 6 to the consolidated financial statements, the carrying amounts of the Group's financial assets and financial liabilities as reflected in the consolidated statement of financial position approximate their respective fair values.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 5. FINANCIAL RISK MANAGEMENT *(Continued)*

### (g) Capital management

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for the shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital and to support the Group's stability and growth.

The Group monitors its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, issue new shares, raise new debt financing or sell assets to reduce debts. No changes were made in the objectives, policies or processes during the current financial year and last year. Management regards total equity as capital for capital management purposes.

The Group monitors capital using a gearing ratio, which is net debt divided by the equity attributable to owners of the Company plus net debt. Net debt includes bank borrowings, trade payables, contract liabilities, accruals and other payables and amounts due to related parties, less cash and cash equivalents and restricted bank deposit. The gearing ratios as at the end of the reporting periods were as follows:

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
Bank borrowings	<b>380,395</b>	301,821
Trade payables	<b>251</b>	10
Contract liabilities	<b>33,362</b>	21,838
Accruals and other payables	<b>41,217</b>	36,555
Amounts due to related parties	<b>11,953</b>	7,353
Less: Bank and cash balances	<b>(13,079)</b>	(29,944)
Less: Restricted bank deposit	<b>(7,105)</b>	(6,550)
Net debt	<b>446,994</b>	331,083
Equity attributable to owners of the Company	<b>1,248,503</b>	1,201,604
Capital and net debt	<b>1,695,497</b>	1,532,687
Gearing ratio	<b>26.4%</b>	21.6%

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 6. FAIR VALUE MEASUREMENTS

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following disclosures of fair value measurements use a fair value hierarchy that categorises into three levels the inputs to valuation techniques used to measure fair value:

Level 1 inputs: quoted prices (unadjusted) in active markets for identical assets or liabilities that the Group can access at the measurement date

Level 2 inputs: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 inputs: unobservable inputs for the asset or liability

The Group's policy is to recognise transfers into and transfers out of any of the three levels as of the date of the event or change in circumstances that caused the transfer.

(a) Disclosures of level in fair value hierarchy at 31 December 2025:

Description	Fair value measurements using:			Total 2025 HK\$'000
	Level 1 HK\$'000	Level 2 HK\$'000	Level 3 HK\$'000	
<b>Recurring fair value measurements:</b>				
<i>Financial assets at FVTOCI</i>				
– Unlisted equity investments	–	–	8,499	8,499
<i>Financial assets at FVTPL</i>				
– Unlisted equity investments	–	23,372	12,598	35,970
– Derivative financial assets				
– Call options	–	–	107	107
– Put options	–	–	159	159
<b>Total recurring fair value measurements</b>	<b>–</b>	<b>23,372</b>	<b>21,363</b>	<b>44,735</b>

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 6. FAIR VALUE MEASUREMENTS (Continued)

(a) (Continued)

Disclosures of level in fair value hierarchy at 31 December 2024:

Description	Fair value measurements using:			Total
	Level 1 HK\$'000	Level 2 HK\$'000	Level 3 HK\$'000	2024 HK\$'000
<b>Recurring fair value measurements:</b>				
<i>Financial assets at FVTOCI</i>				
– Unlisted equity investments	–	–	6,122	6,122
<i>Financial assets at FVTPL</i>				
– Unlisted equity investments	–	21,582	25,441	47,023
– Derivative financial assets				
– Call options	–	–	150	150
– Put options	–	–	15	15
<b>Total recurring fair value measurements</b>	–	21,582	31,728	53,310

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 6. FAIR VALUE MEASUREMENTS *(Continued)*

(b) Reconciliation of assets measured at fair value based on Level 3:

Description	Unlisted equity investments (classified as equity investments at FVTOCI)	Unlisted equity investments (classified as financial assets at FVTPL)	Derivative financial assets – Call options (classified as financial assets at FVTPL)	Derivative financial assets – put options (classified as financial assets at FVTPL)	2025 Total
	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
As at 1 January	6,122	25,441	150	15	31,728
Total gains or losses recognised					
in profit or loss (#)	-	(13,625)	(48)	140	(13,533)
in other comprehensive loss	2,676	-	-	-	2,676
Disposal	(543)	-	-	-	(543)
Exchange differences	244	782	5	4	1,035
As at 31 December	8,499	12,598	107	159	21,363
(#) Include gains or losses for assets held at end of Reporting Period	-	(13,625)	(48)	140	(13,533)

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 6. FAIR VALUE MEASUREMENTS (Continued)

(b) (Continued)

Description	Unlisted equity investments (classified as equity investments at FVTOCI) HK\$'000	Unlisted equity investments (classified as financial assets at FVTPL) HK\$'000	Derivative financial assets – Call options (classified as financial assets at FVTPL) HK\$'000	Derivative financial assets – put options (classified as financial assets at FVTPL) HK\$'000	2024 Total HK\$'000
As at 1 January	24,470	27,911	877	–	53,258
Total gains or losses recognised					
in profit or loss (#)	–	20,170	(711)	–	19,459
in other comprehensive loss	(20,109)	–	–	–	(20,109)
Transfer out of level 3	–	(21,751)	–	–	(21,751)
Purchases	2,272	–	–	16	2,288
Exchange differences	(511)	(889)	(16)	(1)	(1,417)
As at 31 December	6,122	25,441	150	15	31,728
(#) Include gains or losses for assets held at end of Reporting Period	–	20,170	(711)	–	19,459

The total gains or losses recognised in other comprehensive loss are presented in “Fair value changes of equity investments at FVTOCI, net of tax” in the consolidated statement of comprehensive income.

During the year ended 31 December 2024, unlisted equity investment classified as financial assets at FVTPL amounting to HK\$21,751,000 was transferred from measurement based on Level 3 to Level 2 as a result of an existing of observable market data.

Other than the transfer disclosed above, there were no transfers of fair value measurements between Level 1 and Level 2 and no other transfers into or out of Level 3 for financial assets during the both years.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 6. FAIR VALUE MEASUREMENTS *(Continued)*

- (c) Disclosure of valuation processes used by the Group and valuation techniques and inputs used in fair value measurements:

The management of the Group is responsible for the fair value measurements of assets and liabilities required for financial reporting purposes, including Level 3 fair value measurements. The management of the Group reports directly to the Board for these fair value measurements. Discussions of valuation processes and results are held between the management of the Group and the Board at least twice a year for interim and annual financial reporting.

For Level 3 fair value measurements, the Group will normally engage external valuation experts with the recognised professional qualifications and recent experience to perform the valuations.

### Level 2 fair value measurements

Description	Valuation technique and key input	Fair value	
		2025 HK\$'000	2024 HK\$'000
Unlisted equity investments classified as financial assets at FVTPL	Recent transaction prices of similar deals	<b>23,372</b>	21,582

### Level 3 fair value measurements

Description	Valuation technique	Unobservable inputs	Range	Effect on fair value for increase of inputs	Fair value	
					2025 HK\$'000	2024 HK\$'000
Unlisted equity investments classified as financial assets at FVTOCI	Valuation multiples	Average price-to-sales multiple of peers	2025: 4.46 to 5.48 (2024: 0.04 to 6.88)	Increase	<b>8,499</b>	6,122
		Discount for lack of marketability	2025: 15.6% (2024: 15.6%)	Decrease		
Unlisted equity investments classified as financial assets at FVTPL	Valuation multiples	Average price-to-sales multiple of peers	2025: 4.46 to 5.48 (2024: 0.73 to 6.88)	Increase	<b>12,598</b>	25,441
		Discount for lack of marketability	2025: 15.6% (2024: 15.6%)	Decrease		
Derivative financial assets – Call options (classified as financial assets at FVTPL)	Black-Scholes option pricing model	Expected volatility	2025: 82.7% (2024: 89.9%)	Increase	<b>107</b>	150
Derivative financial assets – Put Options (classified as financial assets at FVTPL)	Black-Scholes option pricing model	Expected volatility	2025: 8.21% (2024: 11.57%)	Increase	<b>159</b>	15

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 7. SEGMENT INFORMATION

The Group has four (2024: four) reportable segments as follows:

- (a) healthcare-related business – health management services, aesthetic medical services and sale of healthcare-related and CBD downstream products;
- (b) trading business – trading of construction materials and renewable energy products, provision of procurement services of renewable energy products and healthcare-related products sale agency services;
- (c) property-related business – real estate agency services, leasing of investment properties and development and selling of residential properties; and
- (d) equity investment business – management of investment portfolio.

The Group's reportable segments are strategic business units that offer different products and services. They are managed separately because each business requires different technology and marketing strategies.

Segment profits or losses do not include interest income, equity-settled share options expenses, reversal of equity-settled share options expenses, net, finance costs as well as other unallocated corporate income and expenses. Segment assets do not include deferred tax assets as well as other unallocated corporate assets. Segment liabilities do not include deferred tax liabilities, current tax liabilities as well as other unallocated corporate liabilities.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 7. SEGMENT INFORMATION *(Continued)*

### Segment revenues and results

The following is an analysis of the Group's revenues and results from reportable and operating segments:

	Healthcare-related business HK\$'000	Trading business HK\$'000	Property-related business HK\$'000	Equity investment business HK\$'000	Total HK\$'000
<b>For the year ended 31 December 2025</b>					
Revenue from external customers	16,146	1,170	19,202	-	36,518
Segment (loss)/profit	(4,150)	(4,367)	31,879	(9,717)	13,645
Interest income					29,303
Equity-settled share options expenses					(54)
Finance costs					(9,290)
Unallocated income					8,484
Unallocated expenses					(11,551)
Profit before tax					30,537
	Healthcare-related business HK\$'000	Trading business HK\$'000	Property-related business HK\$'000	Equity investment business HK\$'000	Total HK\$'000
<b>For the year ended 31 December 2024</b>					
Revenue from external customers	19,613	13,824	17,239	-	50,676
Segment (loss)/profit	(19,314)	7,176	39,575	15,608	43,045
Interest income					22,045
Equity-settled share options expenses					(190)
Finance costs					(10,294)
Unallocated income					33
Unallocated expenses					(9,238)
Profit before tax					45,401

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 7. SEGMENT INFORMATION *(Continued)*

### Segment assets and liabilities

The following is an analysis of the Group's assets and liabilities by reportable and operating segments:

#### Segment assets

	2025 HK\$'000	2024 HK\$'000
Healthcare-related business	23,591	13,134
Trading business	48,349	90,501
Property-related business	1,085,910	929,544
Equity investment business	106,942	116,418
Total assets of reportable segments	1,264,792	1,149,597
Deferred tax assets	31,215	31,464
Unallocated corporate assets	519,579	487,590
Consolidated total assets	1,815,586	1,668,651

#### Segment liabilities

	2025 HK\$'000	2024 HK\$'000
Healthcare-related business	39,204	41,337
Trading business	111,354	107,532
Property-related business	308,003	217,585
Equity investment business	942	122
Total liabilities of reportable segments	459,503	366,576
Deferred tax liabilities	96,484	89,494
Current tax liabilities	3,118	8,973
Unallocated corporate liabilities	8,238	2,244
Consolidated total liabilities	567,343	467,287

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 7. SEGMENT INFORMATION *(Continued)*

### Other segment information

The following is an analysis of other segment information:

	Healthcare-related business HK\$'000	Trading business HK\$'000	Property-related business HK\$'000	Equity investment business HK\$'000	Reportable segment total HK\$'000	Unallocated HK\$'000	Consolidated total HK\$'000
<b>For the year ended 31 December 2025</b>							
Depreciation and amortisation	(1,093)	-	-	-	(1,093)	(4)	(1,097)
Fair value gains on investment properties	-	-	21,727	-	21,727	-	21,727
Fair value losses on investment at FVTPL	-	-	-	(12,752)	(12,752)	-	(12,752)
Gain on disposal of investment properties	-	-	270	-	270	-	270
Gain on partial disposal of investment in a joint venture	-	-	-	1,207	1,207	-	1,207
Gain on deemed partial disposal of investment in a joint venture	-	-	-	7,081	7,081	-	7,081
Impairment losses of investment in an associate	-	-	-	(854)	(854)	-	(854)
Impairment losses of trade receivables, net	2,521	(3,691)	-	-	(1,170)	-	(1,170)
Reversal of impairment loss/ (impairment losses) of other receivables, net	(282)	(260)	(851)	197	(1,196)	-	(1,196)
Additions to segment non-current assets*	579	-	-	-	579	4	583
<b>As at 31 December 2025</b>							
Investments in associates	-	-	-	4,011	4,011	-	4,011
Investments in a joint venture	-	-	-	46,407	46,407	-	46,407

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 7. SEGMENT INFORMATION (Continued)

### Other segment information (Continued)

	Healthcare-related business HK\$'000	Trading business HK\$'000	Property-related business HK\$'000	Equity investment business HK\$'000	Reportable segment total HK\$'000	Unallocated HK\$'000	Consolidated total HK\$'000
<b>For the year ended 31 December 2024</b>							
Depreciation and amortisation	(1,543)	-	(83)	-	(1,626)	(5)	(1,631)
Fair value gains on investment properties	-	-	23,813	-	23,813	-	23,813
Gain on disposal of property, plant and equipment	57	-	-	-	57	-	57
Loss on written off of inventories	-	(26)	-	-	(26)	-	(26)
Impairment losses of goodwill	(18,500)	-	-	-	(18,500)	-	(18,500)
Impairment losses of investment in an associate	-	-	-	(795)	(795)	-	(795)
Impairment losses of inventories	-	(929)	-	-	(929)	-	(929)
Impairment losses of trade receivables, net	(1,596)	1,392	-	-	(204)	-	(204)
Reversal of impairment loss/ (impairment losses) of other receivables, net	(43)	5,357	(202)	(430)	4,682	-	4,682
Additions to segment non-current assets*	132	-	-	-	132	-	132
<b>As at 31 December 2024</b>							
Investments in associates	-	-	-	4,907	4,907	-	4,907
Investments in a joint venture	-	-	-	49,889	49,889	-	49,889

This segment information has been included in the measures of segment results or assets.

\* Additions to segment non-current assets consist of additions to property, plant and equipment and intangible assets.

### Geographical information

	Revenue		Non-current assets	
	2025 HK\$'000	2024 HK\$'000	2025 HK\$'000	2024 HK\$'000
PRC	35,103	46,516	717,065	668,983
Hong Kong	220	-	7	7
Europe	1,195	2,868	12	21
Others	-	1,292	-	-
Consolidated total	36,518	50,676	717,084	669,011

In presenting the geographical information, revenue is based on the locations of the customers and non-current asset are based on the locations of the assets. Non-current assets are excluding financial assets at FVTPL, equity instruments designated at FVTOCI, derivative financial assets, prepayments, loans and other receivables and deferred tax assets.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 7. SEGMENT INFORMATION *(Continued)*

### Revenue from major customers

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
Trading business segment		
Customer A	<b>N/A<sup>1</sup></b>	8,401
Property related business segment		
Customer B	<b>7,592</b>	N/A <sup>1</sup>

<sup>1</sup> The corresponding revenue did not contribute over 10% of the total revenue of the Group.

## 8. REVENUE

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
Sale of healthcare-related products	<b>9,418</b>	7,516
Healthcare management service income	<b>1,299</b>	4,511
Aesthetic medical service income	<b>5,429</b>	7,577
Sale of CBD downstream products	–	9
Sale of construction materials	–	10,476
Procurement service income of renewable energy products	<b>357</b>	1,006
Sale of renewable energy products	–	1,050
Healthcare-related products sale agency service income	<b>813</b>	1,292
Revenue from contracts with customers	<b>17,316</b>	33,437
Rental income	<b>19,202</b>	17,239
Total revenue	<b>36,518</b>	50,676

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 8. REVENUE (Continued)

### Disaggregation of revenue from contracts with customers

Year ended 31 December 2025

Segments	Healthcare-related business HK\$'000	Trading business HK\$'000	Property related business HK\$'000	Total HK\$'000
<b>Major products/services</b>				
Sale of healthcare-related products	9,418	–	–	9,418
Healthcare management services	1,299	–	–	1,299
Aesthetic medical services	5,429	–	–	5,429
Procurement service of renewable energy products	–	357	–	357
Healthcare-related products sale agency services	–	813	–	813
<b>Total</b>	<b>16,146</b>	<b>1,170</b>	<b>–</b>	<b>17,316</b>
<b>Geographical markets</b>				
PRC	15,544	357	–	15,901
Europe	602	593	–	1,195
Hong Kong	–	220	–	220
<b>Total</b>	<b>16,146</b>	<b>1,170</b>	<b>–</b>	<b>17,316</b>
<b>Timing of revenue recognition</b>				
At a point in time	14,847	1,170	–	16,017
Over time	1,299	–	–	1,299
<b>Total</b>	<b>16,146</b>	<b>1,170</b>	<b>–</b>	<b>17,316</b>

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 8. REVENUE *(Continued)*

### Disaggregation of revenue from contracts with customers *(Continued)*

Year ended 31 December 2024

Segments	Healthcare-related business HK\$'000	Trading business HK\$'000	Property related business HK\$'000	Total HK\$'000
<b>Major products/services</b>				
Sale of healthcare-related products	7,516	–	–	7,516
Healthcare management services	4,511	–	–	4,511
Aesthetic medical services	7,577	–	–	7,577
Sale of CBD downstream products	9	–	–	9
Sale of construction materials	–	10,476	–	10,476
Procurement service of renewable energy products	–	1,006	–	1,006
Sale of renewable energy products	–	1,050	–	1,050
Healthcare-related products sale agency services	–	1,292	–	1,292
Total	19,613	13,824	–	33,437
<b>Geographical markets</b>				
PRC	18,176	11,101	–	29,277
Europe	1,437	1,431	–	2,868
Hong Kong	–	1,292	–	1,292
Total	19,613	13,824	–	33,437
<b>Timing of revenue recognition</b>				
At a point in time	15,102	13,824	–	28,926
Over time	4,511	–	–	4,511
Total	19,613	13,824	–	33,437

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 8. REVENUE *(Continued)*

### **Provision of healthcare management services**

The Group provides healthcare management services to the customers. The customers would generally pay a fixed amount of package fee and generally be entitled to specific healthcare management services throughout the contractual service period. The Group satisfied the performance obligation by providing healthcare management services to the customers within the contractual service period, and these customers would be entitled to consume healthcare management services throughout the contract period. As the Directors considered that the Group has fulfilled its performance obligations throughout a period of time and revenue is therefore recognised over time in a pattern which approximates to the time elapsed. The Group receives three to twelve months of healthcare management service fees in advance from the customers. This gives rise to the contract liabilities, which will be recognised as revenue throughout the period of services.

### **Provision of healthcare-related products sale agency services**

The Group provides healthcare-related products (such as anesthetics) sale agency services to the customer (i.e. the supplier and the buyer of healthcare-related products). Service income is recognised for transactions where the Group is not the primary obligor, is not subject to inventory risk, and does not have latitude in establishing prices. Service income is recognised on a net basis which is based on a fixed percentage of the sales amount. Service income is recognised when the buyer has accepted the goods and the related risks and rewards of ownership. Service income is due for payment upon rendering of services.

### **Sale of healthcare-related products**

The Group sells healthcare-related products to the customers. Sales are recognised when control of the products has been transferred, being when the products are delivered to a customer, and there is no unfulfilled obligation that could affect the customer's acceptance of the products, and the customer has obtained legal titles to the products. Payment of the transaction price is due immediately at the point the customer purchases the products. Sale is made on an advance payment or cash on delivery basis.

### **Provision of aesthetic medical services**

The Group provides aesthetic medical services to the customers. Aesthetic medical service income is recognised in the accounting year when the services have been rendered to customers. Receipt of proceeds in respect of treatment packages for which the relevant services have not been rendered is deferred and recognised as contract liabilities.

### **Sale of construction materials and renewable energy products**

The Group sells construction materials and renewable energy products to the customers. Sales are recognised when control of the products has been transferred, being when the products are delivered to a customer, and there is no unfulfilled obligation that could affect the customer's acceptance of the products, and the customer has obtained legal titles to the products. Sales to customers are normally made with credit terms of 0 to 180 days. For new customers, deposits or cash on delivery may be required. Deposits received are recognised as contract liabilities. A receivable is recognised when the products are delivered to the customers as this is the point in time that the consideration is unconditional because only the passage of time is required before the payment is due.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 8. REVENUE *(Continued)*

### **Provision of property sales and consultancy services**

The Group provides property sales and consultancy services in primary markets to its customers (i.e. property developers). Service income is recognised at a point in time when the service is rendered, and the property buyer has executed the sale and purchase agreement and made the required payments according to the terms and conditions stated in different agency contracts since only by that time the Group has an enforceable right to payment from the property developer for the services performed. Service income is recognised on a net basis which is based on a fixed percentage of the sales amount. The Group generally allows a credit period of not exceeding 1 month to its customers.

### **Sale of residential properties**

The Group sells residential properties to the customers. Sales are recognized when control of the property has been transferred, being when the following conditions are fulfilled: (i) the construction of the property is completed; (ii) the significant risks and rewards of ownership of the completed property are passed to the customer, or when customer has taken physical possession or obtained legal title of the completed property; and (iii) the Group has present right to payment and the collection of the consideration is probable. Deposits and instalments received on properties sold prior to the date of revenue recognition are included in the consolidated statement of financial position under contract liabilities.

### **Provision of procurement service of renewable energy products**

The Group has certain contracts with customers to acquire renewable energy products produced by certain suppliers. Under these contracts, The Group determines that it does not have control of the renewable energy products before they are being transferred to the customer and is in substance providing procurement services to its customers. The Group is acting as an agent and recognises revenue at the net amount that is retained for these arrangements. Revenue is recognised at a point in time (i.e., upon receipt of the customer of the renewable energy products) because this is when the customer benefits from the Group's procurement services.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 9. OTHER INCOME AND GAINS, NET

	2025 HK\$'000	2024 HK\$'000
<b>Other income</b>		
Interest income	<b>29,303</b>	22,045
Dividend income from investments at FVTPL	–	456
Government grants (Note a)	–	904
Compensation income from construction contract	–	6,030
Others	<b>369</b>	401
	<b>29,672</b>	29,836
<b>Gains, net</b>		
Fair value (losses)/gains on investments at FVTPL		
– Designated as such upon initial recognition	<b>(12,752)</b>	20,170
Gain on lease termination	<b>30</b>	–
Fair value gains/(losses) on derivative financial instruments	<b>92</b>	(711)
Gain on disposal of property, plant and equipment	<b>1</b>	57
Loss on written off of inventories	–	(26)
Net foreign exchange gains	<b>8,376</b>	4,013
	<b>(4,253)</b>	23,503
	<b>25,419</b>	53,339

Note:

- (a) Government grants of Nil (2024: HK\$904,000) represented the subsidies received from the local government in support of the business operation. There were no unfulfilled conditions or contingencies relating to these subsidies.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 10. FINANCE COSTS

	<b>2025</b>	2024
	<b>HK\$'000</b>	HK\$'000
Interest on bank loans	<b>9,168</b>	10,263
Interest on amount due to related parties	<b>77</b>	–
Interest on lease liabilities	<b>45</b>	31
	<b>9,290</b>	10,294

## 11. INCOME TAX (CREDIT)/EXPENSE

	<b>2025</b>	2024
	<b>HK\$'000</b>	HK\$'000
Current tax – PRC		
Provision for the year	<b>87</b>	270
(Over)/under-provision in prior years	<b>(5,339)</b>	2
Current tax – Swiss		
Under-provision in prior year	<b>8</b>	137
Withholding tax on interest income – Australia		
Provision for the year	<b>633</b>	579
Withholding tax on dividend – PRC		
Provision for the year	<b>–</b>	3,246
Deferred tax (Note 39)	<b>(2,850)</b>	9,122
	<b>(7,461)</b>	13,356

Hong Kong Profits Tax has been provided at the rate of 16.5% (2024: 16.5%) on the estimated assessable profits arising from Hong Kong for the year, except for one group entity operating in Hong Kong, which is a qualifying corporate under the two-tiered Profits Tax rate regime. For the qualifying group entity, the first HK\$2 million of assessable profits are taxed at the rate of 8.25% (2024: 8.25%), and the remaining assessable profits are taxed at the rate of 16.5% (2024: 16.5%).

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 11. INCOME TAX (CREDIT)/EXPENSE *(Continued)*

Enterprise Income Tax of the PRC has been provided at the rate of 25% (2024: 25%) on the estimated assessable profits arising from the PRC for the year, except for certain group entities operating in PRC, which are taxed at preferential tax rates. Group entities operating in PRC that are qualified as small and thin-profit enterprises with assessable profits of RMB3 million or less, the assessable profits are taxed at the effective rate of 5% (2024: 5%). In addition, group entities operating in the PRC that are qualified as high and new technology enterprises are subject to income tax at a preferential tax rate of 15% (2024: 15%).

Australia corporate income tax has been provided at the rate of 30% (2024: 30%) on the estimated assessable profits arising from Australia for the year.

A group entity, which is a non-tax resident enterprise in Australia, is subject to Australia withholding tax at the tax rate of 10% (2024: 10%) on the gross interest income arising from its loans provided to another group entity, which is a tax resident enterprise in Australia.

Corporate income tax in other jurisdictions has been provided at the rates of taxation prevailing in the jurisdictions in which the group entities operate on the estimated assessable profits arising from those jurisdictions for both years.

The reconciliation between the income tax expense and the product of profit before tax multiplied by the weighted average tax rate of the consolidated companies is as follows:

	<b>2025</b>	2024
	<b>HK\$'000</b>	HK\$'000
Profit before tax	<b>30,537</b>	45,401
Tax at the weighted average tax rate of 5% to 30% (2024: 5% to 30%)	<b>4,371</b>	19,028
Tax effect of share of losses of joint ventures and associates	<b>1,029</b>	754
Tax effect of expenses that are not deductible	<b>973</b>	4,077
Tax effect of income that is not taxable	<b>(23,127)</b>	(14,020)
Tax effect of tax losses not recognised	<b>14,632</b>	3,893
Tax effect of utilisation of tax losses not previously recognised	-	(218)
Tax effect of reversal of tax losses previously recognised	-	43
Tax effect of reversal of deductible temporary difference previously recognised	-	-
Tax effect of deductible temporary difference	-	(340)
(Over)/under-provision in prior years	<b>(5,339)</b>	139
Others	-	-
Income tax expense	<b>(7,461)</b>	13,356

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 12. PROFIT FOR THE YEAR

The Group's profit for the year is stated after charging/(crediting) the following:

	<b>2025</b>	2024
	<b>HK\$'000</b>	HK\$'000
Depreciation of property, plant and equipment	<b>737</b>	1,189
Depreciation of right-of-use assets	<b>360</b>	442
Gain on lease termination	<b>(30)</b>	–
Gain on disposal of property, plant and equipment	<b>(1)</b>	(57)
Loss on written off of inventories	<b>–</b>	26
Gain on disposals of investment properties	<b>270</b>	–
Gain on partial disposal of investment in a joint venture	<b>1,207</b>	–
Gain on deemed partial disposal of investment in a joint venture	<b>7,081</b>	–
Fair value gains on investment properties	<b>(21,727)</b>	(23,813)
Auditor's remuneration:		
Audit services	<b>1,260</b>	1,240
Non-audit services	<b>100</b>	100
	<b>1,360</b>	1,340
Cost of inventories sold	<b>7,761</b>	15,058
Impairment losses of assets:		
Goodwill	<b>–</b>	18,500
Investment in an associate	<b>854</b>	795
Inventories	<b>–</b>	929
	<b>854</b>	20,224
Impairment losses/(reversal of impairment losses) of receivables, net:		
Trade receivables	<b>1,170</b>	204
Other receivables	<b>–</b>	(5,786)
Loan and interest receivables	<b>1,196</b>	1,104
	<b>2,366</b>	(4,478)
Staff costs, including directors' emoluments:		
Salaries, bonus and allowances	<b>11,825</b>	13,023
Equity-settled share options expenses, net	<b>54</b>	190
Retirement benefits scheme contributions	<b>583</b>	499
	<b>12,462</b>	13,712

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 13. DIRECTORS' EMOLUMENTS

The emoluments of each director were as follows:

Name of director	Fees HK\$'000	Salaries and allowances HK\$'000	Equity-settled share-based payments HK\$'000	Retirement benefit scheme contributions HK\$'000	Total HK\$'000
<b>Executive directors</b>					
Mr. Zhou Xuzhou	-	800	-	-	800
Dr. Zeng Wentao	-	-	-	-	-
Ms. Zhou Wen Chuan (Note b)	-	1,200	-	18	1,218
<b>Non-executive director</b>					
Dr. Mao Zhenhua	180	-	-	-	180
<b>Independent non-executive directors</b>					
Professor Chau Chi Wai, Wilton	180	-	-	-	180
Mr. Chen Shi (Note a)	120	-	-	-	120
Mr. Wu Peng	120	-	-	-	120
Total for 2025	600	2,000	-	18	2,618
<b>Executive directors</b>					
Mr. Zhou Xuzhou	-	800	-	-	800
Dr. Zeng Wentao	-	-	-	-	-
Ms. Zhou Wen Chuan (Note b)	-	1,200	-	18	1,218
<b>Non-executive director</b>					
Dr. Mao Zhenhua	180	-	-	-	180
<b>Independent non-executive directors</b>					
Professor Chau Chi Wai, Wilton	180	-	-	-	180
Mr. Chen Shi (Note a)	87	-	-	-	87
Mr. Wu Peng	120	-	-	-	120
Total for 2024	567	2,000	-	18	2,585

Notes:

- (a) Appointed on 10 April 2024.
- (b) Executive Director and Chief Executive Officer.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 13. DIRECTORS' EMOLUMENTS *(Continued)*

During the year ended 31 December 2025, Dr. Zeng Wentao, executive directors of the Company, have agreed to waive his emoluments of HK\$300,000 (2024: HK\$300,000). Save as aforesaid, there was no other arrangement under which a director waived or agreed to waive any emoluments during the year.

During the year, no emoluments were paid by the Group to any of the Directors as an inducement to join or upon joining the Group or as compensation for loss of office.

In prior years, certain directors were granted share options, in respect of their services to the Group, under the 2019 Share Option Scheme, further details of which are set out in note 44 to the consolidated financial statements. The fair value of such options, which has been recognised in the consolidated statement of profit or loss over the vesting period, was determined as at the date of grant and the amount included in the consolidated financial statements for the current year is included in the above directors' emoluments disclosures.

## 14. FIVE HIGHEST PAID INDIVIDUALS

The five highest paid individuals in the Group during the year included two (2024: two) directors, whose emoluments are set out in note 13 to the consolidated financial statements. The emoluments of the remaining three (2024: three) individuals are set out below:

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
Salaries and allowances	<b>2,658</b>	3,187
Provision for equity-settled share options expenses, net	-	9
Retirement benefit scheme contributions	<b>54</b>	109
	<b>2,712</b>	3,305

The emoluments fell within the following bands:

	<b>Number of individuals</b>	
	<b>2025</b>	2024
Nil to HK\$1,000,000	<b>2</b>	1
HK\$1,000,001 to HK\$1,500,000	-	1
HK\$1,500,001 to HK\$2,000,000	<b>1</b>	1

During the year, no emoluments were paid by the Group to any of the highest paid individuals as an inducement to join or upon joining the Group or as compensation for loss of office.

In prior years, share options were granted to the above non-directors highest paid individuals in respect of their services to the Group, under the 2019 Share Option Scheme, further details of which are included in the disclosures in note 44 to the consolidated financial statements. The fair value of such options, which has been recognised in the consolidated statement of profit or loss over the vesting period, was determined as at the date of grant and the amount included in the consolidated financial statements for the year is included in the above non-director highest paid individuals' emoluments disclosure.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 15. RETIREMENT BENEFIT SCHEMES

The Group operates a mandatory provident fund scheme (the “MPF Scheme”) under the Hong Kong Mandatory Provident Fund Schemes Ordinance for all qualifying employees in Hong Kong. The Group’s contributions to the MPF Scheme are calculated at 5% of the salaries and wages subject to a monthly maximum amount of contribution of HK\$1,500 per employee and vest fully with employees when contributed into the MPF Scheme.

The employees of the Group’s subsidiaries established in the PRC are members of a central pension scheme operated by the local municipal government. These subsidiaries are required to contribute a certain percentage of the employees’ basic salaries and wages to the central pension scheme to fund the retirement benefits. The local municipal government undertakes to assume the retirement benefits obligations of all existing and future retired employees of these subsidiaries. The only obligation of these subsidiaries with respect to the central pension scheme is to meet the required contributions under the scheme.

The Group also operates several defined contribution retirement plans for its overseas subsidiaries and pays contributions to publicly or privately administered pension plans on a mandatory, contractual or voluntary basis. Contributions to the schemes by the Group and employees are calculated at fixed percentages of employees’ basic salaries or at agreed fixed amounts.

## 16. DIVIDENDS

	2025 HK\$’000	2024 HK\$’000
<b>Dividends recognized as distribution during the year</b>		
Interim dividend for 2025 paid of HK0.15 cents (2024: Nil) per share	6,141	–
Final dividend for 2024 paid of HK0.4 cents (2024: final dividend for 2023 paid of HK0.4 cents) per share	16,375	16,375
	<b>22,516</b>	16,375

The Board recommend the payment of a 2025 final dividend of HK0.4 cents (2024: HK0.4 cents) per share, totalling approximately HK\$16,375,000 (2024: HK\$16,375,000). Such dividend is subject to approval by the shareholders at the forthcoming annual general meeting. These consolidated financial statements do not reflect this dividend payable.

	2025 HK\$’000	2024 HK\$’000
<b>Dividends proposed subsequent to the end of the reporting period</b>		
Proposed 2025 final dividend of HK0.4 cents (2024: HK0.4 cents) per share	16,375	16,375

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 17. EARNINGS PER SHARE

The calculation of basic and diluted earnings per share is based on the following:

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
<b>Earnings</b>		
Profit attributable to owners of the Company, used in the basic and diluted earnings per share calculation	<b>37,983</b>	32,480
	<b>2025</b>	2024
<b>Number of shares</b>		
Weighted average number of ordinary shares for the purpose of calculating basic earnings per share	<b>4,063,776,115</b>	4,092,562,636
Effect of dilutive potential ordinary shares arising from share options (Note a)	-	-
Weighted average number of ordinary shares used in diluted earnings per share calculation	<b>4,063,776,115</b>	4,092,562,636

Note:

- (a) For the year ended 31 December 2025 and 2024, as the average market share price of the Company's share was lower than assumed exercise price including the fair value of any services to be supplied to the Group in the future under the share option arrangement, accordingly, there would be no dilutive impact.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 18. PROPERTY, PLANT AND EQUIPMENT

	Furniture, fixtures and equipment HK\$'000	Leasehold improvements HK\$'000	Total HK\$'000
<b>Cost</b>			
As at 1 January 2024	3,526	5,176	8,702
Additions	–	132	132
Disposal	(115)	–	(115)
Exchange differences	(108)	(172)	(280)
As at 31 December 2024 and 1 January 2025	<b>3,303</b>	<b>5,136</b>	<b>8,439</b>
Additions	<b>583</b>	–	<b>583</b>
Disposal	<b>(12)</b>	–	<b>(12)</b>
Exchange differences	<b>154</b>	<b>216</b>	<b>370</b>
As at 31 December 2025	<b>4,028</b>	<b>5,352</b>	<b>9,380</b>
<b>Accumulated depreciation</b>			
As at 1 January 2024	1,185	3,623	4,808
Charge for the year	741	448	1,189
Disposal	(19)	–	(19)
Exchange differences	(91)	(126)	(217)
As at 31 December 2024 and 1 January 2025	<b>1,816</b>	<b>3,945</b>	<b>5,761</b>
Charge for the year	<b>481</b>	<b>256</b>	<b>737</b>
Disposal	<b>(12)</b>	–	<b>(12)</b>
Exchange differences	<b>88</b>	<b>171</b>	<b>259</b>
As at 31 December 2025	<b>2,373</b>	<b>4,372</b>	<b>6,745</b>
<b>Carrying amount</b>			
As at 31 December 2025	<b>1,655</b>	<b>980</b>	<b>2,635</b>
As at 31 December 2024	1,487	1,191	2,678

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 19. LEASES AND RIGHT-OF-USE ASSETS

Disclosures of lease-related items:

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
<b>As at 31 December:</b>		
Right-of-use assets		
– Properties	<b>643</b>	1,245
Lease commitments of short-term leases	<b>720</b>	720
The maturity analysis, based on undiscounted cash flows, of the Group's lease liabilities is as follows:		
– Less than 1 year	<b>340</b>	495
– Between 1 and 5 years	<b>255</b>	854
	<b>595</b>	1,349
<b>Year ended 31 December:</b>		
Depreciation charge of right-of-use assets		
– Properties	<b>360</b>	442
Interest on lease liabilities	<b>45</b>	31
Expenses related to short-term leases	<b>1,368</b>	1,243
Total cash outflow for leases	<b>1,818</b>	1,834
Additions to right-of-use assets	–	1,381
Lease modification	<b>281</b>	–

The Group leases various items of properties and other equipment. Lease agreements are typically made for fixed periods of 1 to 3 years (2024: 1 to 3 years). Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose any covenants, and the leased assets may not be used as security for borrowing purposes.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 20. INVESTMENT PROPERTIES

	<b>Investment properties</b> HK\$'000
As at 1 January 2024	598,509
Additions (Note a)	8,131
Fair value gains	23,813
Exchange differences	(20,161)
As at 31 December 2024 and 1 January 2025	<b>610,292</b>
Additions (Note b)	<b>8,037</b>
Disposal (Note c)	<b>(2,867)</b>
Fair value gains	<b>21,727</b>
Exchange differences	<b>26,199</b>
As at 31 December 2025	<b>663,388</b>

Notes:

- (a) During the year ended 31 December 2024, the Group acquired one investment property situated in the PRC with a cash consideration of RMB7,515,000 (equivalent to HK\$8,131,000).
- (b) During the year ended 31 December 2025, the Group acquired one investment property situated in the PRC with a cash consideration of RMB7,400,000 (equivalent to HK\$8,037,000).
- (c) During the year ended 31 December 2025, the Group disposed of one of the investment property (net of tax) of RMB2,889,000 (equivalent to HK\$3,137,000), resulting in a gain on disposal of HK\$270,000.
- (d) As at 31 December 2025, the investment properties with the fair value of HK\$663,388,000 (2024: HK\$610,292,000) were situated in the PRC and were held under medium-term lease. As at 31 December 2025 and 2024, the fair value of the investment properties situated in the PRC was arrived at on the basis of a valuation carried out by Roma Appraisals Limited, an independent professional valuer. The fair values were determined by using the income approach – term and reversionary approach, in which fair value was estimated by taking into account the rental amount in existing agreements of the properties and the reversionary potentials of the tenancies and market approach – direct comparison approach.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 20. INVESTMENT PROPERTIES (Continued)

Notes: (Continued)

- (e) The Group leases out certain of its investment properties under operating leases. The lease terms are ranged from 1 to 8 years (2024: 1 to 8 years). All leases are on a fixed rental basis and do not include variable lease payments.

The minimum rent receivables under non-cancellable operating leases are as follows:

	2025 HK\$'000	2024 HK\$'000
Not later than one year	20,681	17,772
Later than one year and not later than two years	19,209	16,897
Later than two years and not later than three years	17,624	16,400
Later than three years and not later than four years	17,299	16,094
Later than four years and not later than five years	14,934	15,066
Later than five years	27,528	39,671
	<b>117,275</b>	121,900

- (f) As at 31 December 2025, the investment properties situated in the PRC with a carrying amount of HK\$500,743,000 (2024: HK\$452,969,000) were pledged as security for the banking facilities granted to the Group (Note 37).
- (g) Disclosures of level in fair value hierarchy at 31 December 2025:

Description	Fair value measurements using:			Total 2025 HK\$'000
	Level 1 HK\$'000	Level 2 HK\$'000	Level 3 HK\$'000	
<b>Recurring fair value measurements:</b>				
<i>Investment properties</i>				
– Investment properties in PRC	–	–	663,388	663,388
<b>Total recurring fair value measurements</b>	–	–	663,388	663,388

- (h) Disclosures of level in fair value hierarchy at 31 December 2024:

Description	Fair value measurements using:			Total 2024 HK\$'000
	Level 1 HK\$'000	Level 2 HK\$'000	Level 3 HK\$'000	
<b>Recurring fair value measurements:</b>				
<i>Investment properties</i>				
– Investment properties in PRC	–	–	610,292	610,292
<b>Total recurring fair value measurements</b>	–	–	610,292	610,292

During the year, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 (2024: Nil).

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 20. INVESTMENT PROPERTIES (Continued)

Notes: (Continued)

(i) Reconciliation of assets measured at fair value based on Level 3:

Description	2025 HK\$'000	2024 HK\$'000
As at 1 January	<b>610,292</b>	598,509
Total gains recognised in profit or loss (#)	<b>21,727</b>	23,813
Purchases	<b>8,037</b>	8,131
Disposal	<b>(2,867)</b>	–
Exchange differences	<b>26,199</b>	(20,161)
As at 31 December	<b>663,388</b>	610,292
(#): Include gains or losses for assets held at end of Reporting Period	<b>21,727</b>	23,813

### Level 3 fair value measurements

Description	Valuation technique	Unobservable inputs	Range	Effect on fair value for increase of inputs	Fair value	
					2025 HK\$'000	2024 HK\$'000
Investment properties in PRC	Term and reversionary method	Estimated rental value (per sq.m. and per month)	2025: RMB102 to RMB209 (2024: RMB108 to RMB222)	Increase	<b>332,592</b>	531,525
		Rent growth (p.a.)	2025: 0% to 3% (2024: 0% to 3%)	Increase		
		Discount rate	2025: 5.25% to 6.25% (2024: 4.75% to 6%)	Decrease		
Investment properties in PRC	Direct comparison method	Estimated sales value (per sq.m.)	2025: RMB26,569 to RMB28,717 (2024: RMB17,752 to RMB18,312)	Increase	<b>330,796</b>	78,767

As at 31 December 2025, certain investment properties in the PRC amounting to approximately HK\$203,771,000 had their valuation technique changed from the term and reversionary method to the direct comparison method (2024: no change).

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 21. OTHER INTANGIBLE ASSETS

	<b>Computer systems</b> HK\$'000
<b>Cost</b>	
As at 1 January 2024	252
Exchange differences	(8)
As at 31 December 2024 and 1 January 2025	<b>244</b>
Exchange differences	<b>10</b>
As at 31 December 2025	<b>254</b>
<b>Accumulated amortisation</b>	
As at 1 January 2024	252
Exchange differences	(8)
As at 31 December 2024 and 1 January 2025	<b>244</b>
Exchange differences	<b>10</b>
As at 31 December 2025	<b>254</b>
<b>Carrying amount</b>	
As at 31 December 2025	-
As at 31 December 2024	-

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 22. SUBSIDIARIES

Particulars of the subsidiaries as at 31 December 2025 are as follows:

Name	Place of incorporation/ registration and business	Issued/ registered capital	Percentage of ownership interest/ voting power/ profit sharing		Principal activities
			Direct	Indirect	
Meilleure Hemp International Holdings Limited	BVI	USD50,000	100%	–	Investment holding
Meipro Biological Technology Company Limited	Hong Kong	HK\$10,000,000	–	71%	Investment holding
Meilleure Hemp Health Europe SA	Switzerland	CHF100,000	–	100%	Industrial hemp-related business
Green Gold Health SA	Switzerland	CHF100,000	–	100%	Industrial hemp-related business
Meilleure Hemp Holding Limited	Hong Kong	HK\$1,000,000	–	100%	Investment holding
Shenzhen Ruima Technology Co., Ltd. (深圳瑞麻科技有限公司) <sup>1,4</sup>	PRC	RMB10,000,000	–	100%	Investment holding
Shenzhen Meilleure Health Technology Co., Ltd. (深圳市美瑞健康科技有限公司) <sup>2,4</sup>	PRC	RMB30,000,000	–	100%	Sale of healthcare-related products
Shenzhen Jixiaojian Hanking Aesthetic Medical Clinic (深圳肌小簡漢京醫療美容診所) <sup>2,4</sup>	PRC	RMB5,000,000	–	100%	Aesthetic medical services
Shenzhen Jixiaojian Beauty Technology Services Co., Ltd. (深圳肌小簡美容科技服務有限公司) <sup>2,4</sup>	PRC	RMB100,000	–	100%	Investment holding
Shenzhen Ruima Biotechnology Co., Ltd. (深圳市瑞麻生物科技有限公司) <sup>2,4</sup>	PRC	RMB1,000,000	–	100%	Investment holding

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 22. SUBSIDIARIES (Continued)

Name	Place of incorporation/ registration/ and business	Issued/ registered capital	Percentage of ownership interest/ voting power/ profit sharing		Principal activities
			Direct	Indirect	
Wuhu Ruima Tianyu Investment Co., Ltd. ("Wuhu Ruima") (蕪湖瑞麻天宇投資有限公司) <sup>2,4</sup>	PRC	RMB20,000,000	–	100%	Investment holding
Meilleure Group Development Company Ltd	BVI	USD1	100%	–	Investment holding
Meilleure Enterprise Development Company Limited	Hong Kong	HK\$100	–	100%	Investment holding
Wuhu Meilleure Health Management Co., Ltd. (蕪湖美瑞健康管理有限公司) <sup>1,4</sup>	PRC	RMB150,000,000	–	100%	Property leasing, trading of construction materials and agency services
Meilleure Property Management and Consultancy Co. Limited	Hong Kong	HK\$100	–	100%	Investment holding
Nanjing Tuoyu Property Management Co., Ltd. (南京拓宇置業管理有限公司) <sup>1,4</sup>	PRC	RMB2,000,000	–	100%	Agency services
U-Home International Enterprises Limited	BVI	USD1,000	100%	–	Investment holding
U-Home Oceania Pty Limited	Australia	AUD100	–	100%	Property development
Australia Hemp Health Pty Ltd	Australia	AUD100	–	100%	Industrial hemp-related business
Meilleure Group Health Service Company Limited	Hong Kong	HK\$10,000,000	–	100%	Investment holding
Bairui (Shenzhen) Health Management Company Limited (柏瑞(深圳)健康管理有限公司) <sup>1,4</sup>	PRC	RMB5,000,000	–	100%	Health management

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 22. SUBSIDIARIES (Continued)

Name	Place of incorporation/ registration and business	Issued/ registered capital	Percentage of ownership interest/ voting power/ profit sharing		Principal activities
			Direct	Indirect	
Nanjing Bairui Medical Health Management Co., Ltd. (南京柏瑞醫療健康管理有限公司) <sup>2,4</sup>	PRC	RMB10,000,000	–	100%	Health management
Shenzhen Jibenfenxi Aesthetic Medical Clinic (深圳肌本分析醫療美容診所) <sup>2,4</sup>	PRC	RMB10,000,000	–	80%	Health management and aesthetic medical services
Meilleure Health Investment Limited	Hong Kong	HK\$10,000	–	100%	Investment holding
Wuhu Jinmeng Health Management Co., Ltd. (蕪湖金萌健康管理有限公司) <sup>1,4</sup>	PRC	RMB10,000,000	–	100%	Investment holding
Nanjing Mei Jia Rui Business Information Consulting Co., Ltd. (南京美加瑞商務信息諮詢有限公司) <sup>2,4</sup>	PRC	RMB8,000,000	–	100%	Property leasing and agency services
Wuhu Xiaozhou Investment Co., Ltd. (蕪湖曉舟投資有限公司) <sup>2,4</sup>	PRC	RMB1,000,000	–	100%	Investment holding
Meilleure Group Health Service Company Limited	BVI	USD1	100%	–	Investment holding
Meilleure Healthcare Company Limited	Hong Kong	HK\$10,000	–	100%	Investment holding
Shenzhen Qianhai Meilleure Health Management Consulting Co., Ltd (深圳市前海美瑞健康管理諮詢有限公司) <sup>1,4</sup>	PRC	RMB20,000,000	–	100%	Health management
U-Seraphim Company Limited	Hong Kong	HK\$29,000,000	–	100%	Trading of renewable energy products
U-home Solar SA	Switzerland	CHF100,000	–	100%	Trading of renewable energy products
Wuhu Ruimei Kuncheng Industrial Investment Co., Ltd. (蕪湖瑞美昆城產業有限公司) <sup>2,4</sup>	PRC	RMB5,000,000	–	100%	Property leasing services

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 22. SUBSIDIARIES (Continued)

Name	Place of incorporation/ registration and business	Issued/ registered capital	Percentage of ownership interest/ voting power/ profit sharing		Principal activities
			Direct	Indirect	
Wuhu Ruimei Kunhe Industrial Investment Co., Ltd. (蕪湖瑞美昆和產業投資有限公司) <sup>2,4</sup>	PRC	RMB6,000,000	–	100%	Property leasing business
Kunshan Ruimei Kunrun Industrial Investment Co., Ltd. (昆山瑞美昆潤產業投資有限公司) <sup>2,4</sup>	PRC	RMB5,000,000	–	100%	Property leasing business
Kunshan Ruixiao Kunyi Commercial Management Co., Ltd. <sup>2,3,4</sup> (昆山瑞曉昆逸商業管理有限公司)	PRC	RMB3,000,000	–	100%	Property leasing services
Kunshan Ruizhou Kunjun Commercial Management Co., Ltd. <sup>2,3,4</sup> (昆山瑞州昆郡商業管理有限公司)	PRC	RMB3,000,000	–	100%	Property leasing services

<sup>1</sup> These are registered as wholly foreign-owned and limited liability companies under PRC law.

<sup>2</sup> These are registered as limited liability companies under PRC law.

<sup>3</sup> The subsidiaries were established by the Group in 2024.

<sup>4</sup> English company names are translated for identification purposes only.

The above table lists the subsidiaries of the Company which, in the opinion of the Directors, principally affected the results for the year or formed a substantial portion of the net assets of the Group. To give details of other subsidiaries would, in the opinion of the Directors, result in particulars of excessive length.

None of the subsidiaries of the Group had any debt securities outstanding at the end of the Reporting Period or at any time during the year.

The Directors are of the opinion that none of the Group's subsidiaries that have non-controlling interests is material to the consolidated financial statements as a whole; therefore, the financial information in respect of those subsidiaries that have non-controlling interests are not presented.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 23. INVESTMENTS IN ASSOCIATES

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
Unlisted investments in PRC:		
Share of net assets	<b>1,234</b>	1,405
Goodwill	<b>8,115</b>	7,788
Impairment	<b>(5,338)</b>	(4,286)
	<b>4,011</b>	4,907

The following table shows information of associates that are material to the Group. These associates are accounted for in the consolidated financial statements using the equity method. The summarised financial information presented is based on the HKFRS financial statements of the associates.

Although the Group holds less than 20% of the voting power of Guangdong U-light, the Group exercises significant influence over Guangdong U-light because the Group is entitled to appoint one director out of the three directors of Guangdong U-light.

<b>Name</b>	<b>Mei Ai Kang</b>	
	<b>2025</b>	2024
Principal place of business/country of incorporation	<b>PRC</b>	
Principal activities	<b>Immune cells R&amp;D</b>	
% of ownership interests/ voting rights held by the Group	<b>20.83%/ 20.83%</b>	20.83%/ 20.83%

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 23. INVESTMENTS IN ASSOCIATES *(Continued)*

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
<b>As at 31 December:</b>		
Non-current assets	<b>1,428</b>	1,439
Current assets	<b>2,152</b>	3,079
Current liabilities	<b>(72)</b>	(94)
Net assets	<b>3,508</b>	4,424
Group's share of net assets	<b>731</b>	922
Goodwill	<b>8,115</b>	7,788
Impairment	<b>(5,338)</b>	(4,286)
Group's share of carrying amount of interests	<b>3,508</b>	4,424
<b>Year ended 31 December:</b>		
Revenue	-	-
Loss for the year	<b>(1,079)</b>	(1,005)
Other comprehensive gain/(loss)	<b>163</b>	(167)
Total comprehensive loss	<b>(916)</b>	(1,172)
Dividends received from associates	-	-

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 23. INVESTMENTS IN ASSOCIATES (Continued)

Name	Guangdong U-light	
	2025	2024
Principal place of business/country of incorporation	PRC	
Principal activities	Investment, construction and operation of zero-carbon parks	
% of ownership interests/ voting rights held by the Group	10%/ 10%	10%/ 10%
	HK\$'000	HK\$'000
<b>As at 31 December:</b>		
Non-current assets	6,728	5,022
Current assets	1,739	6,553
Non-current liabilities	(3,405)	(3,738)
Current liabilities	(32)	(3,006)
Net assets	5,030	4,831
Group's share of net assets	503	483
Goodwill	–	–
Group's share of carrying amount of interests	503	483
<b>Year ended 31 December:</b>		
Revenue	1,223	676
(Loss)/profit for the year	(5)	43
Other comprehensive gain/(loss)	204	(99)
Total comprehensive gain/(loss)	199	(56)
Dividends received from associates	–	–

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 23. INVESTMENTS IN ASSOCIATES (Continued)

Mei Ai Kang is a strategic investment of the Group, enabling the Group to establish its presence in the immune cells R&D and related business.

As at 31 December 2025, the bank and cash balances of the Group's associates in the PRC denominated in RMB amounted to HK\$1,082,000 (2024: HK\$95,000). Conversion of RMB into foreign currencies is subject to the PRC's Foreign Exchange Control Regulations.

## 24. INVESTMENT IN A JOINT VENTURE

	2025 HK\$'000	2024 HK\$'000
Unlisted investments in PRC:		
Share of net assets	19,105	16,366
Goodwill	27,302	33,523
	<b>46,407</b>	49,889

The following tables show information of a joint venture that is material to the Group. The joint venture is accounted for in the consolidated financial statements using the equity method. The summarised financial information presented is based on the HKFRS financial statements of the joint ventures.

Name	Wingor Bio	
	2025	2024
Principal place of business/country of incorporation	PRC	
Principal activities	Biological service and storage	
% of ownership interests/ voting rights held by the Group	27.51%/ 27.51%	35.20%/ 35.20%

Notes:

- During the year ended 31 December 2025, the Group disposed of 3% share to Ms. Jiang Shu (姜舒), who is a director of an invested entity of the Group. The consideration of the share is RMB3,685,200 (equivalent to HK\$4,002,000), resulting in a loss on disposal of HK\$127,000.
- During the year ended 31 December 2025, the Group disposed of 3.375% share to a third-party. The consideration of the share is RMB5,400,000 (equivalent to HK\$5,865,000), resulting in a gain on disposal of HK\$1,334,000.
- During the year ended 31 December 2025, a third-party performed capital injection of RMB29,600,000 (equivalent to HK\$32,145,000) into Wingor Bio. The group deemed disposal of 1.314% share, resulting in a deemed gain on disposal of HK\$7,081,000.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 24. INVESTMENT IN A JOINT VENTURE *(Continued)*

Name	Wingor Bio	
	2025 HK\$'000	2024 HK\$'000
<b>As at 31 December:</b>		
Non-current assets	<b>33,651</b>	27,968
Current assets	<b>48,788</b>	31,351
Non-current liabilities	<b>(3,447)</b>	(4,890)
Current liabilities	<b>(10,074)</b>	(8,919)
Net assets	<b>68,918</b>	45,510
Non-controlling interests	<b>524</b>	981
	<b>69,442</b>	46,491
Group's share of net assets	<b>19,105</b>	16,366
Goodwill	<b>27,302</b>	33,523
Group's share of carrying amount of interests	<b>46,407</b>	49,889
Cash and cash equivalents included in current assets	<b>37,288</b>	7,365
Current financial liabilities (excluding trade and other payables and provisions) included in current liabilities	<b>1,672</b>	1,785
Non-current financial liabilities (excluding trade and other payables and provisions) included in non-current liabilities	<b>2,736</b>	3,984

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 24. INVESTMENT IN A JOINT VENTURE *(Continued)*

Name	Wingor Bio	
	2025 HK\$'000	2024 HK\$'000
<b>Year ended 31 December:</b>		
Revenue	<b>26,775</b>	24,439
Depreciation and amortisation	<b>(3,254)</b>	(4,354)
Interest income	<b>6</b>	40
Interest expense	<b>(302)</b>	(395)
Income tax credit	<b>5,045</b>	3,536
Loss for the year	<b>(12,563)</b>	(8,004)
Other comprehensive gain/(loss)	<b>2,354</b>	(1,633)
Total comprehensive loss	<b>(10,209)</b>	(9,637)
Dividends received from joint ventures	<b>–</b>	–

Wingor Bio is a strategic investment of the Group, enabling the Group to solidify its existing competitive position in the health management service field.

As at 31 December 2025, the bank and cash balances of the Group's joint ventures in the PRC denominated in RMB amounted to HK\$37,288,000 (2024: HK\$7,365,000). Conversion of RMB into foreign currencies is subject to the PRC's Foreign Exchange Control Regulations.

## 25. EQUITY INVESTMENTS AT FVTOCI

	2025 HK\$'000	2024 HK\$'000
Unlisted equity investments	<b>8,499</b>	6,122

- The above investments amounting to HK\$8,499,000 as at 31 December 2025 (2024: HK\$6,122,000) were intended to be held for the medium to long-term. Designation of these investments as equity investments at FVTOCI could avoid the volatility of the fair value changes of these investments to the profit or loss.
- During the year ended 31 December 2025, the Group did not receive any dividends from its investments (2024: Nil).

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 25. EQUITY INVESTMENTS AT FVTOCI *(Continued)*

- (c) During the year ended 31 December 2025, the Group disposed one equity investment of all remaining share to a third-party. The consideration of the share is RMB500,000 (equivalent to HK\$543,000), resulting the loss on disposal of HK\$56,000 are charged into other comprehensive income, and HK\$31,156,000 related equity invested revaluation reserve are release into retained profits.

## 26. DERIVATIVE FINANCIAL ASSETS

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
Call Options (Note a)	<b>107</b>	150
Put Options (Note b)	<b>159</b>	15
	<b>266</b>	165

Note:

- (a) The balance represents the call option arising from a subscription of certain equity interest in Mei Ai Kang (Note 24). Pursuant to the Capital Injection Agreement (amended by the supplementary agreement dated 28 December 2020 entered into between the Group, Mei Ai Kang and the controlling shareholder of Mei Ai Kang), Mei Ai Kang granted the Group the following rights:
- right to inject not more than RMB10,000,000 into Mei Ai Kang upon the fulfilment of certain conditions, which resulted in the increase in the Group's equity interest in Mei Ai Kang to 30%; and
  - right to further inject RMB10,000,000 into Mei Ai Kang as the operation requires and the funding needs of Mei Ai Kang, which resulted in the further increase in the Group's equity interest in Mei Ai Kang to 37%.
- (b) The balance represents the put option arising from a right to sell back the investment property acquired during the year ended 31 December 2025 (Note 20). Pursuant to the agreement dated 29 November 2024 entered into between the Group and Suzhou Yurun, the Group is entitled to sell back the investment property to Suzhou Yurun within three years from the date of completion. Further details are set out in the announcement of the Company dated 29 November 2024.
- (c) The amount of derivative financial assets expected to be recovered after more than one year is HK\$266,000 (2024: HK\$165,000).

The derivative financial assets are not designated for hedge purposes and are measured at FVTPL. Fair value gains on derivative financial assets amounting to HK\$92,000 (2024: losses on derivative financial assets amounting to HK\$711,000) were charged to profit or loss during the year.

## 27. INVENTORIES

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
Renewable energy products for sale	–	499
Medicines, consumables and other supplies for healthcare-related business	<b>826</b>	1,014
CBD downstream products for sales and other supplies	<b>388</b>	349
	<b>1,214</b>	1,862

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 28. PROPERTIES HELD FOR SALE UNDER DEVELOPMENT

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
As at 1 January	<b>255,086</b>	262,485
Capitalised expenditure	<b>92,596</b>	18,755
Exchange differences	<b>25,390</b>	(26,154)
As at 31 December	<b>373,072</b>	255,086

Note:

- (a) As at 31 December 2025, the properties held for sale under development situated in Australia with a carrying amount of HK\$197,266,000 (2024: HK\$181,850,000) were pledged as security for the banking facilities granted to the Group (Note 37).

According to the accounting policy of the Group, properties held for sale under development are classified as current assets as the construction period of the relevant property development project is expected to be completed in the normal operating cycle.

The carrying amount of properties held for sale under development of approximately HK\$164,915,000 (2024: HK\$255,086,000) as at 31 December 2025 is expected not to be realised within the next twelve months from the end of the reporting period, with the remaining amount expected to be realised within the next twelve months from the end of the reporting period.

## 29. TRADE RECEIVABLES

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
Trade receivables	<b>22,371</b>	32,363
Provision for loss allowance	<b>(6,272)</b>	(5,122)
	<b>16,099</b>	27,241

The Group generally allows a credit period of 0 to 180 days (2024: 0 to 180 days) to its customers in trading business and agency service business. Overdue balances are reviewed regularly by the management of the Group. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

Included in the Group's trade receivables are amounts due from fellow subsidiaries of the Group of HK\$Nil (2024: HK\$281,000), which are repayable on credit terms similar to those offered to the major customers of the Group.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 29. TRADE RECEIVABLES *(Continued)*

The ageing analysis of the trade receivables, based on the invoice date, and net of allowance, is as follows:

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
0 to 30 days	<b>4,331</b>	4,480
31 to 90 days	<b>10,407</b>	14,886
Over 90 days	<b>1,361</b>	7,875
	<b>16,099</b>	27,241

Reconciliation of loss allowance for trade receivables:

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
As at 1 January	<b>5,122</b>	5,056
Increase in loss allowance for the year	<b>1,170</b>	204
Written off	<b>(215)</b>	–
Exchange differences	<b>195</b>	(138)
As at 31 December	<b>6,272</b>	5,122

The Group applies the simplified approach under HKFRS 9 to provide for expected credit losses using the lifetime expected loss provision for all trade receivables. To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics and the days past due. The expected credit losses also incorporate forward-looking information.

	<b>Past due</b>				<b>Total</b>
	<b>Current</b>	<b>Less than 30 days</b>	<b>30 to 90 days</b>	<b>Over 90 days</b>	
As at 31 December 2025					
Weighted average expected loss rate	<b>4.2%</b>	<b>N/A</b>	<b>0%</b>	<b>83.36%</b>	<b>28.04%</b>
Receivable amount (HK\$'000)	<b>15,384</b>	<b>–</b>	<b>238</b>	<b>6,749</b>	<b>22,371</b>
Loss allowance (HK\$'000)	<b>646</b>	<b>–</b>	<b>–</b>	<b>5,626</b>	<b>6,272</b>
As at 31 December 2024					
Weighted average expected loss rate	2.13%	4.17%	7.60%	54.26%	15.83%
Receivable amount (HK\$'000)	6,417	14,194	4,251	7,501	32,363
Loss allowance (HK\$'000)	137	592	323	4,070	5,122

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 30. PREPAYMENTS, LOANS AND OTHER RECEIVABLES

	2025 HK\$'000	2024 HK\$'000
Loan receivables (Note a)	491,243	452,285
Loan interest receivables	33,178	15,927
	<b>524,421</b>	468,212
Provision for loss allowance (Note b)	<b>(2,410)</b>	(1,086)
Loan and interest receivables, net	<b>522,011</b>	467,126
Prepayments to suppliers (Note c)	44,277	32,412
Prepayments for acquisition of an investment property	–	7,513
Consideration receivables in relation to:		
– Partial disposal of investment in an associate (Note d)	–	7,461
– Partial disposal of investment in a joint venture (Note e)	6,501	6,169
Deposits in escrow account (Note f)	29,849	15,982
Other receivables	2,443	3,671
Performance bond receivables (Note g)	5,544	58,531
Other tax receivables	1,434	2,918
Deposits paid	185	178
	<b>612,244</b>	601,961
Provision for loss allowance (Note h)	<b>(261)</b>	(7,778)
<b>TOTAL PREPAYMENTS, LOANS AND OTHER RECEIVABLES</b>	<b>611,983</b>	594,183
Analysed as:		
Current assets	<b>605,198</b>	367,612
Non-current assets	<b>6,785</b>	226,571
	<b>611,983</b>	594,183

Notes:

- (a) As at 31 December 2025, a loan receivable with the carrying amount of approximately HK\$221,780,000 (2024: HK\$212,840,000) was made to U-light Energy, which is denominated in RMB, bears interest rate based on the one-year LPR plus 3.05% per annum and repayable in full in or before 2026. The loan receivable is secured by a personal guarantee provided by Mr. Zhou Xuzhou.

The remaining loan receivables with a total carrying amount of approximately HK\$269,463,000 (2024: HK\$239,445,000) were made to third parties, which are denominated in RMB, bear fixed interest rates ranging from 3% to 8% per annum (2024: 3% to 8% per annum) and repayable in full within one year from the date of the respective loan agreements.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 30. PREPAYMENTS, LOANS AND OTHER RECEIVABLES *(Continued)*

Notes: *(Continued)*

- (b) The movements in the loss allowance for loan and interest receivables during the year are as follows:

	<b>2025</b>	2024
	<b>HK\$'000</b>	HK\$'000
As at 1 January	<b>1,086</b>	–
Increase in loss allowance for the year	<b>1,196</b>	1,104
Exchange differences	<b>128</b>	(18)
As at 31 December	<b>2,410</b>	1,086

- (c) The amounts mainly represented the advance payment to suppliers for renewable energy products (2024: advance payment to suppliers for renewable energy products).
- (d) The amount represented the consideration receivable in relation to the partial disposal of investment in Yunnan Hansu during the year ended 31 December 2020. Pursuant to the relevant sale and purchase agreement amended by the first supplemental agreement dated 31 December 2020 and the second supplemental agreement dated 30 November 2021 entered into between the Group and the relevant purchaser, undiscounted consideration receivable of approximately RMB16,500,000 (equivalent to approximately HK\$20,244,000) as at 31 December 2021 shall be received in 11 instalments from 2022 to 2024. As at 31 December 2025, the remaining amount of approximately RMB7,100,000 (equivalent to approximately HK\$7,615,000) was defaulted and written off in 2025 (2024: RMB7,100,000 (equivalent to approximately HK\$7,461,000)).
- The management made the expected credit loss assessment and no additional loss allowance made for the year ended 31 December 2025 (2024: reversal of loss allowance of approximately HK\$433,000).
- (e) The amount represented the consideration receivable in relation to the partial disposal of investment in Wingor Bio during the year ended 31 December 2021. Pursuant to the relevant sale and purchase agreement, the cash consideration shall be received in or before 2028.
- (f) The amount represented deposits held in an escrow account for the pre-sale of properties held for sale under development received from customers.
- (g) The amount of performance bond receivables is paid to suppliers of renewable energy products to secure more favourable pricing over the next two to three years. The Company has a right to demand repayment at its discretion.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 30. PREPAYMENTS, LOANS AND OTHER RECEIVABLES *(Continued)*

Notes: *(Continued)*

(h) The movements in the loss allowance for prepayments and other receivables during the year are as follows:

	<b>2025</b>	2024
	<b>HK\$'000</b>	HK\$'000
As at 1 January	<b>7,778</b>	13,917
Written off	<b>(7,615)</b>	–
Decrease in loss allowance for the year	–	(5,786)
Exchange differences	<b>98</b>	(353)
As at 31 December	<b>261</b>	7,778

## 31. INVESTMENTS AT FVTPL

	<b>2025</b>	2024
	<b>HK\$'000</b>	HK\$'000
Unlisted equity investments	<b>35,970</b>	47,023

## 32. RESTRICTED BANK DEPOSIT AND BANK AND CASH BALANCES

The Group's restricted bank deposit amounted to HK\$7,105,000 (2024: HK\$6,550,000) as at 31 December 2025 represented a deposit placed with a bank to secure the bank borrowing of the Group in the relevant financial institution. The deposit was denominated in AUD and therefore was subject to foreign currency risk.

As at 31 December 2025, the aggregated amount of restricted bank deposit and bank and cash balances of the Group denominated in RMB amounted to HK\$5,109,000 (2024: HK\$2,392,000). Conversion of RMB into foreign currencies is subject to the PRC's Foreign Exchange Control Regulations.

## 33. TRADE PAYABLES

The ageing analysis of trade payables, based on the invoice date, is as follows:

	<b>2025</b>	2024
	<b>HK\$'000</b>	HK\$'000
0 to 90 days	<b>241</b>	–
Over 90 days	<b>10</b>	10
	<b>251</b>	10

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 34. CONTRACT LIABILITIES

Disclosures of revenue-related items:

	<b>As at 31 December 2025 HK\$'000</b>	As at 31 December 2024 HK\$'000	As at 1 January 2024 HK\$'000
Contract liabilities – Healthcare management services	<b>548</b>	903	387
Contract liabilities – Aesthetic medical services	<b>3,683</b>	4,042	3,810
Contract liabilities – Sales of CBD downstream products	–	38	39
Contract liabilities – Sales of healthcare-related products	<b>709</b>	779	1,858
Contract liabilities – Sales of residential properties	<b>28,422</b>	15,982	4,009
Contract liabilities – Sales of renewable energy products	–	94	55
<b>Total contract liabilities</b>	<b>33,362</b>	21,838	10,158
Transaction prices allocated to performance obligations unsatisfied at end of year and expected to be recognised as revenue in:			
– 2025	–	5,856	
– 2026	<b>184,515</b>	41,782	
– 2027	<b>76,855</b>	–	
– 2028	<b>27,793</b>	–	
	<b>289,163</b>	47,638	
		<b>2025 HK\$'000</b>	2024 HK\$'000
<b>Year ended 31 December</b>			
Revenue recognised in the year that was included in contract liabilities at beginning of year		<b>5,855</b>	5,894
Significant changes in contract liabilities during the year:			
		<b>2025 HK\$'000</b>	2024 HK\$'000
Increase due to operations in the year		<b>18,850</b>	30,196
Transfer of contract liabilities to revenue		<b>(9,370)</b>	(17,293)

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 34. CONTRACT LIABILITIES *(Continued)*

A contract liability represents the Group's obligation to transfer products or services to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer.

Included in the Group's contract liabilities balance are aggregate amount of HK\$587,000 (2024: HK\$413,000) received from related parties, which are (i) three of the members of key management personnel of the Group; (ii) a close family member of one of the Directors; and (iii) fellow subsidiaries of the Group (2024: (i) three of the members of key management personnel of the Group; (ii) a close family member of one of the Directors; and (iii) fellow subsidiaries of the Group).

## 35. ACCRUALS AND OTHER PAYABLES

	2025 HK\$'000	2024 HK\$'000
Construction cost payable	8,227	15,995
Other tax payables	1,164	1,251
Deposit received for disposal of investment properties	10,423	3,555
Rental income received in advance	5,582	7,186
Accruals and other payables	10,676	4,825
Rental deposits received	4,685	3,247
Payroll payables	460	496
	<b>41,217</b>	36,555
Analysed as:		
Current liabilities	41,217	36,555
Non-current liabilities	-	-
	<b>41,217</b>	36,555

## 36. AMOUNTS DUE TO RELATED PARTIES

The balances of AUD550,000 (equivalent to HK\$2,866,000) are unsecured, 8% interest-bearing and fully repayable on 19 September 2026.

Others balances are unsecured, interest-free and have no fixed terms of repayable.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 37. BANK BORROWINGS

	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
Secured bank loans	<b>380,395</b>	301,821
The carrying amounts of bank loans are repayable*:		
Within one year	<b>271,317</b>	83,176
In the second year	<b>33,429</b>	120,969
In the third to fifth years, inclusive	<b>51,281</b>	66,983
Beyond five years	<b>24,368</b>	30,693
	<b>380,395</b>	301,821
Less: Amounts due within one year shown under current liabilities	<b>(271,317)</b>	(83,176)
Amounts shown under non-current liabilities	<b>109,078</b>	218,645

\* The amounts due are based on scheduled repayment dates set out in the loan agreements.

As at 31 December 2025, certain of the Group's bank loans were secured by:

- (a) the Group's investment properties situated in the PRC with a carrying amount of HK\$500,743,000 (2024: HK\$452,969,000) (Note 20);
- (b) a personal guarantee provided by Mr. Zhou Xuzhou (2024: a personal guarantee provided by Mr. Zhou Xuzhou) (Note 47(b)(i));
- (c) a personal guarantee provided by Ms. Zhou Wen Chuan (2024: a personal guarantee provided by Ms. Zhou Wen Chuan) (Note 47(b)(i));
- (d) a personal guarantee provided by a close family member of one of the Directors (2024: a personal guarantee provided by a close family member of one of the Directors) (Note 47(b)(i));
- (e) certain buildings owned by a related company controlled by one of the Directors (2024: certain buildings owned by a related company controlled by one of the Directors) (Note 47(b)(i));
- (f) the Group's restricted bank deposit of HK\$7,105,000 (2024: HK\$6,550,000) (Note 32); and
- (g) the Group's properties held for sale under development with a carrying amount of HK\$197,266,000 (2024: HK\$181,850,000) (Note 28).

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 37. BANK BORROWINGS (Continued)

Secured bank loans comprise:

	2025 HK\$'000	2024 HK\$'000
Fixed-rate borrowings:		
RMB bank loan at 4.45% p.a. <sup>1</sup>	62,098	68,109
RMB bank loan at 2.95% p.a. <sup>7</sup>	5,545	–
RMB bank loan at 3.1% p.a. <sup>7</sup>	1,663	–
RMB bank loan at 3.5% p.a. <sup>2</sup>	6,831	7,449
RMB bank loan at 3.95% p.a. <sup>7</sup>	11,089	10,642
RMB bank loan at 4% p.a. <sup>3</sup>	–	37,247
RMB bank loan at 3.3% p.a. <sup>12</sup>	33,267	–
RMB bank loan at 4% p.a. <sup>4</sup>	6,432	6,917
RMB bank loan at 4% p.a. <sup>9</sup>	4,159	–
RMB bank loan at 4.5% p.a. <sup>5</sup>	6,175	6,499
RMB bank loan at 5.62% p.a. <sup>8</sup>	340	–
Floating-rate borrowings:		
RMB bank loan at 0.65% higher than the benchmark interest rate for RMB loans for one year published by People's Bank of China for the same period <sup>3, 11</sup>	–	3,001
RMB bank loan at 22.449% higher than the benchmark interest rate for RMB loans for more than five years published by People's Bank of China for the same period <sup>6, 10</sup>	57,663	71,834
AUD bank loan at benchmark interest rate published by Australia's central bank <sup>7, 10</sup>	185,133	90,123
	<b>380,395</b>	301,821

<sup>1</sup> Repayable by instalments commencing in 2022 to 2032. The bank loans are subject to several covenants that require the borrower, a subsidiary of the Group, to maintain capital reserve and surplus reserve that shall not be reduced during the loan period. The covenants are tested at the end of each quarter until the maturity of the borrowings. The Group has no indication that it will have difficulty complying with these covenants.

<sup>2</sup> Repayable by instalments commencing in 2024 to 2029.

<sup>3</sup> Repayable in full in 2025.

<sup>4</sup> Repayable by instalments commencing in 2024 to 2032.

<sup>5</sup> Repayable by instalments commencing in 2024 to 2034.

<sup>6</sup> Repayable by instalments commencing in 2019 to 2029.

<sup>7</sup> Repayable in full in 2026.

<sup>8</sup> Repayable by instalments commencing in 2025 to 2030.

<sup>9</sup> Repayable by instalments commencing in 2025 to 2033.

<sup>10</sup> The interest rate will be reset every month.

<sup>11</sup> The interest rate will be reset every quarter.

<sup>12</sup> Repayable in full in 2026. The bank loans are subject to several covenants that require the borrower, a subsidiary of the Group, to maintain capital reserve and surplus reserve that shall not be reduced during the loan period. The covenants are tested at the end of each quarter until the maturity of the borrowings. The Group has no indication that it will have difficulty complying with these covenants.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 38. LEASE LIABILITIES

	Lease payments		Present value of lease payments	
	2025 HK\$'000	2024 HK\$'000	2025 HK\$'000	2024 HK\$'000
Within one year	<b>340</b>	495	<b>302</b>	437
In the second year	<b>255</b>	495	<b>261</b>	494
In the third to fifth years, inclusive	<b>–</b>	359	<b>–</b>	312
	<b>595</b>	1,349		
Less: Future finance charges	<b>(32)</b>	(106)		
Present value of lease liabilities	<b>563</b>	1,243	<b>563</b>	1,243
Less: Amount due for settlement within 12 months (shown under current liabilities)			<b>(302)</b>	(437)
Amount due for settlement after 12 months			<b>261</b>	806

As at 31 December 2025, the average effective borrowing rate ranged from 2% to 6% (2024: from 2% to 6%). Interest rates are fixed at the contract dates and thus expose the Group to fair value interest rate risk.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 39. DEFERRED TAX

The following is the major deferred tax liabilities and assets recognised by the Group:

	Fair value change of financial instruments HK\$'000	Fair value change of investment properties HK\$'000	Withholding tax HK\$'000	Impairment of assets HK\$'000	Depreciation charge of right-of-use assets HK\$'000	Tax losses HK\$'000	Total HK\$'000
As at 1 January 2024	(1,777)	78,032	704	(3,301)	(29)	(19,124)	54,505
Charge/(credit) to profit or loss for the year (Note 11)							
– origination and reversal of temporary differences	4,865	7,705	–	(478)	29	(2,999)	9,122
Charge to other comprehensive loss							
– origination and reversal of temporary differences	(5,027)	–	–	–	–	–	(5,027)
Exchange differences	61	(2,686)	(23)	116	–	1,962	(570)
As at 31 December 2024 and 1 January 2025	<b>(1,878)</b>	<b>83,051</b>	<b>681</b>	<b>(3,663)</b>	<b>–</b>	<b>(20,161)</b>	<b>58,030</b>
Charge/(credit) to profit or loss for the year (Note 11)							
– origination and reversal of temporary differences	<b>(3,806)</b>	<b>6,307</b>	<b>–</b>	<b>824</b>	<b>–</b>	<b>(6,175)</b>	<b>(2,850)</b>
Charge to other comprehensive loss							
– origination and reversal of temporary differences	<b>8,458</b>	<b>–</b>	<b>–</b>	<b>–</b>	<b>–</b>	<b>–</b>	<b>8,458</b>
Exchange differences	<b>19</b>	<b>3,666</b>	<b>28</b>	<b>(138)</b>	<b>–</b>	<b>(1,944)</b>	<b>1,631</b>
As at 31 December 2025	<b>2,793</b>	<b>93,024</b>	<b>709</b>	<b>(2,977)</b>	<b>–</b>	<b>(28,280)</b>	<b>65,269</b>

The following is the analysis of the deferred tax balances for the consolidated statement of financial position purposes:

	2025 HK\$'000	2024 HK\$'000
Deferred tax liabilities	<b>96,484</b>	89,494
Deferred tax assets	<b>(31,215)</b>	(31,464)
	<b>65,269</b>	58,030

At the end of the Reporting Period, the Group has unused tax losses of HK\$236,397,000 (2024: HK\$136,215,000) available for offset against future profits. A deferred tax asset has been recognised in respect of HK\$106,214,000 (2024: HK\$68,366,000) of such losses. No deferred tax asset has been recognised in respect of the remaining HK\$130,183,000 (2024: HK\$67,849,000) due to the unpredictability of future profit streams. Included in unrecognised tax losses are losses arising from the PRC and Switzerland of HK\$82,845,000 (2024: HK\$28,400,000) that will expire within 5 years. Other tax losses may be carried forward indefinitely.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 39. DEFERRED TAX *(Continued)*

Pursuant to the PRC Corporate Income Tax Law, a 10% withholding tax is levied on dividends declared to foreign investors from the foreign investment enterprises established in the PRC. The requirement is effective from 1 January 2008 and applies to earnings after 31 December 2007. The Group is therefore liable for withholding taxes on dividends distributed by those subsidiaries established in the PRC in respect of earnings generated from 1 January 2008. As at 31 December 2025, the aggregate amount of temporary differences associated with undistributed earnings of subsidiaries for which deferred tax liabilities have not been recognised is HK\$46,135,000 (2024: HK\$45,553,000). No liability has been recognised in respect of these differences because the Group controls the dividend policy of these subsidiaries, and it has been determined that no dividend will be distributed by these subsidiaries in the foreseeable future.

## 40. SHARE CAPITAL

	Number of shares	Amount HK\$'000
Authorised:		
Ordinary shares of HK\$0.01 each		
As at 1 January 2024, 31 December 2024, 1 January 2025 and 31 December 2025	10,000,000,000	100,000
Issued and fully paid:		
Ordinary shares of HK\$0.01 each		
As at 1 January 2024, 31 December 2024, 1 January 2025 and 31 December 2025	4,093,756,636	40,938

## 41. TREASURY SHARES

	Number of shares	Amount HK\$'000
As at 1 January 2024, 31 December 2024 and 1 January 2025	1,194,000	335
Repurchase of shares (Note a)	29,706,000	8,864
As at 31 December 2025	30,900,000	9,199

Note:

- (a) During the year ended 31 December 2025, the Group repurchased a total of 29,706,000 ordinary shares listed on the Stock Exchange. The total amount paid to repurchase these ordinary shares was approximately HK\$8,864,000.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 42. STATEMENT OF FINANCIAL POSITION OF THE COMPANY

	Notes	2025 HK\$'000	2024 HK\$'000
<b>Non-current assets</b>			
Investments in subsidiaries		85,742	85,688
		<b>85,742</b>	85,688
<b>Current assets</b>			
Prepayments, deposits and other receivables		250	539
Amounts due from subsidiaries		964,507	1,002,619
Bank and cash balances		6,402	22,253
		<b>971,159</b>	1,025,411
<b>Current liabilities</b>			
Accruals and other payables		8,093	2,097
Amounts due to subsidiaries		203,336	258,350
		<b>211,429</b>	260,447
<b>Net current assets</b>		<b>759,730</b>	764,964
<b>NET ASSETS</b>		<b>845,472</b>	850,652
<b>Equity</b>			
Share capital	40	40,938	40,938
Treasury shares	41	(9,199)	(335)
Reserves	43(b)	813,733	810,049
<b>TOTAL EQUITY</b>		<b>845,472</b>	850,652

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 43. RESERVES

### (a) Nature and purpose of reserves of the Group

The amounts of the Group's reserves and the movements therein for the current and prior years are presented in the consolidated statement of changes in equity on page 75 of the consolidated financial statements.

#### (i) *Share premium*

This represents the premium arising from the issue of shares at a price in excess of their par value per share, less expense incurred in connection with the issue of shares.

#### (ii) *Contributed surplus*

The contributed surplus of the Group consists of:

- Pursuant to the corporate reorganisation of the Group during the period from 2002 to 2003 (the "Reorganisation"), the Company became the holding company of the Group on 24 September 2003. The excess of the consolidated net assets represented by the shares acquired over the nominal value of the shares issued by the Company in the exchange under the Reorganisation was transferred to contributed surplus.
- In the AGM held on 24 May 2017, shareholders duly passed a special resolution to adopt a share premium reduction. Accordingly, the share premium of HK\$408,621,000 was credited to the contributed surplus.

According to Bermuda law, the Company can make a distribution out of the contributed surplus, provided that the Company is, or would after the payment be, able to pay its liabilities as they become due, or the realisable value of the Company's assets exceeds the aggregate of its liabilities and its issued share capital and share premium accounts.

#### (iii) *Share-based payment reserve*

The share-based payment reserve represents the fair value of the actual or estimated number of unexercised share options granted to employees and consultants of the Group recognised in accordance with the accounting policy adopted for equity-settled share-based payments in note 3(y) to the consolidated financial statements.

#### (iv) *Statutory surplus reserve*

In accordance with the Company Law of the PRC, certain subsidiaries of the Group, which are domestic enterprises, are required to allocate 10% of their profit after tax, as determined in accordance with the relevant PRC accounting standards, to their respective statutory surplus reserves until the reserves reach 50% of their respective registered capital. Subject to certain restrictions set out in the Company Law of the PRC, part of the statutory surplus reserves may be converted to increase the share capital, provided that the remaining balance after the capitalisation is not less than 25% of the registered capital.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 43. RESERVES (Continued)

### (a) Nature and purpose of reserves of the Group (Continued)

#### (v) Equity investment revaluation reserve

The equity investment revaluation reserve comprises the cumulative net change in the fair value of equity investments at FVTOCI held at the end of the Reporting Period and is dealt with in accordance with the accounting policy in note 3(n)(ii) to the consolidated financial statements.

#### (vi) Foreign currency translation reserve

The foreign currency translation reserve comprises all foreign exchange differences arising from the translation of the financial statements of foreign operations. The reserve is dealt with in accordance with the accounting policy set out in note 3(e)(iii) to the consolidated financial statements.

#### (vii) Other reserve

This represents the share of reserves of an associate and a joint venture of the Group. The reserve is dealt with in accordance with the accounting policies set out in notes 3(c) and 3(d) to the consolidated financial statements.

### (b) Reserves of the Company

	Share premium account HK\$'000	Contributed surplus account HK\$'000	Share-based payment reserve HK\$'000	Accumulated losses HK\$'000	Total HK\$'000
As at 1 January 2024	572,574	490,801	3,953	(211,084)	856,244
Total comprehensive losses for the year	-	-	-	(30,010)	(30,010)
Provision for equity-settled share-based payments	-	-	190	-	190
Release of share-based payment reserve	-	-	(34)	34	-
Dividend recognised as a distribution	-	-	-	(16,375)	(16,375)
As at 31 December 2024	572,574	490,801	4,109	(257,435)	810,049
As at 1 January 2025	<b>572,574</b>	<b>490,801</b>	<b>4,109</b>	<b>(257,435)</b>	<b>810,049</b>
Total comprehensive losses for the year	-	-	-	<b>26,146</b>	<b>26,146</b>
Provision for equity-settled share-based payments	-	-	<b>54</b>	-	<b>54</b>
Release of share-based payment reserve	-	-	<b>(1,252)</b>	<b>1,252</b>	-
Dividend recognised as a distribution	-	-	-	<b>(22,516)</b>	<b>(22,516)</b>
As at 31 December 2025	<b>572,574</b>	<b>490,801</b>	<b>2,911</b>	<b>(252,553)</b>	<b>813,733</b>

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 44. SHARE-BASED PAYMENTS

### Equity-settled share option scheme

The 2019 Share Option Scheme was adopted pursuant to a resolution passed on 20 June 2019, which will expire on 19 June 2029, for the primary purpose of providing incentives to employees, executives, officers or directors of the Group, its invested entities and substantial shareholders; and advisors, consultants, agents, suppliers, customers, distributors, contractors, business partners and joint venture partners of the Group (collectively the “**Eligible Participants**”). Accordingly, the remaining life of the 2019 Share option Scheme is approximately 3.5 years.

The maximum number of shares which may be issued upon exercise of all outstanding share options to be granted and yet to be exercised under the 2019 Share Option Scheme and other schemes of the Company at any time shall not exceed 30% of the total number of the shares of the Company in issue from time to time. The total number of shares issued and may fall to be issued upon exercise of the share options granted under the 2019 Share Option Scheme and any other share option schemes of the Company (including both exercised and outstanding options) to each Eligible Participant in any 12-month period up to and including the date of grant shall not exceed 1% of the shares of the Company in issue as at the date of grant. Any further grant of shares options in excess of this limit is subject to shareholders’ approval in a GM.

Any grant of share options to a director, chief executive or substantial shareholder of the Company or any of their respective associates is required to be approved by the Independent Non-Executive Directors (excluding any Independent Non-Executive Director who is the grantee of the share options). In addition, any share options granted to a substantial shareholder of the Company or any Independent Non-Executive Directors, or to any of their associates, in excess of 0.1% of the shares of the Company in issue at any time or with an aggregate value (based on the price of the Company’s shares at the date of the grant) in excess of HK\$5 million, within any 12-month period, are subject to shareholders’ approval in advance in a GM.

The offer of a grant of share options may be accepted within 30 days from the date of the offer, upon payment of a nominal consideration of HK\$1 in total by the grantee. A share option may be exercised in accordance with the terms of the 2019 Share Option Scheme at any time after the date upon which the share option is deemed to be granted and accepted and prior to the expiry of 10 years from that date. The period during which a share option may be exercised will be determined by the Board in its absolute discretion, save that no share option may be exercised more than 10 years after it has been granted and accepted.

The exercise price in relation to each share option offered to an Eligible Participant shall be such price as the Board in its absolute discretion shall determine, save that such price must be at least the higher of:

- (i) the official closing price of the Company’s shares as stated in the daily quotation sheets of the Stock Exchange on the date of the grant, which must be a day on which the Stock Exchange is open for the business of dealing in securities;
- (ii) the average of the official closing price of the Company’s shares as stated in the daily quotation sheets of the Stock Exchange for the 5 business days immediately preceding the date of grant; and
- (iii) the nominal value of the Company’s share.

Share options do not confer rights on the holder to dividends or to vote at shareholders’ meetings.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 44. SHARE-BASED PAYMENTS *(Continued)*

Details of the movements of share options outstanding during the year are as follows:

Category of participants	Date of grant (Note a)	Exercise period	Exercise price HK\$	Number of share options		
				Outstanding as at 1/1/2025	Lapsed during the year	Outstanding as at 31/12/2025
Directors	12.5.2020 (Note b)	12.5.2021 – 11.5.2030 (Note d)	0.33	2,500,500	-	2,500,500
	24.6.2020 (Note c)	24.6.2021 – 23.6.2030 (Note e)	0.33	4,500,000	-	4,500,000
Employees	12.5.2020 (Note b)	12.5.2021 – 11.5.2030 (Note d)	0.33	501,000	-	501,000
	12.5.2020 (Note b)	12.5.2022 – 11.5.2030 (Note f)	0.33	501,000	(501,000)	-
	12.5.2020 (Note b)	12.5.2021 – 11.5.2030 (Note g)	0.33	5,418,000	(2,208,000)	3,210,000
	12.5.2020 (Note b)	12.5.2020 – 11.5.2030 (Note i)	0.33	996,000	(996,000)	-
Others	12.5.2020 (Note b)	12.5.2021 – 11.5.2030 (Note d)	0.33	750,000	-	750,000
	12.5.2020 (Note b)	12.5.2022 – 11.5.2030 (Note h)	0.33	504,000	-	504,000
	12.5.2020 (Note b)	N/A (Note i)	0.33	5,004,000	-	5,004,000
<b>Total for Scheme</b>				<b>20,674,500</b>	<b>(3,705,000)</b>	<b>16,969,500</b>
<b>Exercisable at the end of the year</b>				<b>15,043,500</b>		<b>11,965,500</b>
<b>Weighted average exercise price (HK\$)</b>				<b>0.33</b>	<b>0.33</b>	<b>0.33</b>

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 44. SHARE-BASED PAYMENTS *(Continued)*

Details of the movements of share options outstanding during the prior year are as follows:

Category of participants	Date of grant (Note a)	Exercise period	Exercise price HK\$	Number of share options		
				Outstanding as at 1/1/2024	Lapsed during the year	Outstanding as at 31/12/2024
Directors	12.5.2020 (Note b)	12.5.2021 – 11.5.2030 (Note d)	0.33	5,001,000	(2,500,500)	2,500,500
	24.6.2020 (Note c)	24.6.2021 – 23.6.2030 (Note e)	0.33	9,000,000	(4,500,000)	4,500,000
Employees	12.5.2020 (Note b)	12.5.2021 – 11.5.2030 (Note d)	0.33	1,002,000	(501,000)	501,000
	12.5.2020 (Note b)	12.5.2022 – 11.5.2030 (Note f)	0.33	1,002,000	(501,000)	501,000
	12.5.2020 (Note b)	12.5.2021 – 11.5.2030 (Note g)	0.33	5,622,000	(204,000)	5,418,000
	12.5.2020 (Note b)	12.5.2020 – 11.5.2030 (Note i)	0.33	996,000	–	996,000
Others	12.5.2020 (Note b)	12.5.2021 – 11.5.2030 (Note d)	0.33	1,500,000	(750,000)	750,000
	12.5.2020 (Note b)	12.5.2022 – 11.5.2030 (Note h)	0.33	504,000	–	504,000
	12.5.2020 (Note b)	N/A (Note i)	0.33	5,004,000	–	5,004,000
<b>Total for Scheme</b>				<b>29,631,000</b>	<b>(8,956,500)</b>	<b>20,674,500</b>
<b>Exercisable at the end of the year</b>				<b>13,716,000</b>		<b>15,043,500</b>
<b>Weighted average exercise price (HK\$)</b>				<b>0.33</b>	<b>0.33</b>	<b>0.33</b>

Notes:

- The vesting period of the share options is from the date of grant until the commencement of the exercise period.
- On 12 May 2020, the Company granted 61,248,000 share options to certain Eligible Participants pursuant to the 2019 Share Option Scheme. Further details are set out in the announcement of the Company dated 12 May 2020 and the circular of the Company dated 3 June 2020.
- On 12 May 2020, the Company proposed to grant 18,000,000 share options to Ms. Zhou Wen Chuan pursuant to the 2019 Share Option Scheme. At the 2020 SGM, the resolution in respect of approving the proposed grant of share options to Ms. Zhou Wen Chuan was duly passed by the independent shareholders of the Company by way of poll. Further details are set out in the announcements of the Company dated 12 May 2020 and 24 June 2020 and the circular of the Company dated 3 June 2020.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 44. SHARE-BASED PAYMENTS *(Continued)*

Notes: *(Continued)*

- (d) Subject to the fulfilment of certain annual performance targets as determined by the Board, the share option granted shall be vested during the relevant periods in 4 tranches: (i) 25% of which shall be vested after 12 months of the Date of Acceptance; (ii) another 25% of which shall be vested after 24 months of the Date of Acceptance; (iii) another 25% of which shall be vested after 36 months of the Date of Acceptance; and (iv) the remaining 25% of which shall be vested after 48 months of the Date of Acceptance.
- (e) Subject to the fulfilment of certain annual performance targets as determined by the Board, the share option granted shall be vested during the relevant periods in 4 tranches: (i) 25% of which shall be vested after 12 months of the date of 2020 SGM; (ii) another 25% of which shall be vested after 24 months of the date of 2020 SGM; (iii) another 25% of which shall be vested after 36 months of the date of 2020 SGM; and (iv) the remaining 25% of which shall be vested after 48 months of the date of 2020 SGM.
- (f) Subject to the fulfilment of certain annual performance targets as determined by the Board, the share option granted shall be vested during the relevant periods in 4 tranches: (i) 25% of which shall be vested after 24 months of the Date of Acceptance; (ii) another 25% of which shall be vested after 36 months of the Date of Acceptance; (iii) another 25% of which shall be vested after 48 months of the Date of Acceptance; and (iv) the remaining 25% of which shall be vested after 60 months of the Date of Acceptance.
- (g) The share option granted shall be vested during the relevant periods in 4 tranches: (i) 25% of which shall be vested after 12 months of the Date of Acceptance; (ii) another 25% of which shall be vested after 24 months of the Date of Acceptance; (iii) another 25% of which shall be vested after 36 months of the Date of Acceptance; and (iv) the remaining 25% of which shall be vested after 48 months of the Date of Acceptance.
- (h) The share option granted shall be vested during the relevant periods in 4 tranches: (i) 25% of which shall be vested after 24 months of the Date of Acceptance; (ii) another 25% of which shall be vested after 36 months of the Date of Acceptance; (iii) another 25% of which shall be vested after 48 months of the Date of Acceptance; and (iv) the remaining 25% of which shall be vested after 60 months of the Date of Acceptance.
- (i) The share option granted shall be vested immediately upon the fulfilment of certain vesting conditions, including the achievement of certain R&D milestones for certain pharmaceutical products, completion of designated tasks and satisfactory business performance of the relevant entities (subject to the Board's opinion). The share option is exercisable the date on which the Share Option are vested, which is 11 May 2030.

No options were exercised or expired during the years ended 31 December 2024 and 2025.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 44. SHARE-BASED PAYMENTS *(Continued)*

These fair values were calculated using the Binomial model. The inputs into the model are as follows:

	12 May 2020	24 June 2020
Share price on grant date	HK\$0.33	HK\$0.33
Exercise price	HK\$0.33	HK\$0.33
Expected life	10 years	10 years
Expected volatility	58.66%	58.74%
Expected dividend yield	Nil	Nil
Annual risk-free interest rate	0.66%	0.70%
Suboptimal factor	2.2 to 2.8	2.8
Expected post-vesting forfeiture rate	0% to 8.57%	0%

Expected volatility was determined by calculating the historical volatility of the Company's share price over the previous 10 years. The expected life used in the model has been adjusted, based on the Group's best estimate, for the effects of non-transferability, exercise restrictions and behavioural considerations.

The Binomial model has been used to estimate the fair value of the options. The variables and assumptions used in computing the fair value of the share options are based on the Directors' best estimate. The value of an option varies with different variables of certain subjective assumptions.

Share options granted to consultants were incentives for their contributions or potential contributions to the Group so as to motivate them to optimise their performance efficiency for the benefit of the Group. The fair value of such benefit could not be estimated reliably, and as a result, the fair value is measured by reference to the fair value of share options granted.

## 45. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS

### (a) Major non-cash transactions

Save as disclosed elsewhere in the consolidated financial statements, the Group had the following major non-cash transactions:

- (i) During the year ended 31 December 2025, the Group entered into supplement lease agreements for the use of leased properties. On the lease modification, the Group derecognised HK\$281,000 of right-of-use assets and HK\$311,000 of lease liabilities respectively. During the year ended 31 December 2024, the Group entered into new lease agreements for the use of leased properties for 3 years. On the lease commencement, the Group recognised HK\$1,381,000 of right-of-use assets and HK\$1,381,000 of lease liabilities respectively.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 45. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS *(Continued)*

### (b) Changes in liabilities arising from financing activities

The following table shows the Group's changes in liabilities arising from financing activities during the year:

	<b>Bank borrowings</b> HK\$'000	<b>Interest payables</b> HK\$'000	<b>Lease liabilities</b> HK\$'000
As at 1 January 2024	296,613	–	450
Change in cash flows	20,838	(10,262)	(591)
Non-cash changes			
– additions	–	–	1,381
– interest charged	–	10,262	31
– exchange differences	(15,630)	–	(28)
As at 31 December 2024 and 1 January 2025	<b>301,821</b>	<b>–</b>	<b>1,243</b>
Change in cash flows	<b>59,147</b>	<b>(9,245)</b>	<b>(450)</b>
Non-cash changes			
– modification	–	–	<b>(311)</b>
– interest charged	–	<b>9,245</b>	<b>45</b>
– exchange differences	<b>19,427</b>	–	<b>36</b>
As at 31 December 2025	<b>380,395</b>	<b>–</b>	<b>563</b>

## 46. CAPITAL COMMITMENTS

The Group's capital commitments at the end of the Reporting Period are as follows:

	<b>2025</b> HK\$'000	2024 HK\$'000
Contracted, but not provided for:		
Capital contribution to associates	<b>10,465</b>	10,163
Construction cost commitments to properties held for sale under development	<b>12,439</b>	86,030
	<b>22,904</b>	96,193

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 47. RELATED PARTY TRANSACTIONS

(a) In addition to those related party transactions and balances disclosed elsewhere in the consolidated financial statements, the Group had the following transactions with its related parties during the year:

	Notes	2025 HK\$'000	2024 HK\$'000
Fellow subsidiaries of the Group:			
Loan interest income paid to the Group	(ii)	<b>13,283</b>	11,651
Purchases from the Group	(iii)	<b>380</b>	2,066
Healthcare management service income paid to the Group	(iii)	<b>584</b>	1,010
Rental expenses paid from the Group	(iii)	<b>1,368</b>	720
Aesthetic medical service income paid to the Group	(iii)	<b>237</b>	300
Loan interest expense paid by the Group	(iii)	<b>77</b>	–
The Directors:			
Aesthetic medical service income paid to the Group	(iii)	–	1
Healthcare management service income paid to the Group	(iii)	–	321
Members of key management personnel of the Group (excluding the Directors):			
Aesthetic medical service income paid to the Group		<b>16</b>	4
Other related parties:			
Aesthetic medical service income paid to the Group	(iii)	<b>3</b>	–
Healthcare management service income paid to the Group	(iii)	–	161

Notes:

- (i) The related parties are (i) a company owned and controlled by one of the Directors; and (ii) an entity of which one of the Directors is a member of key management personnel; or (iii) a close member of the family of one of the Directors.
- (ii) The related party transactions constitute continuing connected transactions as defined in Chapter 14A of the Listing Rules. The disclosures required by Chapter 14A of the Listing Rules are provided in sub-section "Connected Transactions and Continuing Connected Transactions" of the Directors' Report contained in this Annual Report.
- (iii) The related party transactions constitute connected transactions as defined in Chapter 14A of the Listing Rules. However, those transactions are exempt from the disclosure requirements in Chapter 14A of the Listing Rules as they are sales of goods or services on normal commercial terms in the ordinary and usual course of business under Rule 14A.97 or below the de minimis threshold under Rule 14A.76(1).

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

## 47. RELATED PARTY TRANSACTIONS *(Continued)*

### (b) Other transactions with related parties:

- (i) As at 31 December 2025, certain of the Group's bank loans were secured by certain buildings owned by a related company controlled by one of the Directors, personal guarantee provided by Mr. Zhou Xuzhou, Ms. Zhou Wen Chuan and a close family member of one of the Directors (2024: certain buildings owned by a related company controlled by one of the Directors, corporate guarantee provided by a related company controlled by one of the Directors, personal guarantee provided by Mr. Zhou Xuzhou, Ms. Zhou Wen Chuan and a close family member of one of the Directors), as further detailed in note 37 to the consolidated financial statements.
- (ii) On 29 November 2024, the Group entered into an agreement with a fellow subsidiary of the Group to acquire investment properties at an aggregate consideration of RMB13,400,000 (equivalent to HK\$15,659,000).

### (c) Compensation of key management personnel of the Group:

	2025 HK\$'000	2024 HK\$'000
Short term employee benefits	6,243	6,686
Post-employment benefits	130	179
Provision for Equity-settled share options expenses	535	40
Total compensation paid to key management personnel	6,908	6,905

Further details of directors' emoluments are included in note 13 to the consolidated financial statements.

## 48. APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements were approved and authorised for issue by the Board on 27 March 2026.

## FIVE YEAR FINANCIAL SUMMARY

A summary of the results and of the assets, liabilities and non-controlling interests of the Group for the last five financial years, as extracted from the published audited consolidated financial statements and restated/reclassified as appropriate, is set out below.

	Year ended 31 December				2025 HK\$'000
	2021 HK\$'000	2022 HK\$'000	2023 HK\$'000	2024 HK\$'000	
<b>RESULTS</b>					
Revenue	253,031	119,894	129,304	50,676	<b>36,518</b>
Profit before tax	85,704	25,385	52,983	45,401	<b>30,537</b>
Income tax (expense)/credit	(25,248)	(7,605)	(14,493)	(13,356)	<b>7,461</b>
Profit for the year	60,456	17,780	38,490	32,045	<b>37,998</b>
Attributable to:					
Owners of the Company	60,323	17,822	40,830	32,480	<b>37,983</b>
Non-controlling interests	133	(42)	(2,340)	(435)	<b>15</b>
	60,456	17,780	38,490	32,045	<b>37,998</b>
<b>As at 31 December</b>					
	2021 HK\$'000	2022 HK\$'000	2023 HK\$'000	2024 HK\$'000	2025 HK\$'000
<b>ASSETS, LIABILITIES AND NON-CONTROLLING INTERESTS</b>					
Total assets	1,736,994	1,711,261	1,697,209	1,668,651	<b>1,815,586</b>
Total liabilities	(306,349)	(384,176)	(442,888)	(467,287)	<b>(567,343)</b>
Non-controlling interests	(2,603)	(2,509)	(166)	240	<b>260</b>
	1,428,042	1,324,576	1,254,155	1,201,604	<b>1,248,503</b>

# PARTICULARS OF PROPERTIES

As at 31 December 2025

## INVESTMENT PROPERTIES

Location	Use	Tenure	Attributable interest of the Group
Certain shops of Commercial Pedestrian Street of Dong Fang Hong County, New Zone of East Town, Wuhu City, Anhui Province, the PRC	Shop	Medium term lease	100%
(i) 10/F and 11/F at Building No. 18; and (ii) part of the 1/F, 2/F to 11/F and basement at Building No. 19, Dongfanghong County Garden, 128 Yue Min Street, Qi Lin Street, Jiangning District, Nanjing City, Jiangsu Province, the PRC	Hotel/Shop	Medium term lease	100%
(i) No. 3, No. 6 and No. 8; and (ii) unit 7 and unit 12 of No. 13 building located in Yuye Tianyi Commercial Plaza, Zhou Shi Town, Kunshan City, Jiangsu Province, the PRC	Commercial	Medium term lease	100%

## PROPERTIES UNDER DEVELOPMENT

Location	Use	Site area (sq.m.)	Gross floor area (sq.m.)	Stage of completion	Expected completion date	Attributable interest of the Group
Lot A & B, 626 Heidelberg Road, Alphington, VIC, 3078, Australia	Residential	11,488	18,752	All civil works completed	2026-2028	100%

## GLOSSARY

In this Annual Report, unless the context otherwise requires, the following expressions shall have the following meanings:

Term(s)	Definition
"14th Five-Year Plan"	the Outline of the 14th Five-Year Plan for the National Economic and Social Development of the PRC and the Long-Range Objectives Through the Year 2035
"15th Five-Year Plan"	the Outline of the 15th Five-Year Plan for the National Economic and Society Development of the PRC
"2019 Share Option Scheme"	the share option scheme adopted by the Company on 20 June 2019 and became effective on 28 June 2019
"2020 SGM"	the SGM held on Wednesday, 24 June 2020
"2024 AGM"	the AGM held on Thursday, 27 June 2024 at 11:00 a.m.
"2024 SGM"	the SGM held on Wednesday, 31 January 2024 at 11:00 a.m.
"2025 AGM"	the AGM held on Friday, 27 June 2025 at 11:00 a.m.
"2026 SGM"	the SGM to be convened on Tuesday, 21 April 2026 at 11:00 a.m. or any adjournment or postponement thereof
"AGM(s)"	the annual general meeting(s) of the Company
"AlpReleaf"	the Group's brand "AlpReleaf", which launches a variety of high-end CBD health consumption goods in 22 European countries
"Annual Report"	the annual report of the Company
"AUD"	Australian dollars, the lawful currency of Australia
"Audit Committee"	the audit committee of the Board
"Board"	the board of Directors
"Bye-Laws"	the Bye-Laws of the Company
"CBD"	Cannabidiol
"CHF"	Swiss Franc, the lawful currency of Switzerland
"Chief Executive Officer"	the chief executive officer of the Company
"Chief Financial Officer"	the chief financial officer of the Company

## GLOSSARY

“China” or “PRC”	the People’s Republic of China and for the purposes of this Annual Report, excludes Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“Co-Chairman” or “Co-Chairmen”	the co-chairman/co-chairmen of the Board
“Company”	Meilleure Health International Industry Group Limited, a company incorporated in Bermuda with limited liability, the issued shares of which are listed on the Main Board of the Stock Exchange
“Company Secretary”	the company secretary of the Company
“Controlling Shareholder”	the controlling shareholder of the Company
“Corporate Communication”	has meaning as ascribed to it under the Listing Rules
“Corporate Treasury Department”	the corporate treasury department of the Group
“COVID-19”	2019 novel coronavirus (COVID-19) disease
“Date of Acceptance”	the date of acceptance of the offer of the share options granted under the 2019 Share Option Scheme
“Director(s)”	the director(s) of the Company
“Drawdown Period”	the period commencing on 1 January 2024 (or a later date subject to the fulfilment of the conditions precedent as stipulated in the Facility Agreement) and ending on but excluding the earlier of (i) 31 December 2026; and (ii) the date on which the Revolving Facility is terminated upon the occurrence of an Event of Default under the provisions of the Facility Agreement
“EUR”	Euro, the lawful currency of 20 European countries
“Event(s) of Default”	event(s) of default as set out in the Facility Agreement
“Executive Director(s)”	the executive director(s) of the Company
“Facility Agreement”	the facility agreement dated 27 November 2023 and entered into between the Company and U-light Energy in relation to the provision of a revolving loan facility up to a maximum of RMB200,000,000
“FVTOCI”	fair value through other comprehensive income
“FVTPL”	fair value through profit or loss
“GM(s)”	the general meeting(s) of the Company

## GLOSSARY

“Group”, “our” or “us”	the Company and its subsidiaries
“Guangdong U-light”	Guangdong U-light Zhaoneng New Energy Co., Ltd.* (廣東光宇兆能新能源有限公司)
“Healthy China 2030”	the Outline of Healthy China 2030 Plan
“HKD” or “HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“HKICPA”	Hong Kong Institute of Certified Public Accountants
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Independent Non-Executive Director(s)”	the independent non-executive director(s) of the Company
“Jixiaojian”	the Group’s brand “Jixiaojian* (肌小簡)”, which launches a variety of light medical aesthetic services targeting the young consumer market with a range of skincare products complementing the treatments to achieve optimum results in the PRC
“Joint Company Secretaries”	the joint company secretaries of the Company
“Listing Rules”	The Rules Governing the Listing of Securities on the Stock Exchange
“LPR”	the loan prime rate (貸款市場報價利率) announced by the National Interbank Funding Center in the PRC (全國銀行間同業拆借中心) from time to time
“Mei Ai Kang”	Beijing Mei Ai Kang Technology Co., Ltd.* (北京美艾康科技有限公司)
“Model Code”	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
“Nomination Committee”	the nomination committee of the Board
“Non-Executive Director(s)”	the non-executive director(s) of the Company
“R&D”	research and development
“Remuneration Committee”	the remuneration committee of the Board
“Reporting Period”	the year ended 31 December 2025
“Revolving Facility”	the unsecured revolving loan facility up to a maximum of RMB200,000,000 to be granted by the Company to U-light Energy pursuant to the Facility Agreement

## GLOSSARY

“RMB”	Renminbi, the lawful currency of the PRC
“SGM(s)”	the special general meeting(s) of the Company
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time
“Share(s)”	the ordinary share(s) of HK\$0.01 each in the share capital of the Company
“Shareholder(s)”	the holder(s) of the Share(s)
“sq.m.”	square meter(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Strategic Committee”	the strategic committee of the Company
“Suzhou Yurun”	Suzhou Yurun Real Estate Co., Ltd.* (蘇州宇潤置業有限公司), a company established in the PRC with limited liability and is wholly owned by U-Home Group International Limited, a company that is wholly and beneficially owned by Shunda Investment Limited, which is in turn wholly and beneficially owned by Mr. Zhou Xuzhou
“treasury share(s)”	has the meaning ascribed to it under the Listing Rules
“U-light Energy”	Guangyu Zhaoneng New Energy Group Co., Ltd.* (光宇兆能新能源集團有限公司) (formerly known as Jiangsu U-light Zhaoneng New Energy Technology Co., Ltd.* (江蘇光宇兆能新能源科技有限公司)), a company established in the PRC with limited liability which is owned as to 3.636% by Wuhu Ruima, an indirect wholly owned subsidiary of the Company
“USD”	United States dollars, the lawful currency of the United States of America
“Wingor Bio”	Shenzhen Wingor Biotechnology Co., Ltd.* (深圳市茵冠生物科技股份有限公司), a company established in the PRC with limited liability
“Wuhu Ruima”	Wuhu Ruima Tianyu Investment Co., Ltd.* (蕪湖瑞麻天宇投資有限公司), a company established in the PRC with limited liability which is an indirect wholly-owned subsidiary of the Company
“Vice-Chairman”	the vice-chairman of the Board
“Yunnan Hansu”	Yunnan Hansu Biotechnology Co., Ltd.* (雲南漢素生物科技股份有限公司)
“%”	per cent

\* For identification purposes only